6	PRISTIQ.xml:S1:4:1	O
ADVERSE	PRISTIQ.xml:S1:6:7	O
REACTIONS	PRISTIQ.xml:S1:14:9	O

The	PRISTIQ.xml:S1:27:3	O
following	PRISTIQ.xml:S1:31:9	O
adverse	PRISTIQ.xml:S1:41:7	O
reactions	PRISTIQ.xml:S1:49:9	O
are	PRISTIQ.xml:S1:59:3	O
discussed	PRISTIQ.xml:S1:63:9	O
in	PRISTIQ.xml:S1:73:2	O
greater	PRISTIQ.xml:S1:76:7	O
detail	PRISTIQ.xml:S1:84:6	O
in	PRISTIQ.xml:S1:91:2	O
other	PRISTIQ.xml:S1:94:5	O
sections	PRISTIQ.xml:S1:100:8	O
of	PRISTIQ.xml:S1:109:2	O
the	PRISTIQ.xml:S1:112:3	O
label	PRISTIQ.xml:S1:116:5	O
.	PRISTIQ.xml:S1:121:1	O

Hypersensitivity	PRISTIQ.xml:S1:132:16	B-AdverseReaction
[	PRISTIQ.xml:S1:149:1	O
see	PRISTIQ.xml:S1:150:3	O
Contraindications	PRISTIQ.xml:S1:155:17	O
(	PRISTIQ.xml:S1:173:1	O
4	PRISTIQ.xml:S1:174:1	O
)	PRISTIQ.xml:S1:175:1	O
]	PRISTIQ.xml:S1:178:1	O

Suicidal	PRISTIQ.xml:S1:188:8	B-AdverseReaction
Thoughts	PRISTIQ.xml:S1:197:8	I-AdverseReaction
and	PRISTIQ.xml:S1:206:3	O
Behaviors	PRISTIQ.xml:S1:210:9	I-AdverseReaction
in	PRISTIQ.xml:S1:220:2	O
Adolescents	PRISTIQ.xml:S1:223:11	O
and	PRISTIQ.xml:S1:235:3	O
Young	PRISTIQ.xml:S1:239:5	O
Adults	PRISTIQ.xml:S1:245:6	O
[	PRISTIQ.xml:S1:252:1	O
see	PRISTIQ.xml:S1:253:3	O
Warnings	PRISTIQ.xml:S1:258:8	O
and	PRISTIQ.xml:S1:267:3	O
Precautions	PRISTIQ.xml:S1:271:11	O
(	PRISTIQ.xml:S1:283:1	O
5.1	PRISTIQ.xml:S1:284:3	O
)	PRISTIQ.xml:S1:287:1	O
]	PRISTIQ.xml:S1:290:1	O

Serotonin	PRISTIQ.xml:S1:300:9	B-AdverseReaction
Syndrome	PRISTIQ.xml:S1:310:8	I-AdverseReaction
[	PRISTIQ.xml:S1:319:1	O
see	PRISTIQ.xml:S1:320:3	O
Warnings	PRISTIQ.xml:S1:325:8	O
and	PRISTIQ.xml:S1:334:3	O
Precautions	PRISTIQ.xml:S1:338:11	O
(	PRISTIQ.xml:S1:350:1	O
5.2	PRISTIQ.xml:S1:351:3	O
)	PRISTIQ.xml:S1:354:1	O
]	PRISTIQ.xml:S1:357:1	O

Elevated	PRISTIQ.xml:S1:367:8	B-AdverseReaction
Blood	PRISTIQ.xml:S1:376:5	I-AdverseReaction
Pressure	PRISTIQ.xml:S1:382:8	I-AdverseReaction
[	PRISTIQ.xml:S1:391:1	O
see	PRISTIQ.xml:S1:392:3	O
Warnings	PRISTIQ.xml:S1:397:8	O
and	PRISTIQ.xml:S1:406:3	O
Precautions	PRISTIQ.xml:S1:410:11	O
(	PRISTIQ.xml:S1:422:1	O
5.3	PRISTIQ.xml:S1:423:3	O
)	PRISTIQ.xml:S1:426:1	O
]	PRISTIQ.xml:S1:429:1	O

Abnormal	PRISTIQ.xml:S1:439:8	B-AdverseReaction
Bleeding	PRISTIQ.xml:S1:448:8	I-AdverseReaction
[	PRISTIQ.xml:S1:457:1	O
see	PRISTIQ.xml:S1:458:3	O
Warnings	PRISTIQ.xml:S1:463:8	O
and	PRISTIQ.xml:S1:472:3	O
Precautions	PRISTIQ.xml:S1:476:11	O
(	PRISTIQ.xml:S1:488:1	O
5.4	PRISTIQ.xml:S1:489:3	O
)	PRISTIQ.xml:S1:492:1	O
]	PRISTIQ.xml:S1:495:1	O

Angle	PRISTIQ.xml:S1:505:5	B-AdverseReaction
Closure	PRISTIQ.xml:S1:511:7	I-AdverseReaction
Glaucoma	PRISTIQ.xml:S1:519:8	I-AdverseReaction
[	PRISTIQ.xml:S1:528:1	O
see	PRISTIQ.xml:S1:530:3	O
Warnings	PRISTIQ.xml:S1:535:8	O
and	PRISTIQ.xml:S1:544:3	O
Precautions	PRISTIQ.xml:S1:548:11	O
(	PRISTIQ.xml:S1:560:1	O
5.5	PRISTIQ.xml:S1:561:3	O
)	PRISTIQ.xml:S1:564:1	O
]	PRISTIQ.xml:S1:567:1	O

Activation	PRISTIQ.xml:S1:577:10	O
of	PRISTIQ.xml:S1:588:2	O
Mania	PRISTIQ.xml:S1:591:5	B-AdverseReaction
Hypomania	PRISTIQ.xml:S1:597:9	B-AdverseReaction
[	PRISTIQ.xml:S1:607:1	O
see	PRISTIQ.xml:S1:608:3	O
Warnings	PRISTIQ.xml:S1:613:8	O
and	PRISTIQ.xml:S1:622:3	O
Precautions	PRISTIQ.xml:S1:626:11	O
(	PRISTIQ.xml:S1:638:1	O
5.6	PRISTIQ.xml:S1:639:3	O
)	PRISTIQ.xml:S1:642:1	O
]	PRISTIQ.xml:S1:645:1	O

Discontinuation	PRISTIQ.xml:S1:655:15	B-AdverseReaction
Syndrome	PRISTIQ.xml:S1:671:8	I-AdverseReaction
[	PRISTIQ.xml:S1:680:1	O
see	PRISTIQ.xml:S1:681:3	O
Warnings	PRISTIQ.xml:S1:686:8	O
and	PRISTIQ.xml:S1:695:3	O
Precautions	PRISTIQ.xml:S1:699:11	O
(	PRISTIQ.xml:S1:711:1	O
5.7	PRISTIQ.xml:S1:712:3	O
)	PRISTIQ.xml:S1:715:1	O
]	PRISTIQ.xml:S1:718:1	O

Seizure	PRISTIQ.xml:S1:728:7	B-AdverseReaction
[	PRISTIQ.xml:S1:736:1	O
see	PRISTIQ.xml:S1:737:3	O
Warnings	PRISTIQ.xml:S1:742:8	O
and	PRISTIQ.xml:S1:751:3	O
Precautions	PRISTIQ.xml:S1:755:11	O
(	PRISTIQ.xml:S1:767:1	O
5.8	PRISTIQ.xml:S1:768:3	O
)	PRISTIQ.xml:S1:771:1	O
]	PRISTIQ.xml:S1:774:1	O

Hyponatremia	PRISTIQ.xml:S1:784:12	B-AdverseReaction
[	PRISTIQ.xml:S1:797:1	O
see	PRISTIQ.xml:S1:798:3	O
Warnings	PRISTIQ.xml:S1:803:8	O
and	PRISTIQ.xml:S1:812:3	O
Precautions	PRISTIQ.xml:S1:816:11	O
(	PRISTIQ.xml:S1:828:1	O
5.9	PRISTIQ.xml:S1:829:3	O
)	PRISTIQ.xml:S1:832:1	O
]	PRISTIQ.xml:S1:835:1	O

Interstitial	PRISTIQ.xml:S1:845:12	B-AdverseReaction
Lung	PRISTIQ.xml:S1:858:4	I-AdverseReaction
Disease	PRISTIQ.xml:S1:863:7	I-AdverseReaction
and	PRISTIQ.xml:S1:871:3	O
Eosinophilic	PRISTIQ.xml:S1:875:12	B-AdverseReaction
Pneumonia	PRISTIQ.xml:S1:888:9	I-AdverseReaction
[	PRISTIQ.xml:S1:898:1	O
see	PRISTIQ.xml:S1:899:3	O
Warnings	PRISTIQ.xml:S1:904:8	O
and	PRISTIQ.xml:S1:913:3	O
Precautions	PRISTIQ.xml:S1:917:11	O
(	PRISTIQ.xml:S1:929:1	O
5.10	PRISTIQ.xml:S1:930:4	O
)	PRISTIQ.xml:S1:934:1	O
]	PRISTIQ.xml:S1:937:1	O

EXCERPT	PRISTIQ.xml:S1:947:7	O
:	PRISTIQ.xml:S1:954:1	O
Most	PRISTIQ.xml:S1:958:4	O
common	PRISTIQ.xml:S1:963:6	O
adverse	PRISTIQ.xml:S1:970:7	O
reactions	PRISTIQ.xml:S1:978:9	O
(	PRISTIQ.xml:S1:988:1	O
incidence	PRISTIQ.xml:S1:989:9	O
5%	PRISTIQ.xml:S1:1001:2	O
and	PRISTIQ.xml:S1:1004:3	O
twice	PRISTIQ.xml:S1:1008:5	O
the	PRISTIQ.xml:S1:1014:3	O
rate	PRISTIQ.xml:S1:1018:4	O
of	PRISTIQ.xml:S1:1023:2	O
placebo	PRISTIQ.xml:S1:1026:7	O
in	PRISTIQ.xml:S1:1034:2	O
the	PRISTIQ.xml:S1:1037:3	O
50	PRISTIQ.xml:S1:1041:2	O
or	PRISTIQ.xml:S1:1044:2	O
100	PRISTIQ.xml:S1:1047:3	O
mg	PRISTIQ.xml:S1:1051:2	O
dose	PRISTIQ.xml:S1:1054:4	O
groups	PRISTIQ.xml:S1:1059:6	O
)	PRISTIQ.xml:S1:1065:1	O
were	PRISTIQ.xml:S1:1067:4	O
:	PRISTIQ.xml:S1:1071:1	O
nausea	PRISTIQ.xml:S1:1073:6	B-AdverseReaction
,	PRISTIQ.xml:S1:1079:1	O
dizziness	PRISTIQ.xml:S1:1081:9	B-AdverseReaction
,	PRISTIQ.xml:S1:1090:1	O
insomnia	PRISTIQ.xml:S1:1092:8	B-AdverseReaction
,	PRISTIQ.xml:S1:1100:1	O
hyperhidrosis	PRISTIQ.xml:S1:1102:13	B-AdverseReaction
,	PRISTIQ.xml:S1:1115:1	O
constipation	PRISTIQ.xml:S1:1117:12	B-AdverseReaction
,	PRISTIQ.xml:S1:1129:1	O
somnolence	PRISTIQ.xml:S1:1131:10	B-AdverseReaction
,	PRISTIQ.xml:S1:1141:1	O
decreased	PRISTIQ.xml:S1:1143:9	B-AdverseReaction
appetite	PRISTIQ.xml:S1:1153:8	I-AdverseReaction
,	PRISTIQ.xml:S1:1161:1	O
anxiety	PRISTIQ.xml:S1:1163:7	B-AdverseReaction
,	PRISTIQ.xml:S1:1170:1	O
and	PRISTIQ.xml:S1:1172:3	O
specific	PRISTIQ.xml:S1:1176:8	O
male	PRISTIQ.xml:S1:1185:4	B-AdverseReaction
sexual	PRISTIQ.xml:S1:1190:6	I-AdverseReaction
function	PRISTIQ.xml:S1:1197:8	I-AdverseReaction
disorders	PRISTIQ.xml:S1:1206:9	I-AdverseReaction
(	PRISTIQ.xml:S1:1216:1	O
6.1	PRISTIQ.xml:S1:1219:3	O
)	PRISTIQ.xml:S1:1224:1	O
.	PRISTIQ.xml:S1:1225:1	O

To	PRISTIQ.xml:S1:1233:2	O

report	PRISTIQ.xml:S1:1236:6	O
SUSPECTED	PRISTIQ.xml:S1:1243:9	O
ADVERSE	PRISTIQ.xml:S1:1253:7	O
REACTIONS	PRISTIQ.xml:S1:1261:9	O
,	PRISTIQ.xml:S1:1270:1	O
contact	PRISTIQ.xml:S1:1272:7	O
Wyeth	PRISTIQ.xml:S1:1280:5	O
Pharmaceuticals	PRISTIQ.xml:S1:1286:15	O
Inc	PRISTIQ.xml:S1:1302:3	O
.	PRISTIQ.xml:S1:1305:1	O
,	PRISTIQ.xml:S1:1306:1	O
a	PRISTIQ.xml:S1:1308:1	O
subsidiary	PRISTIQ.xml:S1:1310:10	O
of	PRISTIQ.xml:S1:1321:2	O
Pfizer	PRISTIQ.xml:S1:1324:6	O
Inc	PRISTIQ.xml:S1:1331:3	O
.	PRISTIQ.xml:S1:1334:1	O
,	PRISTIQ.xml:S1:1335:1	O
at	PRISTIQ.xml:S1:1337:2	O
1	PRISTIQ.xml:S1:1340:1	O
-	PRISTIQ.xml:S1:1341:1	O
800	PRISTIQ.xml:S1:1342:3	O
-	PRISTIQ.xml:S1:1345:1	O
438	PRISTIQ.xml:S1:1346:3	O
-	PRISTIQ.xml:S1:1349:1	O
1985	PRISTIQ.xml:S1:1350:4	O
or	PRISTIQ.xml:S1:1355:2	O
FDA	PRISTIQ.xml:S1:1358:3	O
at	PRISTIQ.xml:S1:1362:2	O
1	PRISTIQ.xml:S1:1365:1	O
-	PRISTIQ.xml:S1:1366:1	O
800	PRISTIQ.xml:S1:1367:3	O
-	PRISTIQ.xml:S1:1370:1	O
FDA	PRISTIQ.xml:S1:1371:3	O
-	PRISTIQ.xml:S1:1374:1	O
1088	PRISTIQ.xml:S1:1375:4	O
or	PRISTIQ.xml:S1:1380:2	O
www	PRISTIQ.xml:S1:1383:3	O
.	PRISTIQ.xml:S1:1386:1	O
fda	PRISTIQ.xml:S1:1387:3	O
.	PRISTIQ.xml:S1:1390:1	O
gov	PRISTIQ.xml:S1:1391:3	O
medwatch	PRISTIQ.xml:S1:1395:8	O

6.1	PRISTIQ.xml:S1:1414:3	O

Clinical	PRISTIQ.xml:S1:1418:8	O
Studies	PRISTIQ.xml:S1:1427:7	O
Experience	PRISTIQ.xml:S1:1435:10	O

Because	PRISTIQ.xml:S1:1449:7	O
clinical	PRISTIQ.xml:S1:1457:8	O
trials	PRISTIQ.xml:S1:1466:6	O
are	PRISTIQ.xml:S1:1473:3	O
conducted	PRISTIQ.xml:S1:1477:9	O
under	PRISTIQ.xml:S1:1487:5	O
widely	PRISTIQ.xml:S1:1493:6	O
varying	PRISTIQ.xml:S1:1500:7	O
conditions	PRISTIQ.xml:S1:1508:10	O
,	PRISTIQ.xml:S1:1518:1	O
adverse	PRISTIQ.xml:S1:1520:7	O
reaction	PRISTIQ.xml:S1:1528:8	O
rates	PRISTIQ.xml:S1:1537:5	O
observed	PRISTIQ.xml:S1:1543:8	O
in	PRISTIQ.xml:S1:1552:2	O
the	PRISTIQ.xml:S1:1555:3	O
clinical	PRISTIQ.xml:S1:1559:8	O
trials	PRISTIQ.xml:S1:1568:6	O
of	PRISTIQ.xml:S1:1575:2	O
a	PRISTIQ.xml:S1:1578:1	O
drug	PRISTIQ.xml:S1:1580:4	O
cannot	PRISTIQ.xml:S1:1585:6	O
be	PRISTIQ.xml:S1:1592:2	O
directly	PRISTIQ.xml:S1:1595:8	O
compared	PRISTIQ.xml:S1:1604:8	O
to	PRISTIQ.xml:S1:1613:2	O
rates	PRISTIQ.xml:S1:1616:5	O
in	PRISTIQ.xml:S1:1622:2	O
the	PRISTIQ.xml:S1:1625:3	O
clinical	PRISTIQ.xml:S1:1629:8	O
studies	PRISTIQ.xml:S1:1638:7	O
of	PRISTIQ.xml:S1:1646:2	O
another	PRISTIQ.xml:S1:1649:7	O
drug	PRISTIQ.xml:S1:1657:4	O
and	PRISTIQ.xml:S1:1662:3	O
may	PRISTIQ.xml:S1:1666:3	O
not	PRISTIQ.xml:S1:1670:3	O
reflect	PRISTIQ.xml:S1:1674:7	O
the	PRISTIQ.xml:S1:1682:3	O
rates	PRISTIQ.xml:S1:1686:5	O
observed	PRISTIQ.xml:S1:1692:8	O
in	PRISTIQ.xml:S1:1701:2	O
clinical	PRISTIQ.xml:S1:1704:8	O
practice	PRISTIQ.xml:S1:1713:8	O
.	PRISTIQ.xml:S1:1721:1	O

Patient	PRISTIQ.xml:S1:1731:7	O
exposure	PRISTIQ.xml:S1:1739:8	O

PRISTIQ	PRISTIQ.xml:S1:1754:7	O
was	PRISTIQ.xml:S1:1762:3	O
evaluated	PRISTIQ.xml:S1:1766:9	O
for	PRISTIQ.xml:S1:1776:3	O
safety	PRISTIQ.xml:S1:1780:6	O
in	PRISTIQ.xml:S1:1787:2	O
8	PRISTIQ.xml:S1:1790:1	O
,	PRISTIQ.xml:S1:1791:1	O
394	PRISTIQ.xml:S1:1792:3	O
patients	PRISTIQ.xml:S1:1796:8	O
diagnosed	PRISTIQ.xml:S1:1805:9	O
with	PRISTIQ.xml:S1:1815:4	O
major	PRISTIQ.xml:S1:1820:5	O
depressive	PRISTIQ.xml:S1:1826:10	O
disorder	PRISTIQ.xml:S1:1837:8	O
who	PRISTIQ.xml:S1:1846:3	O
participated	PRISTIQ.xml:S1:1850:12	O
in	PRISTIQ.xml:S1:1863:2	O
multiple	PRISTIQ.xml:S1:1866:8	O
-	PRISTIQ.xml:S1:1874:1	O
dose	PRISTIQ.xml:S1:1875:4	O
pre	PRISTIQ.xml:S1:1880:3	O
-	PRISTIQ.xml:S1:1883:1	O
marketing	PRISTIQ.xml:S1:1884:9	O
studies	PRISTIQ.xml:S1:1894:7	O
,	PRISTIQ.xml:S1:1901:1	O
representing	PRISTIQ.xml:S1:1903:12	O
2	PRISTIQ.xml:S1:1916:1	O
,	PRISTIQ.xml:S1:1917:1	O
784	PRISTIQ.xml:S1:1918:3	O
patient	PRISTIQ.xml:S1:1922:7	O
-	PRISTIQ.xml:S1:1929:1	O
years	PRISTIQ.xml:S1:1930:5	O
of	PRISTIQ.xml:S1:1936:2	O
exposure	PRISTIQ.xml:S1:1939:8	O
.	PRISTIQ.xml:S1:1947:1	O

Of	PRISTIQ.xml:S1:1949:2	O
the	PRISTIQ.xml:S1:1952:3	O
total	PRISTIQ.xml:S1:1956:5	O
8	PRISTIQ.xml:S1:1962:1	O
,	PRISTIQ.xml:S1:1963:1	O
394	PRISTIQ.xml:S1:1964:3	O
patients	PRISTIQ.xml:S1:1968:8	O
exposed	PRISTIQ.xml:S1:1977:7	O
to	PRISTIQ.xml:S1:1985:2	O
at	PRISTIQ.xml:S1:1988:2	O
least	PRISTIQ.xml:S1:1991:5	O
one	PRISTIQ.xml:S1:1997:3	O
dose	PRISTIQ.xml:S1:2001:4	O
of	PRISTIQ.xml:S1:2006:2	O
PRISTIQ	PRISTIQ.xml:S1:2009:7	O
;	PRISTIQ.xml:S1:2016:1	O
2	PRISTIQ.xml:S1:2018:1	O
,	PRISTIQ.xml:S1:2019:1	O
116	PRISTIQ.xml:S1:2020:3	O
were	PRISTIQ.xml:S1:2024:4	O
exposed	PRISTIQ.xml:S1:2029:7	O
to	PRISTIQ.xml:S1:2037:2	O
PRISTIQ	PRISTIQ.xml:S1:2040:7	O
for	PRISTIQ.xml:S1:2048:3	O
6	PRISTIQ.xml:S1:2052:1	O
months	PRISTIQ.xml:S1:2054:6	O
,	PRISTIQ.xml:S1:2060:1	O
representing	PRISTIQ.xml:S1:2062:12	O
1	PRISTIQ.xml:S1:2075:1	O
,	PRISTIQ.xml:S1:2076:1	O
658	PRISTIQ.xml:S1:2077:3	O
patient	PRISTIQ.xml:S1:2081:7	O
-	PRISTIQ.xml:S1:2088:1	O
years	PRISTIQ.xml:S1:2089:5	O
of	PRISTIQ.xml:S1:2095:2	O
exposure	PRISTIQ.xml:S1:2098:8	O
,	PRISTIQ.xml:S1:2106:1	O
and	PRISTIQ.xml:S1:2108:3	O
421	PRISTIQ.xml:S1:2112:3	O
were	PRISTIQ.xml:S1:2116:4	O
exposed	PRISTIQ.xml:S1:2121:7	O
for	PRISTIQ.xml:S1:2129:3	O
one	PRISTIQ.xml:S1:2133:3	O
year	PRISTIQ.xml:S1:2137:4	O
,	PRISTIQ.xml:S1:2141:1	O
representing	PRISTIQ.xml:S1:2143:12	O
416	PRISTIQ.xml:S1:2156:3	O
patient	PRISTIQ.xml:S1:2160:7	O
-	PRISTIQ.xml:S1:2167:1	O
years	PRISTIQ.xml:S1:2168:5	O
of	PRISTIQ.xml:S1:2174:2	O
exposure	PRISTIQ.xml:S1:2177:8	O
.	PRISTIQ.xml:S1:2185:1	O

Adverse	PRISTIQ.xml:S1:2195:7	O
reactions	PRISTIQ.xml:S1:2203:9	O
reported	PRISTIQ.xml:S1:2213:8	O
as	PRISTIQ.xml:S1:2222:2	O
reasons	PRISTIQ.xml:S1:2225:7	O
for	PRISTIQ.xml:S1:2233:3	O
discontinuation	PRISTIQ.xml:S1:2237:15	O
of	PRISTIQ.xml:S1:2253:2	O
treatment	PRISTIQ.xml:S1:2256:9	O

In	PRISTIQ.xml:S1:2272:2	O
the	PRISTIQ.xml:S1:2275:3	O
pre	PRISTIQ.xml:S1:2279:3	O
-	PRISTIQ.xml:S1:2282:1	O
marketing	PRISTIQ.xml:S1:2283:9	O
pooled	PRISTIQ.xml:S1:2293:6	O
8	PRISTIQ.xml:S1:2300:1	O
-	PRISTIQ.xml:S1:2301:1	O
week	PRISTIQ.xml:S1:2302:4	O
placebo	PRISTIQ.xml:S1:2307:7	O
-	PRISTIQ.xml:S1:2314:1	O
controlled	PRISTIQ.xml:S1:2315:10	O
studies	PRISTIQ.xml:S1:2326:7	O
in	PRISTIQ.xml:S1:2334:2	O
patients	PRISTIQ.xml:S1:2337:8	O
with	PRISTIQ.xml:S1:2346:4	O
MDD	PRISTIQ.xml:S1:2351:3	O
,	PRISTIQ.xml:S1:2354:1	O
1	PRISTIQ.xml:S1:2356:1	O
,	PRISTIQ.xml:S1:2357:1	O
834	PRISTIQ.xml:S1:2358:3	O
patients	PRISTIQ.xml:S1:2362:8	O
were	PRISTIQ.xml:S1:2371:4	O
exposed	PRISTIQ.xml:S1:2376:7	O
to	PRISTIQ.xml:S1:2384:2	O
PRISTIQ	PRISTIQ.xml:S1:2387:7	O
(	PRISTIQ.xml:S1:2395:1	O
50	PRISTIQ.xml:S1:2396:2	O
to	PRISTIQ.xml:S1:2399:2	O
400	PRISTIQ.xml:S1:2402:3	O
mg	PRISTIQ.xml:S1:2406:2	O
)	PRISTIQ.xml:S1:2408:1	O
.	PRISTIQ.xml:S1:2409:1	O

Of	PRISTIQ.xml:S1:2411:2	O
the	PRISTIQ.xml:S1:2414:3	O
1	PRISTIQ.xml:S1:2418:1	O
,	PRISTIQ.xml:S1:2419:1	O
834	PRISTIQ.xml:S1:2420:3	O
patients	PRISTIQ.xml:S1:2424:8	O
,	PRISTIQ.xml:S1:2432:1	O
12%	PRISTIQ.xml:S1:2434:3	O
discontinued	PRISTIQ.xml:S1:2438:12	O
treatment	PRISTIQ.xml:S1:2451:9	O
due	PRISTIQ.xml:S1:2461:3	O
to	PRISTIQ.xml:S1:2465:2	O
an	PRISTIQ.xml:S1:2468:2	O
adverse	PRISTIQ.xml:S1:2471:7	O
reaction	PRISTIQ.xml:S1:2479:8	O
,	PRISTIQ.xml:S1:2487:1	O
compared	PRISTIQ.xml:S1:2489:8	O
with	PRISTIQ.xml:S1:2498:4	O
3%	PRISTIQ.xml:S1:2503:2	O
of	PRISTIQ.xml:S1:2506:2	O
the	PRISTIQ.xml:S1:2509:3	O
1	PRISTIQ.xml:S1:2513:1	O
,	PRISTIQ.xml:S1:2514:1	O
116	PRISTIQ.xml:S1:2515:3	O
placebo	PRISTIQ.xml:S1:2519:7	O
-	PRISTIQ.xml:S1:2526:1	O
treated	PRISTIQ.xml:S1:2527:7	O
patients	PRISTIQ.xml:S1:2535:8	O
.	PRISTIQ.xml:S1:2543:1	O

At	PRISTIQ.xml:S1:2545:2	O
the	PRISTIQ.xml:S1:2548:3	O
recommended	PRISTIQ.xml:S1:2552:11	O
dose	PRISTIQ.xml:S1:2564:4	O
of	PRISTIQ.xml:S1:2569:2	O
50	PRISTIQ.xml:S1:2572:2	O
mg	PRISTIQ.xml:S1:2575:2	O
,	PRISTIQ.xml:S1:2577:1	O
the	PRISTIQ.xml:S1:2579:3	O
discontinuation	PRISTIQ.xml:S1:2583:15	O
rate	PRISTIQ.xml:S1:2599:4	O
due	PRISTIQ.xml:S1:2604:3	O
to	PRISTIQ.xml:S1:2608:2	O
an	PRISTIQ.xml:S1:2611:2	O
adverse	PRISTIQ.xml:S1:2614:7	O
reaction	PRISTIQ.xml:S1:2622:8	O
for	PRISTIQ.xml:S1:2631:3	O
PRISTIQ	PRISTIQ.xml:S1:2635:7	O
(	PRISTIQ.xml:S1:2643:1	O
4.1%	PRISTIQ.xml:S1:2644:4	O
)	PRISTIQ.xml:S1:2648:1	O
was	PRISTIQ.xml:S1:2650:3	O
similar	PRISTIQ.xml:S1:2654:7	O
to	PRISTIQ.xml:S1:2662:2	O
the	PRISTIQ.xml:S1:2665:3	O
rate	PRISTIQ.xml:S1:2669:4	O
for	PRISTIQ.xml:S1:2674:3	O
placebo	PRISTIQ.xml:S1:2678:7	O
(	PRISTIQ.xml:S1:2686:1	O
3.8%	PRISTIQ.xml:S1:2687:4	O
)	PRISTIQ.xml:S1:2691:1	O
.	PRISTIQ.xml:S1:2692:1	O

For	PRISTIQ.xml:S1:2694:3	O
the	PRISTIQ.xml:S1:2698:3	O
100	PRISTIQ.xml:S1:2702:3	O
mg	PRISTIQ.xml:S1:2706:2	O
dose	PRISTIQ.xml:S1:2709:4	O
of	PRISTIQ.xml:S1:2714:2	O
PRISTIQ	PRISTIQ.xml:S1:2717:7	O
the	PRISTIQ.xml:S1:2725:3	O
discontinuation	PRISTIQ.xml:S1:2729:15	O
rate	PRISTIQ.xml:S1:2745:4	O
due	PRISTIQ.xml:S1:2750:3	O
to	PRISTIQ.xml:S1:2754:2	O
an	PRISTIQ.xml:S1:2757:2	O
adverse	PRISTIQ.xml:S1:2760:7	O
reaction	PRISTIQ.xml:S1:2768:8	O
was	PRISTIQ.xml:S1:2777:3	O
8.7%	PRISTIQ.xml:S1:2781:4	O
.	PRISTIQ.xml:S1:2785:1	O

The	PRISTIQ.xml:S1:2791:3	O
most	PRISTIQ.xml:S1:2795:4	O
common	PRISTIQ.xml:S1:2800:6	O
adverse	PRISTIQ.xml:S1:2807:7	O
reactions	PRISTIQ.xml:S1:2815:9	O
leading	PRISTIQ.xml:S1:2825:7	O
to	PRISTIQ.xml:S1:2833:2	O
discontinuation	PRISTIQ.xml:S1:2836:15	O
in	PRISTIQ.xml:S1:2852:2	O
at	PRISTIQ.xml:S1:2855:2	O
least	PRISTIQ.xml:S1:2858:5	O
2%	PRISTIQ.xml:S1:2864:2	O
and	PRISTIQ.xml:S1:2867:3	O
at	PRISTIQ.xml:S1:2871:2	O
a	PRISTIQ.xml:S1:2874:1	O
rate	PRISTIQ.xml:S1:2876:4	O
greater	PRISTIQ.xml:S1:2881:7	O
than	PRISTIQ.xml:S1:2889:4	O
placebo	PRISTIQ.xml:S1:2894:7	O
of	PRISTIQ.xml:S1:2902:2	O
the	PRISTIQ.xml:S1:2905:3	O
PRISTIQ	PRISTIQ.xml:S1:2909:7	O
treated	PRISTIQ.xml:S1:2917:7	O
patients	PRISTIQ.xml:S1:2925:8	O
in	PRISTIQ.xml:S1:2934:2	O
the	PRISTIQ.xml:S1:2937:3	O
short	PRISTIQ.xml:S1:2941:5	O
-	PRISTIQ.xml:S1:2946:1	O
term	PRISTIQ.xml:S1:2947:4	O
studies	PRISTIQ.xml:S1:2952:7	O
,	PRISTIQ.xml:S1:2959:1	O
up	PRISTIQ.xml:S1:2961:2	O
to	PRISTIQ.xml:S1:2964:2	O
8	PRISTIQ.xml:S1:2967:1	O
weeks	PRISTIQ.xml:S1:2969:5	O
,	PRISTIQ.xml:S1:2974:1	O
were	PRISTIQ.xml:S1:2976:4	O
:	PRISTIQ.xml:S1:2980:1	O
nausea	PRISTIQ.xml:S1:2982:6	B-AdverseReaction
(	PRISTIQ.xml:S1:2989:1	O
4%	PRISTIQ.xml:S1:2990:2	O
)	PRISTIQ.xml:S1:2992:1	O
;	PRISTIQ.xml:S1:2993:1	O
dizziness	PRISTIQ.xml:S1:2995:9	B-AdverseReaction
,	PRISTIQ.xml:S1:3004:1	O
headache	PRISTIQ.xml:S1:3006:8	B-AdverseReaction
and	PRISTIQ.xml:S1:3015:3	O
vomiting	PRISTIQ.xml:S1:3019:8	B-AdverseReaction
(	PRISTIQ.xml:S1:3028:1	O
2%	PRISTIQ.xml:S1:3029:2	O
each	PRISTIQ.xml:S1:3032:4	O
)	PRISTIQ.xml:S1:3036:1	O
.	PRISTIQ.xml:S1:3037:1	O

In	PRISTIQ.xml:S1:3039:2	O
a	PRISTIQ.xml:S1:3042:1	O
longer	PRISTIQ.xml:S1:3044:6	O
-	PRISTIQ.xml:S1:3050:1	O
term	PRISTIQ.xml:S1:3051:4	O
study	PRISTIQ.xml:S1:3056:5	O
,	PRISTIQ.xml:S1:3061:1	O
up	PRISTIQ.xml:S1:3063:2	O
to	PRISTIQ.xml:S1:3066:2	O
9	PRISTIQ.xml:S1:3069:1	O
months	PRISTIQ.xml:S1:3071:6	O
,	PRISTIQ.xml:S1:3077:1	O
the	PRISTIQ.xml:S1:3079:3	O
most	PRISTIQ.xml:S1:3083:4	O
common	PRISTIQ.xml:S1:3088:6	O
was	PRISTIQ.xml:S1:3095:3	O
vomiting	PRISTIQ.xml:S1:3099:8	B-AdverseReaction
(	PRISTIQ.xml:S1:3108:1	O
2%	PRISTIQ.xml:S1:3109:2	O
)	PRISTIQ.xml:S1:3111:1	O
.	PRISTIQ.xml:S1:3112:1	O

Common	PRISTIQ.xml:S1:3122:6	O
adverse	PRISTIQ.xml:S1:3129:7	O
reactions	PRISTIQ.xml:S1:3137:9	O
in	PRISTIQ.xml:S1:3147:2	O
placebo	PRISTIQ.xml:S1:3150:7	O
-	PRISTIQ.xml:S1:3157:1	O
controlled	PRISTIQ.xml:S1:3158:10	O
MDD	PRISTIQ.xml:S1:3169:3	O
studies	PRISTIQ.xml:S1:3173:7	O

The	PRISTIQ.xml:S1:3187:3	O
most	PRISTIQ.xml:S1:3191:4	O
commonly	PRISTIQ.xml:S1:3196:8	O
observed	PRISTIQ.xml:S1:3205:8	O
adverse	PRISTIQ.xml:S1:3214:7	O
reactions	PRISTIQ.xml:S1:3222:9	O
in	PRISTIQ.xml:S1:3232:2	O
PRISTIQ	PRISTIQ.xml:S1:3235:7	O
treated	PRISTIQ.xml:S1:3243:7	O
MDD	PRISTIQ.xml:S1:3251:3	O
patients	PRISTIQ.xml:S1:3255:8	O
in	PRISTIQ.xml:S1:3264:2	O
pre	PRISTIQ.xml:S1:3267:3	O
-	PRISTIQ.xml:S1:3270:1	O
marketing	PRISTIQ.xml:S1:3271:9	O
pooled	PRISTIQ.xml:S1:3281:6	O
8	PRISTIQ.xml:S1:3288:1	O
-	PRISTIQ.xml:S1:3289:1	O
week	PRISTIQ.xml:S1:3290:4	O
,	PRISTIQ.xml:S1:3294:1	O
placebo	PRISTIQ.xml:S1:3296:7	O
-	PRISTIQ.xml:S1:3303:1	O
controlled	PRISTIQ.xml:S1:3304:10	O
,	PRISTIQ.xml:S1:3314:1	O
fixed	PRISTIQ.xml:S1:3316:5	O
-	PRISTIQ.xml:S1:3321:1	O
dose	PRISTIQ.xml:S1:3322:4	O
studies	PRISTIQ.xml:S1:3327:7	O
(	PRISTIQ.xml:S1:3335:1	O
incidence	PRISTIQ.xml:S1:3336:9	O
5%	PRISTIQ.xml:S1:3349:2	O
and	PRISTIQ.xml:S1:3352:3	O
at	PRISTIQ.xml:S1:3356:2	O
least	PRISTIQ.xml:S1:3359:5	O
twice	PRISTIQ.xml:S1:3365:5	O
the	PRISTIQ.xml:S1:3371:3	O
rate	PRISTIQ.xml:S1:3375:4	O
of	PRISTIQ.xml:S1:3380:2	O
placebo	PRISTIQ.xml:S1:3383:7	O
in	PRISTIQ.xml:S1:3391:2	O
the	PRISTIQ.xml:S1:3394:3	O
50	PRISTIQ.xml:S1:3398:2	O
or	PRISTIQ.xml:S1:3401:2	O
100	PRISTIQ.xml:S1:3404:3	O
mg	PRISTIQ.xml:S1:3408:2	O
dose	PRISTIQ.xml:S1:3411:4	O
groups	PRISTIQ.xml:S1:3416:6	O
)	PRISTIQ.xml:S1:3422:1	O
were	PRISTIQ.xml:S1:3424:4	O
:	PRISTIQ.xml:S1:3428:1	O
nausea	PRISTIQ.xml:S1:3430:6	B-AdverseReaction
,	PRISTIQ.xml:S1:3436:1	O
dizziness	PRISTIQ.xml:S1:3438:9	B-AdverseReaction
,	PRISTIQ.xml:S1:3447:1	O
insomnia	PRISTIQ.xml:S1:3449:8	B-AdverseReaction
,	PRISTIQ.xml:S1:3457:1	O
hyperhidrosis	PRISTIQ.xml:S1:3459:13	B-AdverseReaction
,	PRISTIQ.xml:S1:3472:1	O
constipation	PRISTIQ.xml:S1:3474:12	B-AdverseReaction
,	PRISTIQ.xml:S1:3486:1	O
somnolence	PRISTIQ.xml:S1:3488:10	B-AdverseReaction
,	PRISTIQ.xml:S1:3498:1	O
decreased	PRISTIQ.xml:S1:3500:9	B-AdverseReaction
appetite	PRISTIQ.xml:S1:3510:8	I-AdverseReaction
,	PRISTIQ.xml:S1:3518:1	O
anxiety	PRISTIQ.xml:S1:3520:7	B-AdverseReaction
,	PRISTIQ.xml:S1:3527:1	O
and	PRISTIQ.xml:S1:3529:3	O
specific	PRISTIQ.xml:S1:3533:8	O
male	PRISTIQ.xml:S1:3542:4	B-AdverseReaction
sexual	PRISTIQ.xml:S1:3547:6	I-AdverseReaction
function	PRISTIQ.xml:S1:3554:8	I-AdverseReaction
disorders	PRISTIQ.xml:S1:3563:9	I-AdverseReaction
.	PRISTIQ.xml:S1:3572:1	O

Table	PRISTIQ.xml:S1:3578:5	O
2	PRISTIQ.xml:S1:3584:1	O
shows	PRISTIQ.xml:S1:3586:5	O
the	PRISTIQ.xml:S1:3592:3	O
incidence	PRISTIQ.xml:S1:3596:9	O
of	PRISTIQ.xml:S1:3606:2	O
common	PRISTIQ.xml:S1:3609:6	O
adverse	PRISTIQ.xml:S1:3616:7	O
reactions	PRISTIQ.xml:S1:3624:9	O
that	PRISTIQ.xml:S1:3634:4	O
occurred	PRISTIQ.xml:S1:3639:8	O
in	PRISTIQ.xml:S1:3648:2	O
2%	PRISTIQ.xml:S1:3654:2	O
of	PRISTIQ.xml:S1:3657:2	O
PRISTIQ	PRISTIQ.xml:S1:3660:7	O
treated	PRISTIQ.xml:S1:3668:7	O
MDD	PRISTIQ.xml:S1:3676:3	O
patients	PRISTIQ.xml:S1:3680:8	O
and	PRISTIQ.xml:S1:3689:3	O
twice	PRISTIQ.xml:S1:3693:5	O
the	PRISTIQ.xml:S1:3699:3	O
rate	PRISTIQ.xml:S1:3703:4	O
of	PRISTIQ.xml:S1:3708:2	O
placebo	PRISTIQ.xml:S1:3711:7	O
at	PRISTIQ.xml:S1:3719:2	O
any	PRISTIQ.xml:S1:3722:3	O
dose	PRISTIQ.xml:S1:3726:4	O
in	PRISTIQ.xml:S1:3731:2	O
the	PRISTIQ.xml:S1:3734:3	O
pre	PRISTIQ.xml:S1:3738:3	O
-	PRISTIQ.xml:S1:3741:1	O
marketing	PRISTIQ.xml:S1:3742:9	O
pooled	PRISTIQ.xml:S1:3752:6	O
8	PRISTIQ.xml:S1:3759:1	O
-	PRISTIQ.xml:S1:3760:1	O
week	PRISTIQ.xml:S1:3761:4	O
,	PRISTIQ.xml:S1:3765:1	O
placebo	PRISTIQ.xml:S1:3767:7	O
-	PRISTIQ.xml:S1:3774:1	O
controlled	PRISTIQ.xml:S1:3775:10	O
,	PRISTIQ.xml:S1:3785:1	O
fixed	PRISTIQ.xml:S1:3787:5	O
dose	PRISTIQ.xml:S1:3793:4	O
clinical	PRISTIQ.xml:S1:3798:8	O
studies	PRISTIQ.xml:S1:3807:7	O

Table	PRISTIQ.xml:S1:3819:5	O
2	PRISTIQ.xml:S1:3825:1	O
:	PRISTIQ.xml:S1:3826:1	O
Common	PRISTIQ.xml:S1:3828:6	O
Adverse	PRISTIQ.xml:S1:3835:7	O
Reactions	PRISTIQ.xml:S1:3843:9	O
(	PRISTIQ.xml:S1:3853:1	O
2%	PRISTIQ.xml:S1:3857:2	O
in	PRISTIQ.xml:S1:3860:2	O
any	PRISTIQ.xml:S1:3863:3	O
Fixed	PRISTIQ.xml:S1:3867:5	O
-	PRISTIQ.xml:S1:3872:1	O
Dose	PRISTIQ.xml:S1:3873:4	O
Group	PRISTIQ.xml:S1:3878:5	O
and	PRISTIQ.xml:S1:3884:3	O
Twice	PRISTIQ.xml:S1:3888:5	O
the	PRISTIQ.xml:S1:3894:3	O
Rate	PRISTIQ.xml:S1:3898:4	O
of	PRISTIQ.xml:S1:3903:2	O
Placebo	PRISTIQ.xml:S1:3906:7	O
)	PRISTIQ.xml:S1:3913:1	O
in	PRISTIQ.xml:S1:3915:2	O
Pre	PRISTIQ.xml:S1:3918:3	O
-	PRISTIQ.xml:S1:3921:1	O
marketing	PRISTIQ.xml:S1:3922:9	O
Pooled	PRISTIQ.xml:S1:3932:6	O
MDD	PRISTIQ.xml:S1:3939:3	O
8	PRISTIQ.xml:S1:3943:1	O
-	PRISTIQ.xml:S1:3944:1	O
Week	PRISTIQ.xml:S1:3945:4	O
Placebo	PRISTIQ.xml:S1:3950:7	O
-	PRISTIQ.xml:S1:3957:1	O
Controlled	PRISTIQ.xml:S1:3958:10	O
Studies	PRISTIQ.xml:S1:3969:7	O

Percentage	PRISTIQ.xml:S1:4008:10	O
of	PRISTIQ.xml:S1:4019:2	O
Patients	PRISTIQ.xml:S1:4022:8	O
Reporting	PRISTIQ.xml:S1:4031:9	O
Reaction	PRISTIQ.xml:S1:4041:8	O

PRISTIQ	PRISTIQ.xml:S1:4102:7	O

System	PRISTIQ.xml:S1:4122:6	O
Organ	PRISTIQ.xml:S1:4129:5	O
Class	PRISTIQ.xml:S1:4135:5	O
Preferred	PRISTIQ.xml:S1:4144:9	O
Term	PRISTIQ.xml:S1:4154:4	O
Placebo	PRISTIQ.xml:S1:4164:7	O
(	PRISTIQ.xml:S1:4175:1	O
n	PRISTIQ.xml:S1:4176:1	O
636	PRISTIQ.xml:S1:4178:3	O
)	PRISTIQ.xml:S1:4181:1	O
50	PRISTIQ.xml:S1:4188:2	O
mg	PRISTIQ.xml:S1:4191:2	O
(	PRISTIQ.xml:S1:4197:1	O
n	PRISTIQ.xml:S1:4198:1	O
317	PRISTIQ.xml:S1:4200:3	O
)	PRISTIQ.xml:S1:4203:1	O
100	PRISTIQ.xml:S1:4210:3	O
mg	PRISTIQ.xml:S1:4214:2	O
(	PRISTIQ.xml:S1:4220:1	O
n	PRISTIQ.xml:S1:4221:1	O
424	PRISTIQ.xml:S1:4223:3	O
)	PRISTIQ.xml:S1:4226:1	O
200	PRISTIQ.xml:S1:4233:3	O
mg	PRISTIQ.xml:S1:4237:2	O
(	PRISTIQ.xml:S1:4243:1	O
n	PRISTIQ.xml:S1:4244:1	O
307	PRISTIQ.xml:S1:4246:3	O
)	PRISTIQ.xml:S1:4249:1	O
400	PRISTIQ.xml:S1:4256:3	O
mg	PRISTIQ.xml:S1:4260:2	O
(	PRISTIQ.xml:S1:4266:1	O
n	PRISTIQ.xml:S1:4267:1	O
317	PRISTIQ.xml:S1:4269:3	O
)	PRISTIQ.xml:S1:4272:1	O

Cardiac	PRISTIQ.xml:S1:4284:7	O

disorders	PRISTIQ.xml:S1:4292:9	O

Blood	PRISTIQ.xml:S1:4316:5	B-AdverseReaction
pressure	PRISTIQ.xml:S1:4322:8	I-AdverseReaction
increased	PRISTIQ.xml:S1:4331:9	I-AdverseReaction
1	PRISTIQ.xml:S1:4344:1	O
1	PRISTIQ.xml:S1:4361:1	O
1	PRISTIQ.xml:S1:4378:1	O
2	PRISTIQ.xml:S1:4395:1	O
2	PRISTIQ.xml:S1:4412:1	O

Gastrointestinal	PRISTIQ.xml:S1:4432:16	O
disorders	PRISTIQ.xml:S1:4449:9	O

Nausea	PRISTIQ.xml:S1:4467:6	B-AdverseReaction
10	PRISTIQ.xml:S1:4492:2	O
22	PRISTIQ.xml:S1:4509:2	O
26	PRISTIQ.xml:S1:4526:2	O
36	PRISTIQ.xml:S1:4543:2	O
41	PRISTIQ.xml:S1:4560:2	O

Dry	PRISTIQ.xml:S1:4582:3	B-AdverseReaction
mouth	PRISTIQ.xml:S1:4586:5	I-AdverseReaction
9	PRISTIQ.xml:S1:4607:1	O
11	PRISTIQ.xml:S1:4624:2	O
17	PRISTIQ.xml:S1:4641:2	O
21	PRISTIQ.xml:S1:4658:2	O
25	PRISTIQ.xml:S1:4675:2	O

Constipation	PRISTIQ.xml:S1:4697:12	B-AdverseReaction
4	PRISTIQ.xml:S1:4722:1	O
9	PRISTIQ.xml:S1:4739:1	O
9	PRISTIQ.xml:S1:4756:1	O
10	PRISTIQ.xml:S1:4773:2	O
14	PRISTIQ.xml:S1:4790:2	O

Vomiting	PRISTIQ.xml:S1:4812:8	B-AdverseReaction
3	PRISTIQ.xml:S1:4837:1	O
3	PRISTIQ.xml:S1:4854:1	O
4	PRISTIQ.xml:S1:4871:1	O
6	PRISTIQ.xml:S1:4888:1	O
9	PRISTIQ.xml:S1:4905:1	O

General	PRISTIQ.xml:S1:4925:7	O
disorders	PRISTIQ.xml:S1:4933:9	O
and	PRISTIQ.xml:S1:4943:3	O
administration	PRISTIQ.xml:S1:4947:14	O
site	PRISTIQ.xml:S1:4962:4	O
conditions	PRISTIQ.xml:S1:4967:10	O

Fatigue	PRISTIQ.xml:S1:4986:7	B-AdverseReaction
4	PRISTIQ.xml:S1:5011:1	O
7	PRISTIQ.xml:S1:5028:1	O
7	PRISTIQ.xml:S1:5045:1	O
10	PRISTIQ.xml:S1:5062:2	O
11	PRISTIQ.xml:S1:5079:2	O

Chills	PRISTIQ.xml:S1:5101:6	B-AdverseReaction
1	PRISTIQ.xml:S1:5126:1	O
1	PRISTIQ.xml:S1:5143:1	O
1	PRISTIQ.xml:S1:5161:1	O
3	PRISTIQ.xml:S1:5177:1	O
4	PRISTIQ.xml:S1:5194:1	O

Feeling	PRISTIQ.xml:S1:5216:7	B-AdverseReaction
jittery	PRISTIQ.xml:S1:5224:7	I-AdverseReaction
1	PRISTIQ.xml:S1:5241:1	O
1	PRISTIQ.xml:S1:5258:1	O
2	PRISTIQ.xml:S1:5275:1	O
3	PRISTIQ.xml:S1:5292:1	O
3	PRISTIQ.xml:S1:5309:1	O

Metabolism	PRISTIQ.xml:S1:5329:10	O
and	PRISTIQ.xml:S1:5340:3	O
nutrition	PRISTIQ.xml:S1:5344:9	O
disorders	PRISTIQ.xml:S1:5354:9	O

Decreased	PRISTIQ.xml:S1:5372:9	B-AdverseReaction
appetite	PRISTIQ.xml:S1:5382:8	I-AdverseReaction
2	PRISTIQ.xml:S1:5397:1	O
5	PRISTIQ.xml:S1:5414:1	O
8	PRISTIQ.xml:S1:5431:1	O
10	PRISTIQ.xml:S1:5448:2	O
10	PRISTIQ.xml:S1:5465:2	O

Nervous	PRISTIQ.xml:S1:5485:7	O
system	PRISTIQ.xml:S1:5493:6	O
disorders	PRISTIQ.xml:S1:5500:9	O

Dizziness	PRISTIQ.xml:S1:5518:9	B-AdverseReaction
5	PRISTIQ.xml:S1:5543:1	O
13	PRISTIQ.xml:S1:5560:2	O
10	PRISTIQ.xml:S1:5577:2	O
15	PRISTIQ.xml:S1:5594:2	O
16	PRISTIQ.xml:S1:5611:2	O

Somnolence	PRISTIQ.xml:S1:5633:10	B-AdverseReaction
4	PRISTIQ.xml:S1:5658:1	O
4	PRISTIQ.xml:S1:5675:1	O
9	PRISTIQ.xml:S1:5692:1	O
12	PRISTIQ.xml:S1:5709:2	O
12	PRISTIQ.xml:S1:5726:2	O

Tremor	PRISTIQ.xml:S1:5748:6	B-AdverseReaction
2	PRISTIQ.xml:S1:5773:1	O
2	PRISTIQ.xml:S1:5790:1	O
3	PRISTIQ.xml:S1:5807:1	O
9	PRISTIQ.xml:S1:5824:1	O
9	PRISTIQ.xml:S1:5841:1	O

Disturbance	PRISTIQ.xml:S1:5863:11	B-AdverseReaction
in	PRISTIQ.xml:S1:5875:2	I-AdverseReaction
attention	PRISTIQ.xml:S1:5878:9	I-AdverseReaction
1	PRISTIQ.xml:S1:5892:1	O
1	PRISTIQ.xml:S1:5909:1	O
1	PRISTIQ.xml:S1:5925:1	O
2	PRISTIQ.xml:S1:5942:1	O
1	PRISTIQ.xml:S1:5959:1	O

Psychiatric	PRISTIQ.xml:S1:5979:11	O
disorders	PRISTIQ.xml:S1:5991:9	O

Insomnia	PRISTIQ.xml:S1:6011:8	B-AdverseReaction
6	PRISTIQ.xml:S1:6036:1	O
9	PRISTIQ.xml:S1:6053:1	O
12	PRISTIQ.xml:S1:6070:2	O
14	PRISTIQ.xml:S1:6087:2	O
15	PRISTIQ.xml:S1:6104:2	O

Anxiety	PRISTIQ.xml:S1:6126:7	B-AdverseReaction
2	PRISTIQ.xml:S1:6151:1	O
3	PRISTIQ.xml:S1:6168:1	O
5	PRISTIQ.xml:S1:6185:1	O
4	PRISTIQ.xml:S1:6202:1	O
4	PRISTIQ.xml:S1:6219:1	O

Nervousness	PRISTIQ.xml:S1:6241:11	B-AdverseReaction
1	PRISTIQ.xml:S1:6266:1	O
1	PRISTIQ.xml:S1:6284:1	O
1	PRISTIQ.xml:S1:6300:1	O
2	PRISTIQ.xml:S1:6317:1	O
2	PRISTIQ.xml:S1:6334:1	O

Abnormal	PRISTIQ.xml:S1:6356:8	B-AdverseReaction
dreams	PRISTIQ.xml:S1:6365:6	I-AdverseReaction
1	PRISTIQ.xml:S1:6381:1	O
2	PRISTIQ.xml:S1:6398:1	O
3	PRISTIQ.xml:S1:6415:1	O
2	PRISTIQ.xml:S1:6432:1	O
4	PRISTIQ.xml:S1:6449:1	O

Renal	PRISTIQ.xml:S1:6469:5	O
and	PRISTIQ.xml:S1:6475:3	O
urinary	PRISTIQ.xml:S1:6479:7	O
disorders	PRISTIQ.xml:S1:6487:9	O

Urinary	PRISTIQ.xml:S1:6505:7	B-AdverseReaction
hesitation	PRISTIQ.xml:S1:6513:10	I-AdverseReaction
0	PRISTIQ.xml:S1:6530:1	O
1	PRISTIQ.xml:S1:6548:1	O
1	PRISTIQ.xml:S1:6564:1	O
2	PRISTIQ.xml:S1:6581:1	O
2	PRISTIQ.xml:S1:6598:1	O

Respiratory	PRISTIQ.xml:S1:6618:11	O
,	PRISTIQ.xml:S1:6629:1	O
thoracic	PRISTIQ.xml:S1:6631:8	O
and	PRISTIQ.xml:S1:6640:3	O
mediastinal	PRISTIQ.xml:S1:6644:11	O
disorders	PRISTIQ.xml:S1:6656:9	O

Yawning	PRISTIQ.xml:S1:6674:7	B-AdverseReaction
1	PRISTIQ.xml:S1:6700:1	O
1	PRISTIQ.xml:S1:6716:1	O
1	PRISTIQ.xml:S1:6733:1	O
4	PRISTIQ.xml:S1:6750:1	O
3	PRISTIQ.xml:S1:6767:1	O

Skin	PRISTIQ.xml:S1:6787:4	O
and	PRISTIQ.xml:S1:6792:3	O
subcutaneous	PRISTIQ.xml:S1:6796:12	O
tissue	PRISTIQ.xml:S1:6809:6	O
disorders	PRISTIQ.xml:S1:6816:9	O

Hyperhidrosis	PRISTIQ.xml:S1:6834:13	B-AdverseReaction
4	PRISTIQ.xml:S1:6859:1	O
10	PRISTIQ.xml:S1:6876:2	O
11	PRISTIQ.xml:S1:6893:2	O
18	PRISTIQ.xml:S1:6910:2	O
21	PRISTIQ.xml:S1:6927:2	O

Special	PRISTIQ.xml:S1:6947:7	O
Senses	PRISTIQ.xml:S1:6955:6	O

Vision	PRISTIQ.xml:S1:6979:6	B-AdverseReaction
blurred	PRISTIQ.xml:S1:6986:7	I-AdverseReaction
1	PRISTIQ.xml:S1:7004:1	O
3	PRISTIQ.xml:S1:7021:1	O
4	PRISTIQ.xml:S1:7038:1	O
4	PRISTIQ.xml:S1:7055:1	O
4	PRISTIQ.xml:S1:7072:1	O

Mydriasis	PRISTIQ.xml:S1:7094:9	B-AdverseReaction
1	PRISTIQ.xml:S1:7120:1	O
2	PRISTIQ.xml:S1:7136:1	O
2	PRISTIQ.xml:S1:7153:1	O
6	PRISTIQ.xml:S1:7170:1	O
6	PRISTIQ.xml:S1:7187:1	O

Vertigo	PRISTIQ.xml:S1:7209:7	B-AdverseReaction
1	PRISTIQ.xml:S1:7234:1	O
2	PRISTIQ.xml:S1:7251:1	O
1	PRISTIQ.xml:S1:7268:1	O
5	PRISTIQ.xml:S1:7285:1	O
3	PRISTIQ.xml:S1:7302:1	O

Tinnitus	PRISTIQ.xml:S1:7324:8	B-AdverseReaction
1	PRISTIQ.xml:S1:7349:1	O
2	PRISTIQ.xml:S1:7366:1	O
1	PRISTIQ.xml:S1:7383:1	O
1	PRISTIQ.xml:S1:7400:1	O
2	PRISTIQ.xml:S1:7417:1	O

Dysgeusia	PRISTIQ.xml:S1:7439:9	B-AdverseReaction
1	PRISTIQ.xml:S1:7464:1	O
1	PRISTIQ.xml:S1:7481:1	O
1	PRISTIQ.xml:S1:7498:1	O
1	PRISTIQ.xml:S1:7515:1	O
2	PRISTIQ.xml:S1:7532:1	O

Vascular	PRISTIQ.xml:S1:7552:8	O
disorders	PRISTIQ.xml:S1:7561:9	O

Hot	PRISTIQ.xml:S1:7584:3	B-AdverseReaction
flush	PRISTIQ.xml:S1:7588:5	I-AdverseReaction
1	PRISTIQ.xml:S1:7610:1	O
1	PRISTIQ.xml:S1:7626:1	O
1	PRISTIQ.xml:S1:7643:1	O
2	PRISTIQ.xml:S1:7660:1	O
2	PRISTIQ.xml:S1:7677:1	O

Sexual	PRISTIQ.xml:S1:7711:6	O
function	PRISTIQ.xml:S1:7718:8	O
adverse	PRISTIQ.xml:S1:7727:7	O
reactions	PRISTIQ.xml:S1:7735:9	O

Table	PRISTIQ.xml:S1:7751:5	O

3	PRISTIQ.xml:S1:7757:1	O
shows	PRISTIQ.xml:S1:7759:5	O
the	PRISTIQ.xml:S1:7765:3	O
incidence	PRISTIQ.xml:S1:7769:9	O
of	PRISTIQ.xml:S1:7779:2	O
sexual	PRISTIQ.xml:S1:7782:6	B-AdverseReaction
function	PRISTIQ.xml:S1:7789:8	I-AdverseReaction
adverse	PRISTIQ.xml:S1:7798:7	I-AdverseReaction
reactions	PRISTIQ.xml:S1:7806:9	I-AdverseReaction
that	PRISTIQ.xml:S1:7816:4	O
occurred	PRISTIQ.xml:S1:7821:8	O
in	PRISTIQ.xml:S1:7830:2	O
2%	PRISTIQ.xml:S1:7836:2	O
of	PRISTIQ.xml:S1:7839:2	O
PRISTIQ	PRISTIQ.xml:S1:7842:7	O
treated	PRISTIQ.xml:S1:7850:7	O
MDD	PRISTIQ.xml:S1:7858:3	O
patients	PRISTIQ.xml:S1:7862:8	O
in	PRISTIQ.xml:S1:7871:2	O
any	PRISTIQ.xml:S1:7874:3	O
fixed	PRISTIQ.xml:S1:7878:5	O
-	PRISTIQ.xml:S1:7883:1	O
dose	PRISTIQ.xml:S1:7884:4	O
group	PRISTIQ.xml:S1:7889:5	O
(	PRISTIQ.xml:S1:7895:1	O
pre	PRISTIQ.xml:S1:7896:3	O
-	PRISTIQ.xml:S1:7899:1	O
marketing	PRISTIQ.xml:S1:7900:9	O
pooled	PRISTIQ.xml:S1:7910:6	O
8	PRISTIQ.xml:S1:7917:1	O
-	PRISTIQ.xml:S1:7918:1	O
week	PRISTIQ.xml:S1:7919:4	O
,	PRISTIQ.xml:S1:7923:1	O
placebo	PRISTIQ.xml:S1:7925:7	O
-	PRISTIQ.xml:S1:7932:1	O
controlled	PRISTIQ.xml:S1:7933:10	O
,	PRISTIQ.xml:S1:7943:1	O
fixed	PRISTIQ.xml:S1:7945:5	O
-	PRISTIQ.xml:S1:7951:1	O
dose	PRISTIQ.xml:S1:7952:4	O
,	PRISTIQ.xml:S1:7956:1	O
clinical	PRISTIQ.xml:S1:7958:8	O
studies	PRISTIQ.xml:S1:7967:7	O
)	PRISTIQ.xml:S1:7974:1	O
.	PRISTIQ.xml:S1:7975:1	O

Table	PRISTIQ.xml:S1:7981:5	O
3	PRISTIQ.xml:S1:7987:1	O
:	PRISTIQ.xml:S1:7988:1	O
Sexual	PRISTIQ.xml:S1:7990:6	B-AdverseReaction
Function	PRISTIQ.xml:S1:7997:8	I-AdverseReaction
Adverse	PRISTIQ.xml:S1:8006:7	I-AdverseReaction
Reactions	PRISTIQ.xml:S1:8014:9	I-AdverseReaction
(	PRISTIQ.xml:S1:8024:1	O
2%	PRISTIQ.xml:S1:8028:2	O
in	PRISTIQ.xml:S1:8031:2	O
Men	PRISTIQ.xml:S1:8034:3	O
or	PRISTIQ.xml:S1:8038:2	O
Women	PRISTIQ.xml:S1:8041:5	O
in	PRISTIQ.xml:S1:8047:2	O
any	PRISTIQ.xml:S1:8050:3	O
PRISTIQ	PRISTIQ.xml:S1:8054:7	O
Group	PRISTIQ.xml:S1:8062:5	O
)	PRISTIQ.xml:S1:8067:1	O
During	PRISTIQ.xml:S1:8069:6	O
the	PRISTIQ.xml:S1:8076:3	O
On	PRISTIQ.xml:S1:8080:2	O
-	PRISTIQ.xml:S1:8082:1	O
Therapy	PRISTIQ.xml:S1:8083:7	O
Period	PRISTIQ.xml:S1:8091:6	O

PRISTIQ	PRISTIQ.xml:S1:8141:7	O

Placebo	PRISTIQ.xml:S1:8184:7	O
(	PRISTIQ.xml:S1:8191:1	O
n	PRISTIQ.xml:S1:8192:1	O
239	PRISTIQ.xml:S1:8194:3	O
)	PRISTIQ.xml:S1:8197:1	O
50	PRISTIQ.xml:S1:8202:2	O
mg	PRISTIQ.xml:S1:8205:2	O
(	PRISTIQ.xml:S1:8207:1	O
n	PRISTIQ.xml:S1:8208:1	O
108	PRISTIQ.xml:S1:8210:3	O
)	PRISTIQ.xml:S1:8213:1	O
100	PRISTIQ.xml:S1:8220:3	O
mg	PRISTIQ.xml:S1:8224:2	O
(	PRISTIQ.xml:S1:8226:1	O
n	PRISTIQ.xml:S1:8227:1	O
157	PRISTIQ.xml:S1:8229:3	O
)	PRISTIQ.xml:S1:8232:1	O
200	PRISTIQ.xml:S1:8238:3	O
mg	PRISTIQ.xml:S1:8242:2	O
(	PRISTIQ.xml:S1:8244:1	O
n	PRISTIQ.xml:S1:8245:1	O
131	PRISTIQ.xml:S1:8247:3	O
)	PRISTIQ.xml:S1:8250:1	O
400	PRISTIQ.xml:S1:8256:3	O
mg	PRISTIQ.xml:S1:8260:2	O
(	PRISTIQ.xml:S1:8262:1	O
n	PRISTIQ.xml:S1:8263:1	O
154	PRISTIQ.xml:S1:8265:3	O
)	PRISTIQ.xml:S1:8268:1	O

Men	PRISTIQ.xml:S1:8277:3	O
only	PRISTIQ.xml:S1:8281:4	O

Anorgasmia	PRISTIQ.xml:S1:8304:10	B-AdverseReaction
0	PRISTIQ.xml:S1:8324:1	O
0	PRISTIQ.xml:S1:8342:1	O
3	PRISTIQ.xml:S1:8360:1	O
5	PRISTIQ.xml:S1:8378:1	O
8	PRISTIQ.xml:S1:8396:1	O

Libido	PRISTIQ.xml:S1:8419:6	B-AdverseReaction
decreased	PRISTIQ.xml:S1:8426:9	I-AdverseReaction
1	PRISTIQ.xml:S1:8439:1	O
4	PRISTIQ.xml:S1:8457:1	O
5	PRISTIQ.xml:S1:8475:1	O
6	PRISTIQ.xml:S1:8493:1	O
3	PRISTIQ.xml:S1:8511:1	O

Orgasm	PRISTIQ.xml:S1:8534:6	B-AdverseReaction
abnormal	PRISTIQ.xml:S1:8541:8	I-AdverseReaction
0	PRISTIQ.xml:S1:8554:1	O
0	PRISTIQ.xml:S1:8572:1	O
1	PRISTIQ.xml:S1:8590:1	O
2	PRISTIQ.xml:S1:8608:1	O
3	PRISTIQ.xml:S1:8626:1	O

Ejaculation	PRISTIQ.xml:S1:8649:11	B-AdverseReaction
delayed	PRISTIQ.xml:S1:8661:7	I-AdverseReaction
1	PRISTIQ.xml:S1:8673:1	O
1	PRISTIQ.xml:S1:8690:1	O
5	PRISTIQ.xml:S1:8708:1	O
7	PRISTIQ.xml:S1:8726:1	O
6	PRISTIQ.xml:S1:8744:1	O

Erectile	PRISTIQ.xml:S1:8767:8	B-AdverseReaction
dysfunction	PRISTIQ.xml:S1:8776:11	I-AdverseReaction
1	PRISTIQ.xml:S1:8791:1	O
3	PRISTIQ.xml:S1:8809:1	O
6	PRISTIQ.xml:S1:8827:1	O
8	PRISTIQ.xml:S1:8845:1	O
11	PRISTIQ.xml:S1:8863:2	O

Ejaculation	PRISTIQ.xml:S1:8886:11	B-AdverseReaction
disorder	PRISTIQ.xml:S1:8898:8	I-AdverseReaction
0	PRISTIQ.xml:S1:8910:1	O
0	PRISTIQ.xml:S1:8928:1	O
1	PRISTIQ.xml:S1:8946:1	O
2	PRISTIQ.xml:S1:8964:1	O
5	PRISTIQ.xml:S1:8982:1	O

Ejaculation	PRISTIQ.xml:S1:9005:11	B-AdverseReaction
failure	PRISTIQ.xml:S1:9017:7	I-AdverseReaction
0	PRISTIQ.xml:S1:9028:1	O
1	PRISTIQ.xml:S1:9046:1	O
0	PRISTIQ.xml:S1:9064:1	O
2	PRISTIQ.xml:S1:9082:1	O
2	PRISTIQ.xml:S1:9100:1	O

Sexual	PRISTIQ.xml:S1:9123:6	B-AdverseReaction
dysfunction	PRISTIQ.xml:S1:9130:11	I-AdverseReaction
0	PRISTIQ.xml:S1:9145:1	O
1	PRISTIQ.xml:S1:9163:1	O
0	PRISTIQ.xml:S1:9181:1	O
0	PRISTIQ.xml:S1:9199:1	O
2	PRISTIQ.xml:S1:9217:1	O

PRISTIQ	PRISTIQ.xml:S1:9278:7	O

Placebo	PRISTIQ.xml:S1:9321:7	O
(	PRISTIQ.xml:S1:9328:1	O
n	PRISTIQ.xml:S1:9329:1	O
397	PRISTIQ.xml:S1:9331:3	O
)	PRISTIQ.xml:S1:9334:1	O
50	PRISTIQ.xml:S1:9339:2	O
mg	PRISTIQ.xml:S1:9342:2	O
(	PRISTIQ.xml:S1:9344:1	O
n	PRISTIQ.xml:S1:9345:1	O
209	PRISTIQ.xml:S1:9347:3	O
)	PRISTIQ.xml:S1:9350:1	O
100	PRISTIQ.xml:S1:9357:3	O
mg	PRISTIQ.xml:S1:9361:2	O
(	PRISTIQ.xml:S1:9363:1	O
n	PRISTIQ.xml:S1:9364:1	O
267	PRISTIQ.xml:S1:9366:3	O
)	PRISTIQ.xml:S1:9369:1	O
200	PRISTIQ.xml:S1:9375:3	O
mg	PRISTIQ.xml:S1:9379:2	O
(	PRISTIQ.xml:S1:9381:1	O
n	PRISTIQ.xml:S1:9382:1	O
176	PRISTIQ.xml:S1:9384:3	O
)	PRISTIQ.xml:S1:9387:1	O
400	PRISTIQ.xml:S1:9393:3	O
mg	PRISTIQ.xml:S1:9397:2	O
(	PRISTIQ.xml:S1:9399:1	O
n	PRISTIQ.xml:S1:9400:1	O
163	PRISTIQ.xml:S1:9402:3	O
)	PRISTIQ.xml:S1:9405:1	O

Women	PRISTIQ.xml:S1:9416:5	O
only	PRISTIQ.xml:S1:9422:4	O

Anorgasmia	PRISTIQ.xml:S1:9441:10	B-AdverseReaction
0	PRISTIQ.xml:S1:9461:1	O
1	PRISTIQ.xml:S1:9479:1	O
1	PRISTIQ.xml:S1:9497:1	O
0	PRISTIQ.xml:S1:9515:1	O
3	PRISTIQ.xml:S1:9533:1	O

Other	PRISTIQ.xml:S1:9568:5	O
adverse	PRISTIQ.xml:S1:9574:7	O
reactions	PRISTIQ.xml:S1:9582:9	O
observed	PRISTIQ.xml:S1:9592:8	O
in	PRISTIQ.xml:S1:9601:2	O
premarketing	PRISTIQ.xml:S1:9604:12	O
and	PRISTIQ.xml:S1:9617:3	O
postmarketing	PRISTIQ.xml:S1:9621:13	O
clinical	PRISTIQ.xml:S1:9635:8	O
studies	PRISTIQ.xml:S1:9644:7	O

Other	PRISTIQ.xml:S1:9658:5	O

infrequent	PRISTIQ.xml:S1:9664:10	O
adverse	PRISTIQ.xml:S1:9675:7	O
reactions	PRISTIQ.xml:S1:9683:9	O
,	PRISTIQ.xml:S1:9692:1	O
not	PRISTIQ.xml:S1:9694:3	O
described	PRISTIQ.xml:S1:9698:9	O
elsewhere	PRISTIQ.xml:S1:9708:9	O
in	PRISTIQ.xml:S1:9718:2	O
the	PRISTIQ.xml:S1:9721:3	O
label	PRISTIQ.xml:S1:9725:5	O
,	PRISTIQ.xml:S1:9730:1	O
occurring	PRISTIQ.xml:S1:9732:9	O
at	PRISTIQ.xml:S1:9742:2	O
an	PRISTIQ.xml:S1:9745:2	O
incidence	PRISTIQ.xml:S1:9748:9	O
of	PRISTIQ.xml:S1:9758:2	O
2%	PRISTIQ.xml:S1:9763:2	O
in	PRISTIQ.xml:S1:9766:2	O
MDD	PRISTIQ.xml:S1:9769:3	O
patients	PRISTIQ.xml:S1:9773:8	O
treated	PRISTIQ.xml:S1:9782:7	O
with	PRISTIQ.xml:S1:9790:4	O
PRISTIQ	PRISTIQ.xml:S1:9795:7	O
were	PRISTIQ.xml:S1:9803:4	O
:	PRISTIQ.xml:S1:9807:1	O

Cardiac	PRISTIQ.xml:S1:9817:7	O
disorders	PRISTIQ.xml:S1:9825:9	O
-	PRISTIQ.xml:S1:9838:1	O
Tachycardia	PRISTIQ.xml:S1:9840:11	B-AdverseReaction
.	PRISTIQ.xml:S1:9851:1	O

General	PRISTIQ.xml:S1:9861:7	O
disorders	PRISTIQ.xml:S1:9869:9	O
and	PRISTIQ.xml:S1:9879:3	O
administration	PRISTIQ.xml:S1:9883:14	O
site	PRISTIQ.xml:S1:9898:4	O
conditions	PRISTIQ.xml:S1:9903:10	O
-	PRISTIQ.xml:S1:9917:1	O
Asthenia	PRISTIQ.xml:S1:9919:8	B-AdverseReaction
.	PRISTIQ.xml:S1:9927:1	O

Investigations	PRISTIQ.xml:S1:9937:14	O
-	PRISTIQ.xml:S1:9952:1	O
Weight	PRISTIQ.xml:S1:9957:6	B-AdverseReaction
increased	PRISTIQ.xml:S1:9964:9	I-AdverseReaction
,	PRISTIQ.xml:S1:9973:1	O
liver	PRISTIQ.xml:S1:9975:5	B-AdverseReaction
function	PRISTIQ.xml:S1:9981:8	I-AdverseReaction
test	PRISTIQ.xml:S1:9990:4	I-AdverseReaction
abnormal	PRISTIQ.xml:S1:9995:8	I-AdverseReaction
,	PRISTIQ.xml:S1:10003:1	O
blood	PRISTIQ.xml:S1:10005:5	B-AdverseReaction
prolactin	PRISTIQ.xml:S1:10011:9	I-AdverseReaction
increased	PRISTIQ.xml:S1:10021:9	I-AdverseReaction
.	PRISTIQ.xml:S1:10030:1	O

Musculoskeletal	PRISTIQ.xml:S1:10040:15	O
and	PRISTIQ.xml:S1:10056:3	O
connective	PRISTIQ.xml:S1:10060:10	O
tissue	PRISTIQ.xml:S1:10071:6	O
disorders	PRISTIQ.xml:S1:10078:9	O
-	PRISTIQ.xml:S1:10088:1	O
Musculoskeletal	PRISTIQ.xml:S1:10093:15	B-AdverseReaction
stiffness	PRISTIQ.xml:S1:10109:9	I-AdverseReaction
.	PRISTIQ.xml:S1:10118:1	O

Nervous	PRISTIQ.xml:S1:10128:7	O
system	PRISTIQ.xml:S1:10136:6	O
disorders	PRISTIQ.xml:S1:10143:9	O
-	PRISTIQ.xml:S1:10153:1	O
Syncope	PRISTIQ.xml:S1:10158:7	B-AdverseReaction
,	PRISTIQ.xml:S1:10165:1	O
convulsion	PRISTIQ.xml:S1:10167:10	B-AdverseReaction
,	PRISTIQ.xml:S1:10177:1	O
dystonia	PRISTIQ.xml:S1:10179:8	B-AdverseReaction
.	PRISTIQ.xml:S1:10187:1	O

Psychiatric	PRISTIQ.xml:S1:10197:11	O
disorders	PRISTIQ.xml:S1:10209:9	O
-	PRISTIQ.xml:S1:10219:1	O
Depersonalization	PRISTIQ.xml:S1:10224:17	B-AdverseReaction
,	PRISTIQ.xml:S1:10241:1	O
bruxism	PRISTIQ.xml:S1:10243:7	B-AdverseReaction
.	PRISTIQ.xml:S1:10250:1	O

Renal	PRISTIQ.xml:S1:10260:5	O
and	PRISTIQ.xml:S1:10266:3	O
urinary	PRISTIQ.xml:S1:10270:7	O
disorders	PRISTIQ.xml:S1:10278:9	O
-	PRISTIQ.xml:S1:10291:1	O
Urinary	PRISTIQ.xml:S1:10293:7	B-AdverseReaction
retention	PRISTIQ.xml:S1:10301:9	I-AdverseReaction
.	PRISTIQ.xml:S1:10310:1	O

Skin	PRISTIQ.xml:S1:10320:4	O
and	PRISTIQ.xml:S1:10325:3	O
subcutaneous	PRISTIQ.xml:S1:10329:12	O
tissue	PRISTIQ.xml:S1:10342:6	O
disorders	PRISTIQ.xml:S1:10349:9	O
-	PRISTIQ.xml:S1:10360:1	O
Rash	PRISTIQ.xml:S1:10363:4	B-AdverseReaction
,	PRISTIQ.xml:S1:10367:1	O
alopecia	PRISTIQ.xml:S1:10369:8	B-AdverseReaction
,	PRISTIQ.xml:S1:10377:1	O
photosensitivity	PRISTIQ.xml:S1:10379:16	B-AdverseReaction
reaction	PRISTIQ.xml:S1:10396:8	O
,	PRISTIQ.xml:S1:10404:1	O
angioedema	PRISTIQ.xml:S1:10406:10	B-AdverseReaction
.	PRISTIQ.xml:S1:10416:1	O

In	PRISTIQ.xml:S1:10422:2	O
clinical	PRISTIQ.xml:S1:10425:8	O
studies	PRISTIQ.xml:S1:10434:7	O
,	PRISTIQ.xml:S1:10441:1	O
there	PRISTIQ.xml:S1:10443:5	O
were	PRISTIQ.xml:S1:10449:4	O
uncommon	PRISTIQ.xml:S1:10454:8	O
reports	PRISTIQ.xml:S1:10463:7	O
of	PRISTIQ.xml:S1:10471:2	O
ischemic	PRISTIQ.xml:S1:10474:8	B-AdverseReaction
cardiac	PRISTIQ.xml:S1:10483:7	I-AdverseReaction
adverse	PRISTIQ.xml:S1:10491:7	I-AdverseReaction
reactions	PRISTIQ.xml:S1:10499:9	I-AdverseReaction
,	PRISTIQ.xml:S1:10508:1	O
including	PRISTIQ.xml:S1:10510:9	O
myocardial	PRISTIQ.xml:S1:10520:10	B-AdverseReaction
ischemia	PRISTIQ.xml:S1:10531:8	I-AdverseReaction
,	PRISTIQ.xml:S1:10539:1	O
myocardial	PRISTIQ.xml:S1:10541:10	B-AdverseReaction
infarction	PRISTIQ.xml:S1:10552:10	I-AdverseReaction
,	PRISTIQ.xml:S1:10562:1	O
and	PRISTIQ.xml:S1:10564:3	O
coronary	PRISTIQ.xml:S1:10568:8	B-AdverseReaction
occlusion	PRISTIQ.xml:S1:10577:9	I-AdverseReaction
requiring	PRISTIQ.xml:S1:10587:9	O
revascularization	PRISTIQ.xml:S1:10597:17	O
;	PRISTIQ.xml:S1:10614:1	O
these	PRISTIQ.xml:S1:10616:5	O
patients	PRISTIQ.xml:S1:10622:8	O
had	PRISTIQ.xml:S1:10631:3	O
multiple	PRISTIQ.xml:S1:10635:8	O
underlying	PRISTIQ.xml:S1:10644:10	O
cardiac	PRISTIQ.xml:S1:10655:7	O
risk	PRISTIQ.xml:S1:10663:4	O
factors	PRISTIQ.xml:S1:10668:7	O
.	PRISTIQ.xml:S1:10675:1	O

More	PRISTIQ.xml:S1:10677:4	O
patients	PRISTIQ.xml:S1:10682:8	O
experienced	PRISTIQ.xml:S1:10691:11	O
these	PRISTIQ.xml:S1:10703:5	O
events	PRISTIQ.xml:S1:10709:6	O
during	PRISTIQ.xml:S1:10716:6	O
PRISTIQ	PRISTIQ.xml:S1:10723:7	O
treatment	PRISTIQ.xml:S1:10731:9	O
as	PRISTIQ.xml:S1:10741:2	O
compared	PRISTIQ.xml:S1:10744:8	O
to	PRISTIQ.xml:S1:10753:2	O
placebo	PRISTIQ.xml:S1:10756:7	O
.	PRISTIQ.xml:S1:10763:1	O

Laboratory	PRISTIQ.xml:S1:10775:10	O
,	PRISTIQ.xml:S1:10785:1	O
ECG	PRISTIQ.xml:S1:10787:3	O
and	PRISTIQ.xml:S1:10791:3	O
vital	PRISTIQ.xml:S1:10795:5	O
sign	PRISTIQ.xml:S1:10801:4	O
changes	PRISTIQ.xml:S1:10806:7	O
observed	PRISTIQ.xml:S1:10814:8	O
in	PRISTIQ.xml:S1:10823:2	O
MDD	PRISTIQ.xml:S1:10826:3	O
clinical	PRISTIQ.xml:S1:10830:8	O
studies	PRISTIQ.xml:S1:10839:7	O

The	PRISTIQ.xml:S1:10855:3	O
following	PRISTIQ.xml:S1:10859:9	O
changes	PRISTIQ.xml:S1:10869:7	O
were	PRISTIQ.xml:S1:10877:4	O
observed	PRISTIQ.xml:S1:10882:8	O
in	PRISTIQ.xml:S1:10891:2	O
pre	PRISTIQ.xml:S1:10894:3	O
-	PRISTIQ.xml:S1:10897:1	O
marketing	PRISTIQ.xml:S1:10898:9	O
placebo	PRISTIQ.xml:S1:10908:7	O
-	PRISTIQ.xml:S1:10915:1	O
controlled	PRISTIQ.xml:S1:10916:10	O
,	PRISTIQ.xml:S1:10926:1	O
short	PRISTIQ.xml:S1:10928:5	O
-	PRISTIQ.xml:S1:10933:1	O
term	PRISTIQ.xml:S1:10934:4	O
MDD	PRISTIQ.xml:S1:10939:3	O
studies	PRISTIQ.xml:S1:10943:7	O
with	PRISTIQ.xml:S1:10951:4	O
PRISTIQ	PRISTIQ.xml:S1:10956:7	O
.	PRISTIQ.xml:S1:10963:1	O

Lipids	PRISTIQ.xml:S1:10975:6	O

Elevations	PRISTIQ.xml:S1:10990:10	B-AdverseReaction
in	PRISTIQ.xml:S1:11001:2	I-AdverseReaction
fasting	PRISTIQ.xml:S1:11004:7	I-AdverseReaction
serum	PRISTIQ.xml:S1:11012:5	I-AdverseReaction
total	PRISTIQ.xml:S1:11018:5	I-AdverseReaction
cholesterol	PRISTIQ.xml:S1:11024:11	I-AdverseReaction
,	PRISTIQ.xml:S1:11035:1	O
LDL	PRISTIQ.xml:S1:11037:3	I-AdverseReaction
(	PRISTIQ.xml:S1:11041:1	O
low	PRISTIQ.xml:S1:11042:3	I-AdverseReaction
density	PRISTIQ.xml:S1:11046:7	I-AdverseReaction
lipoproteins	PRISTIQ.xml:S1:11054:12	I-AdverseReaction
)	PRISTIQ.xml:S1:11066:1	O
cholesterol	PRISTIQ.xml:S1:11068:11	I-AdverseReaction
,	PRISTIQ.xml:S1:11079:1	O
and	PRISTIQ.xml:S1:11081:3	O
triglycerides	PRISTIQ.xml:S1:11085:13	I-AdverseReaction
occurred	PRISTIQ.xml:S1:11099:8	O
in	PRISTIQ.xml:S1:11108:2	O
the	PRISTIQ.xml:S1:11111:3	O
controlled	PRISTIQ.xml:S1:11115:10	O
studies	PRISTIQ.xml:S1:11126:7	O
.	PRISTIQ.xml:S1:11133:1	O

Some	PRISTIQ.xml:S1:11135:4	O
of	PRISTIQ.xml:S1:11140:2	O
these	PRISTIQ.xml:S1:11143:5	O
abnormalities	PRISTIQ.xml:S1:11149:13	O
were	PRISTIQ.xml:S1:11163:4	O
considered	PRISTIQ.xml:S1:11168:10	O
potentially	PRISTIQ.xml:S1:11179:11	O
clinically	PRISTIQ.xml:S1:11191:10	O
significant	PRISTIQ.xml:S1:11202:11	O
.	PRISTIQ.xml:S1:11213:1	O

The	PRISTIQ.xml:S1:11219:3	O
percentage	PRISTIQ.xml:S1:11223:10	O
of	PRISTIQ.xml:S1:11234:2	O
patients	PRISTIQ.xml:S1:11237:8	O
who	PRISTIQ.xml:S1:11246:3	O
exceeded	PRISTIQ.xml:S1:11250:8	O
a	PRISTIQ.xml:S1:11259:1	O
predetermined	PRISTIQ.xml:S1:11261:13	O
threshold	PRISTIQ.xml:S1:11275:9	O
value	PRISTIQ.xml:S1:11285:5	O
is	PRISTIQ.xml:S1:11291:2	O
shown	PRISTIQ.xml:S1:11294:5	O
in	PRISTIQ.xml:S1:11300:2	O
Table	PRISTIQ.xml:S1:11303:5	O
4	PRISTIQ.xml:S1:11309:1	O
.	PRISTIQ.xml:S1:11310:1	O

Table	PRISTIQ.xml:S1:11316:5	O
4	PRISTIQ.xml:S1:11322:1	O
:	PRISTIQ.xml:S1:11323:1	O
Incidence	PRISTIQ.xml:S1:11325:9	O
(	PRISTIQ.xml:S1:11335:1	O
)	PRISTIQ.xml:S1:11337:1	O
of	PRISTIQ.xml:S1:11339:2	O
Patients	PRISTIQ.xml:S1:11342:8	O
With	PRISTIQ.xml:S1:11351:4	O
Lipid	PRISTIQ.xml:S1:11356:5	B-AdverseReaction
Abnormalities	PRISTIQ.xml:S1:11362:13	I-AdverseReaction
of	PRISTIQ.xml:S1:11376:2	O
Potential	PRISTIQ.xml:S1:11379:9	O
Clinical	PRISTIQ.xml:S1:11389:8	O
Significance	PRISTIQ.xml:S1:11398:12	O

PRISTIQ	PRISTIQ.xml:S1:11465:7	O

Placebo	PRISTIQ.xml:S1:11516:7	O
50	PRISTIQ.xml:S1:11531:2	O
mg	PRISTIQ.xml:S1:11534:2	O
100	PRISTIQ.xml:S1:11545:3	O
mg	PRISTIQ.xml:S1:11549:2	O
200	PRISTIQ.xml:S1:11559:3	O
mg	PRISTIQ.xml:S1:11563:2	O
400	PRISTIQ.xml:S1:11573:3	O
mg	PRISTIQ.xml:S1:11577:2	O

Total	PRISTIQ.xml:S1:11592:5	B-AdverseReaction

Cholesterol	PRISTIQ.xml:S1:11598:11	I-AdverseReaction
(	PRISTIQ.xml:S1:11610:1	O
Increase	PRISTIQ.xml:S1:11611:8	O
of	PRISTIQ.xml:S1:11620:2	O
50	PRISTIQ.xml:S1:11626:2	O
mg	PRISTIQ.xml:S1:11629:2	O
dl	PRISTIQ.xml:S1:11632:2	O
and	PRISTIQ.xml:S1:11635:3	O
an	PRISTIQ.xml:S1:11639:2	O
absolute	PRISTIQ.xml:S1:11642:8	O
value	PRISTIQ.xml:S1:11651:5	O
of	PRISTIQ.xml:S1:11657:2	O
261	PRISTIQ.xml:S1:11663:3	I-AdverseReaction
mg	PRISTIQ.xml:S1:11667:2	I-AdverseReaction
dl	PRISTIQ.xml:S1:11670:2	I-AdverseReaction
)	PRISTIQ.xml:S1:11672:1	O
2	PRISTIQ.xml:S1:11677:1	O
3	PRISTIQ.xml:S1:11692:1	O
4	PRISTIQ.xml:S1:11706:1	O
4	PRISTIQ.xml:S1:11720:1	O
10	PRISTIQ.xml:S1:11734:2	O

LDL	PRISTIQ.xml:S1:11751:3	B-AdverseReaction
Cholesterol	PRISTIQ.xml:S1:11755:11	I-AdverseReaction
(	PRISTIQ.xml:S1:11767:1	O
Increase	PRISTIQ.xml:S1:11768:8	O
50	PRISTIQ.xml:S1:11780:2	O
mg	PRISTIQ.xml:S1:11783:2	O
dl	PRISTIQ.xml:S1:11786:2	O
and	PRISTIQ.xml:S1:11789:3	O
an	PRISTIQ.xml:S1:11793:2	O
absolute	PRISTIQ.xml:S1:11796:8	O
value	PRISTIQ.xml:S1:11805:5	O
of	PRISTIQ.xml:S1:11811:2	O
190	PRISTIQ.xml:S1:11817:3	I-AdverseReaction
mg	PRISTIQ.xml:S1:11821:2	I-AdverseReaction
dl	PRISTIQ.xml:S1:11824:2	I-AdverseReaction
)	PRISTIQ.xml:S1:11826:1	O
0	PRISTIQ.xml:S1:11831:1	O
1	PRISTIQ.xml:S1:11846:1	O
0	PRISTIQ.xml:S1:11860:1	O
1	PRISTIQ.xml:S1:11874:1	O
2	PRISTIQ.xml:S1:11888:1	O

Triglycerides	PRISTIQ.xml:S1:11905:13	B-AdverseReaction
,	PRISTIQ.xml:S1:11918:1	I-AdverseReaction
fasting	PRISTIQ.xml:S1:11920:7	I-AdverseReaction
(	PRISTIQ.xml:S1:11928:1	O
Fasting	PRISTIQ.xml:S1:11929:7	O
:	PRISTIQ.xml:S1:11936:1	O
327	PRISTIQ.xml:S1:11941:3	I-AdverseReaction
mg	PRISTIQ.xml:S1:11945:2	I-AdverseReaction
dl	PRISTIQ.xml:S1:11948:2	I-AdverseReaction
)	PRISTIQ.xml:S1:11950:1	O
3	PRISTIQ.xml:S1:11955:1	O
2	PRISTIQ.xml:S1:11970:1	O
1	PRISTIQ.xml:S1:11984:1	O
4	PRISTIQ.xml:S1:11998:1	O
6	PRISTIQ.xml:S1:12012:1	O

Proteinuria	PRISTIQ.xml:S1:12045:11	O

Proteinuria	PRISTIQ.xml:S1:12065:11	B-AdverseReaction

,	PRISTIQ.xml:S1:12076:1	O
greater	PRISTIQ.xml:S1:12078:7	O
than	PRISTIQ.xml:S1:12086:4	O
or	PRISTIQ.xml:S1:12091:2	O
equal	PRISTIQ.xml:S1:12094:5	O
to	PRISTIQ.xml:S1:12100:2	O
trace	PRISTIQ.xml:S1:12103:5	O
,	PRISTIQ.xml:S1:12108:1	O
was	PRISTIQ.xml:S1:12110:3	O
observed	PRISTIQ.xml:S1:12114:8	O
in	PRISTIQ.xml:S1:12123:2	O
the	PRISTIQ.xml:S1:12126:3	O
pre	PRISTIQ.xml:S1:12130:3	O
-	PRISTIQ.xml:S1:12133:1	O
marketing	PRISTIQ.xml:S1:12134:9	O
fixed	PRISTIQ.xml:S1:12144:5	O
-	PRISTIQ.xml:S1:12149:1	O
dose	PRISTIQ.xml:S1:12150:4	O
controlled	PRISTIQ.xml:S1:12155:10	O
studies	PRISTIQ.xml:S1:12166:7	O
(	PRISTIQ.xml:S1:12174:1	O
see	PRISTIQ.xml:S1:12175:3	O
Table	PRISTIQ.xml:S1:12180:5	O
5	PRISTIQ.xml:S1:12186:1	O
)	PRISTIQ.xml:S1:12189:1	O
.	PRISTIQ.xml:S1:12190:1	O

This	PRISTIQ.xml:S1:12192:4	O
proteinuria	PRISTIQ.xml:S1:12197:11	B-AdverseReaction
was	PRISTIQ.xml:S1:12209:3	O
not	PRISTIQ.xml:S1:12213:3	B-Negation
associated	PRISTIQ.xml:S1:12217:10	O
with	PRISTIQ.xml:S1:12228:4	O
increases	PRISTIQ.xml:S1:12233:9	B-AdverseReaction
in	PRISTIQ.xml:S1:12243:2	I-AdverseReaction
BUN	PRISTIQ.xml:S1:12246:3	I-AdverseReaction
or	PRISTIQ.xml:S1:12250:2	O
creatinine	PRISTIQ.xml:S1:12253:10	I-AdverseReaction
and	PRISTIQ.xml:S1:12264:3	O
was	PRISTIQ.xml:S1:12268:3	O
generally	PRISTIQ.xml:S1:12272:9	O
transient	PRISTIQ.xml:S1:12282:9	B-Severity
.	PRISTIQ.xml:S1:12291:1	O

Table	PRISTIQ.xml:S1:12297:5	O
5	PRISTIQ.xml:S1:12303:1	O
:	PRISTIQ.xml:S1:12304:1	O
Incidence	PRISTIQ.xml:S1:12306:9	O
(	PRISTIQ.xml:S1:12316:1	O
)	PRISTIQ.xml:S1:12318:1	O
of	PRISTIQ.xml:S1:12320:2	O
Patients	PRISTIQ.xml:S1:12323:8	O
with	PRISTIQ.xml:S1:12332:4	O
Proteinuria	PRISTIQ.xml:S1:12337:11	B-AdverseReaction
in	PRISTIQ.xml:S1:12349:2	O
the	PRISTIQ.xml:S1:12352:3	O
Fixed	PRISTIQ.xml:S1:12356:5	O
-	PRISTIQ.xml:S1:12361:1	O
dose	PRISTIQ.xml:S1:12362:4	O
Clinical	PRISTIQ.xml:S1:12367:8	O
Studies	PRISTIQ.xml:S1:12376:7	O

PRISTIQ	PRISTIQ.xml:S1:12426:7	O

Placebo	PRISTIQ.xml:S1:12467:7	O
50	PRISTIQ.xml:S1:12484:2	O
mg	PRISTIQ.xml:S1:12487:2	O
100	PRISTIQ.xml:S1:12501:3	O
mg	PRISTIQ.xml:S1:12505:2	O
200	PRISTIQ.xml:S1:12518:3	O
mg	PRISTIQ.xml:S1:12522:2	O
400	PRISTIQ.xml:S1:12535:3	O
mg	PRISTIQ.xml:S1:12539:2	O

Proteinuria	PRISTIQ.xml:S1:12557:11	B-AdverseReaction

4	PRISTIQ.xml:S1:12578:1	O
6	PRISTIQ.xml:S1:12595:1	O
8	PRISTIQ.xml:S1:12612:1	O
5	PRISTIQ.xml:S1:12629:1	O
7	PRISTIQ.xml:S1:12646:1	O

Vital	PRISTIQ.xml:S1:12682:5	O
sign	PRISTIQ.xml:S1:12688:4	O
changes	PRISTIQ.xml:S1:12693:7	O

Table	PRISTIQ.xml:S1:12709:5	O

6	PRISTIQ.xml:S1:12715:1	O
summarizes	PRISTIQ.xml:S1:12717:10	O
the	PRISTIQ.xml:S1:12728:3	O
changes	PRISTIQ.xml:S1:12732:7	O
that	PRISTIQ.xml:S1:12740:4	O
were	PRISTIQ.xml:S1:12745:4	O
observed	PRISTIQ.xml:S1:12750:8	O
in	PRISTIQ.xml:S1:12759:2	O
placebo	PRISTIQ.xml:S1:12762:7	O
-	PRISTIQ.xml:S1:12769:1	O
controlled	PRISTIQ.xml:S1:12770:10	O
,	PRISTIQ.xml:S1:12780:1	O
short	PRISTIQ.xml:S1:12782:5	O
-	PRISTIQ.xml:S1:12787:1	O
term	PRISTIQ.xml:S1:12788:4	O
,	PRISTIQ.xml:S1:12792:1	O
pre	PRISTIQ.xml:S1:12794:3	O
-	PRISTIQ.xml:S1:12797:1	O
marketing	PRISTIQ.xml:S1:12798:9	O
studies	PRISTIQ.xml:S1:12808:7	O
with	PRISTIQ.xml:S1:12816:4	O
PRISTIQ	PRISTIQ.xml:S1:12821:7	O
in	PRISTIQ.xml:S1:12829:2	O
patients	PRISTIQ.xml:S1:12832:8	O
with	PRISTIQ.xml:S1:12841:4	O
MDD	PRISTIQ.xml:S1:12846:3	O
(	PRISTIQ.xml:S1:12850:1	O
doses	PRISTIQ.xml:S1:12851:5	O
50	PRISTIQ.xml:S1:12857:2	O
to	PRISTIQ.xml:S1:12860:2	O
400	PRISTIQ.xml:S1:12863:3	O
mg	PRISTIQ.xml:S1:12867:2	O
)	PRISTIQ.xml:S1:12869:1	O
.	PRISTIQ.xml:S1:12870:1	O

Table	PRISTIQ.xml:S1:12876:5	O
6	PRISTIQ.xml:S1:12882:1	O
:	PRISTIQ.xml:S1:12883:1	O
Mean	PRISTIQ.xml:S1:12885:4	O
Changes	PRISTIQ.xml:S1:12890:7	O
in	PRISTIQ.xml:S1:12898:2	O
Vital	PRISTIQ.xml:S1:12901:5	O
Signs	PRISTIQ.xml:S1:12907:5	O
at	PRISTIQ.xml:S1:12913:2	O
Final	PRISTIQ.xml:S1:12916:5	O
on	PRISTIQ.xml:S1:12922:2	O
Therapy	PRISTIQ.xml:S1:12925:7	O
for	PRISTIQ.xml:S1:12933:3	O
All	PRISTIQ.xml:S1:12937:3	O
Short	PRISTIQ.xml:S1:12941:5	O
-	PRISTIQ.xml:S1:12946:1	O
term	PRISTIQ.xml:S1:12947:4	O
,	PRISTIQ.xml:S1:12951:1	O
Fixed	PRISTIQ.xml:S1:12953:5	O
-	PRISTIQ.xml:S1:12958:1	O
dose	PRISTIQ.xml:S1:12959:4	O
Controlled	PRISTIQ.xml:S1:12964:10	O
Studies	PRISTIQ.xml:S1:12975:7	O

PRISTIQ	PRISTIQ.xml:S1:13025:7	O

Placebo	PRISTIQ.xml:S1:13066:7	O
50	PRISTIQ.xml:S1:13083:2	O
mg	PRISTIQ.xml:S1:13086:2	O
100	PRISTIQ.xml:S1:13100:3	O
mg	PRISTIQ.xml:S1:13104:2	O
200	PRISTIQ.xml:S1:13117:3	O
mg	PRISTIQ.xml:S1:13121:2	O
400	PRISTIQ.xml:S1:13134:3	O
mg	PRISTIQ.xml:S1:13138:2	O

Blood	PRISTIQ.xml:S1:13156:5	O

pressure	PRISTIQ.xml:S1:13162:8	O

Supine	PRISTIQ.xml:S1:13180:6	O
systolic	PRISTIQ.xml:S1:13187:8	O
bp	PRISTIQ.xml:S1:13196:2	O
(	PRISTIQ.xml:S1:13199:1	O
mm	PRISTIQ.xml:S1:13200:2	O
Hg	PRISTIQ.xml:S1:13203:2	O
)	PRISTIQ.xml:S1:13205:1	O
-	PRISTIQ.xml:S1:13210:1	O
1.4	PRISTIQ.xml:S1:13211:3	O
1.2	PRISTIQ.xml:S1:13227:3	O
2.0	PRISTIQ.xml:S1:13244:3	O
2.5	PRISTIQ.xml:S1:13261:3	O
2.1	PRISTIQ.xml:S1:13278:3	O

Supine	PRISTIQ.xml:S1:13298:6	O
diastolic	PRISTIQ.xml:S1:13305:9	O
bp	PRISTIQ.xml:S1:13315:2	O
(	PRISTIQ.xml:S1:13318:1	O
mm	PRISTIQ.xml:S1:13319:2	O
Hg	PRISTIQ.xml:S1:13322:2	O
)	PRISTIQ.xml:S1:13324:1	O
-	PRISTIQ.xml:S1:13329:1	O
0.6	PRISTIQ.xml:S1:13330:3	O
0.7	PRISTIQ.xml:S1:13346:3	O
0.8	PRISTIQ.xml:S1:13363:3	O
1.8	PRISTIQ.xml:S1:13380:3	O
2.3	PRISTIQ.xml:S1:13397:3	O

Pulse	PRISTIQ.xml:S1:13417:5	O
rate	PRISTIQ.xml:S1:13423:4	O

Supine	PRISTIQ.xml:S1:13441:6	O
pulse	PRISTIQ.xml:S1:13448:5	O
(	PRISTIQ.xml:S1:13454:1	O
bpm	PRISTIQ.xml:S1:13455:3	O
)	PRISTIQ.xml:S1:13458:1	O
-	PRISTIQ.xml:S1:13463:1	O
0.3	PRISTIQ.xml:S1:13464:3	O
1.3	PRISTIQ.xml:S1:13480:3	O
1.3	PRISTIQ.xml:S1:13497:3	O
0.9	PRISTIQ.xml:S1:13514:3	O
4.1	PRISTIQ.xml:S1:13531:3	O

Weight	PRISTIQ.xml:S1:13551:6	O
(	PRISTIQ.xml:S1:13558:1	O
kg	PRISTIQ.xml:S1:13559:2	O
)	PRISTIQ.xml:S1:13561:1	O
0.0	PRISTIQ.xml:S1:13572:3	O
-	PRISTIQ.xml:S1:13589:1	O
0.4	PRISTIQ.xml:S1:13590:3	O
-	PRISTIQ.xml:S1:13606:1	O
0.6	PRISTIQ.xml:S1:13607:3	O
-	PRISTIQ.xml:S1:13623:1	O
0.9	PRISTIQ.xml:S1:13624:3	O
-	PRISTIQ.xml:S1:13640:1	O
1.1	PRISTIQ.xml:S1:13641:3	O

Treatment	PRISTIQ.xml:S1:13670:9	O
with	PRISTIQ.xml:S1:13680:4	O
PRISTIQ	PRISTIQ.xml:S1:13685:7	O
at	PRISTIQ.xml:S1:13693:2	O
all	PRISTIQ.xml:S1:13696:3	O
doses	PRISTIQ.xml:S1:13700:5	O
from	PRISTIQ.xml:S1:13706:4	O
50	PRISTIQ.xml:S1:13711:2	O
mg	PRISTIQ.xml:S1:13714:2	O
per	PRISTIQ.xml:S1:13717:3	O
day	PRISTIQ.xml:S1:13721:3	O
to	PRISTIQ.xml:S1:13725:2	O
400	PRISTIQ.xml:S1:13728:3	O
mg	PRISTIQ.xml:S1:13732:2	O
per	PRISTIQ.xml:S1:13735:3	O
day	PRISTIQ.xml:S1:13739:3	O
in	PRISTIQ.xml:S1:13743:2	O
controlled	PRISTIQ.xml:S1:13746:10	O
studies	PRISTIQ.xml:S1:13757:7	O
was	PRISTIQ.xml:S1:13765:3	O
associated	PRISTIQ.xml:S1:13769:10	O
with	PRISTIQ.xml:S1:13780:4	O
sustained	PRISTIQ.xml:S1:13785:9	B-Severity
hypertension	PRISTIQ.xml:S1:13795:12	B-AdverseReaction
,	PRISTIQ.xml:S1:13807:1	O
defined	PRISTIQ.xml:S1:13809:7	O
as	PRISTIQ.xml:S1:13817:2	O
treatment	PRISTIQ.xml:S1:13820:9	O
-	PRISTIQ.xml:S1:13829:1	O
emergent	PRISTIQ.xml:S1:13830:8	O
supine	PRISTIQ.xml:S1:13839:6	B-AdverseReaction
diastolic	PRISTIQ.xml:S1:13846:9	I-AdverseReaction
blood	PRISTIQ.xml:S1:13856:5	I-AdverseReaction
pressure	PRISTIQ.xml:S1:13862:8	I-AdverseReaction
(	PRISTIQ.xml:S1:13871:1	O
SDBP	PRISTIQ.xml:S1:13872:4	O
)	PRISTIQ.xml:S1:13876:1	O
90	PRISTIQ.xml:S1:13880:2	I-AdverseReaction
mm	PRISTIQ.xml:S1:13883:2	I-AdverseReaction
Hg	PRISTIQ.xml:S1:13886:2	I-AdverseReaction
and	PRISTIQ.xml:S1:13889:3	O
10	PRISTIQ.xml:S1:13895:2	O
mm	PRISTIQ.xml:S1:13898:2	O
Hg	PRISTIQ.xml:S1:13901:2	O
above	PRISTIQ.xml:S1:13904:5	O
baseline	PRISTIQ.xml:S1:13910:8	O
for	PRISTIQ.xml:S1:13919:3	O
3	PRISTIQ.xml:S1:13923:1	O
consecutive	PRISTIQ.xml:S1:13925:11	O
on	PRISTIQ.xml:S1:13937:2	O
-	PRISTIQ.xml:S1:13939:1	O
therapy	PRISTIQ.xml:S1:13940:7	O
visits	PRISTIQ.xml:S1:13948:6	O
(	PRISTIQ.xml:S1:13955:1	O
see	PRISTIQ.xml:S1:13956:3	O
Table	PRISTIQ.xml:S1:13961:5	O
7	PRISTIQ.xml:S1:13967:1	O
)	PRISTIQ.xml:S1:13970:1	O
.	PRISTIQ.xml:S1:13971:1	O

Analyses	PRISTIQ.xml:S1:13973:8	O
of	PRISTIQ.xml:S1:13982:2	O
patients	PRISTIQ.xml:S1:13985:8	O
in	PRISTIQ.xml:S1:13994:2	O
PRISTIQ	PRISTIQ.xml:S1:13997:7	O
pre	PRISTIQ.xml:S1:14005:3	O
-	PRISTIQ.xml:S1:14008:1	O
marketing	PRISTIQ.xml:S1:14009:9	O
short	PRISTIQ.xml:S1:14019:5	O
-	PRISTIQ.xml:S1:14024:1	O
term	PRISTIQ.xml:S1:14025:4	O
controlled	PRISTIQ.xml:S1:14030:10	O
studies	PRISTIQ.xml:S1:14041:7	O
who	PRISTIQ.xml:S1:14049:3	O
met	PRISTIQ.xml:S1:14053:3	O
criteria	PRISTIQ.xml:S1:14057:8	O
for	PRISTIQ.xml:S1:14066:3	O
sustained	PRISTIQ.xml:S1:14070:9	B-Severity
hypertension	PRISTIQ.xml:S1:14080:12	B-AdverseReaction
revealed	PRISTIQ.xml:S1:14093:8	O
a	PRISTIQ.xml:S1:14102:1	O
consistent	PRISTIQ.xml:S1:14104:10	O
increase	PRISTIQ.xml:S1:14115:8	O
in	PRISTIQ.xml:S1:14124:2	O
the	PRISTIQ.xml:S1:14127:3	O
proportion	PRISTIQ.xml:S1:14131:10	O
of	PRISTIQ.xml:S1:14142:2	O
patients	PRISTIQ.xml:S1:14145:8	O
who	PRISTIQ.xml:S1:14154:3	O
developed	PRISTIQ.xml:S1:14158:9	O
sustained	PRISTIQ.xml:S1:14168:9	B-Severity
hypertension	PRISTIQ.xml:S1:14178:12	B-AdverseReaction
.	PRISTIQ.xml:S1:14190:1	O

This	PRISTIQ.xml:S1:14192:4	O
was	PRISTIQ.xml:S1:14197:3	O
seen	PRISTIQ.xml:S1:14201:4	O
at	PRISTIQ.xml:S1:14206:2	O
all	PRISTIQ.xml:S1:14209:3	O
doses	PRISTIQ.xml:S1:14213:5	O
with	PRISTIQ.xml:S1:14219:4	O
a	PRISTIQ.xml:S1:14224:1	O
suggestion	PRISTIQ.xml:S1:14226:10	O
of	PRISTIQ.xml:S1:14237:2	O
a	PRISTIQ.xml:S1:14240:1	O
higher	PRISTIQ.xml:S1:14242:6	O
rate	PRISTIQ.xml:S1:14249:4	O
at	PRISTIQ.xml:S1:14254:2	O
400	PRISTIQ.xml:S1:14257:3	O
mg	PRISTIQ.xml:S1:14261:2	O
per	PRISTIQ.xml:S1:14264:3	O
day	PRISTIQ.xml:S1:14268:3	O
.	PRISTIQ.xml:S1:14271:1	O

Table	PRISTIQ.xml:S1:14277:5	O

7	PRISTIQ.xml:S1:14283:1	O
:	PRISTIQ.xml:S1:14284:1	O
Proportion	PRISTIQ.xml:S1:14286:10	O
of	PRISTIQ.xml:S1:14297:2	O
Patients	PRISTIQ.xml:S1:14300:8	O
with	PRISTIQ.xml:S1:14309:4	O
Sustained	PRISTIQ.xml:S1:14314:9	B-Severity
Elevation	PRISTIQ.xml:S1:14324:9	B-AdverseReaction
of	PRISTIQ.xml:S1:14334:2	I-AdverseReaction
Supine	PRISTIQ.xml:S1:14337:6	I-AdverseReaction
Diastolic	PRISTIQ.xml:S1:14344:9	I-AdverseReaction
Blood	PRISTIQ.xml:S1:14354:5	I-AdverseReaction
Pressure	PRISTIQ.xml:S1:14360:8	I-AdverseReaction

Treatment	PRISTIQ.xml:S1:14373:9	O
Group	PRISTIQ.xml:S1:14383:5	O
Proportion	PRISTIQ.xml:S1:14412:10	O
of	PRISTIQ.xml:S1:14423:2	O
Patients	PRISTIQ.xml:S1:14426:8	O
with	PRISTIQ.xml:S1:14435:4	O
Sustained	PRISTIQ.xml:S1:14440:9	O
Hypertension	PRISTIQ.xml:S1:14450:12	O

Placebo	PRISTIQ.xml:S1:14474:7	O

0.5%	PRISTIQ.xml:S1:14513:4	O

PRISTIQ	PRISTIQ.xml:S1:14573:7	O
50	PRISTIQ.xml:S1:14581:2	O
mg	PRISTIQ.xml:S1:14584:2	O
per	PRISTIQ.xml:S1:14587:3	O
day	PRISTIQ.xml:S1:14591:3	O
1.3%	PRISTIQ.xml:S1:14612:4	O

PRISTIQ	PRISTIQ.xml:S1:14672:7	O
100	PRISTIQ.xml:S1:14680:3	O
mg	PRISTIQ.xml:S1:14684:2	O
per	PRISTIQ.xml:S1:14687:3	O
day	PRISTIQ.xml:S1:14691:3	O
0.7%	PRISTIQ.xml:S1:14711:4	O

PRISTIQ	PRISTIQ.xml:S1:14771:7	O
200	PRISTIQ.xml:S1:14779:3	O
mg	PRISTIQ.xml:S1:14783:2	O
per	PRISTIQ.xml:S1:14786:3	O
day	PRISTIQ.xml:S1:14790:3	O
1.1%	PRISTIQ.xml:S1:14810:4	O

PRISTIQ	PRISTIQ.xml:S1:14870:7	O
400	PRISTIQ.xml:S1:14878:3	O
mg	PRISTIQ.xml:S1:14882:2	O
per	PRISTIQ.xml:S1:14885:3	O
day	PRISTIQ.xml:S1:14889:3	O
2.3%	PRISTIQ.xml:S1:14909:4	O

Orthostatic	PRISTIQ.xml:S1:14981:11	O
hypotension	PRISTIQ.xml:S1:14993:11	O

In	PRISTIQ.xml:S1:15013:2	O

the	PRISTIQ.xml:S1:15016:3	O
pre	PRISTIQ.xml:S1:15020:3	O
-	PRISTIQ.xml:S1:15023:1	O
marketing	PRISTIQ.xml:S1:15024:9	O
short	PRISTIQ.xml:S1:15034:5	O
-	PRISTIQ.xml:S1:15039:1	O
term	PRISTIQ.xml:S1:15040:4	O
,	PRISTIQ.xml:S1:15044:1	O
placebo	PRISTIQ.xml:S1:15046:7	O
-	PRISTIQ.xml:S1:15053:1	O
controlled	PRISTIQ.xml:S1:15054:10	O
clinical	PRISTIQ.xml:S1:15065:8	O
studies	PRISTIQ.xml:S1:15074:7	O
with	PRISTIQ.xml:S1:15082:4	O
doses	PRISTIQ.xml:S1:15087:5	O
of	PRISTIQ.xml:S1:15093:2	O
50	PRISTIQ.xml:S1:15096:2	O
to	PRISTIQ.xml:S1:15099:2	O
400	PRISTIQ.xml:S1:15102:3	O
mg	PRISTIQ.xml:S1:15106:2	O
,	PRISTIQ.xml:S1:15108:1	O
systolic	PRISTIQ.xml:S1:15110:8	B-AdverseReaction
orthostatic	PRISTIQ.xml:S1:15119:11	I-AdverseReaction
hypotension	PRISTIQ.xml:S1:15131:11	I-AdverseReaction
(	PRISTIQ.xml:S1:15143:1	O
decrease	PRISTIQ.xml:S1:15144:8	O
30	PRISTIQ.xml:S1:15155:2	O
mm	PRISTIQ.xml:S1:15158:2	O
Hg	PRISTIQ.xml:S1:15161:2	O
from	PRISTIQ.xml:S1:15164:4	O
supine	PRISTIQ.xml:S1:15169:6	O
to	PRISTIQ.xml:S1:15176:2	O
standing	PRISTIQ.xml:S1:15179:8	O
position	PRISTIQ.xml:S1:15188:8	O
)	PRISTIQ.xml:S1:15196:1	O
occurred	PRISTIQ.xml:S1:15198:8	O
more	PRISTIQ.xml:S1:15207:4	O
frequently	PRISTIQ.xml:S1:15212:10	O
in	PRISTIQ.xml:S1:15223:2	O
patients	PRISTIQ.xml:S1:15226:8	O
65	PRISTIQ.xml:S1:15237:2	O
years	PRISTIQ.xml:S1:15240:5	O
of	PRISTIQ.xml:S1:15246:2	O
age	PRISTIQ.xml:S1:15249:3	O
receiving	PRISTIQ.xml:S1:15253:9	O
PRISTIQ	PRISTIQ.xml:S1:15263:7	O
(	PRISTIQ.xml:S1:15271:1	O
8%	PRISTIQ.xml:S1:15272:2	O
,	PRISTIQ.xml:S1:15274:1	O
7	PRISTIQ.xml:S1:15276:1	O
87	PRISTIQ.xml:S1:15278:2	O
)	PRISTIQ.xml:S1:15280:1	O
versus	PRISTIQ.xml:S1:15282:6	O
placebo	PRISTIQ.xml:S1:15289:7	O
(	PRISTIQ.xml:S1:15297:1	O
2.5%	PRISTIQ.xml:S1:15298:4	O
,	PRISTIQ.xml:S1:15302:1	O
1	PRISTIQ.xml:S1:15304:1	O
40	PRISTIQ.xml:S1:15306:2	O
)	PRISTIQ.xml:S1:15308:1	O
,	PRISTIQ.xml:S1:15309:1	O
compared	PRISTIQ.xml:S1:15311:8	O
to	PRISTIQ.xml:S1:15320:2	O
patients	PRISTIQ.xml:S1:15323:8	O
65	PRISTIQ.xml:S1:15333:2	O
years	PRISTIQ.xml:S1:15336:5	O
of	PRISTIQ.xml:S1:15342:2	O
age	PRISTIQ.xml:S1:15345:3	O
receiving	PRISTIQ.xml:S1:15349:9	O
PRISTIQ	PRISTIQ.xml:S1:15359:7	O
(	PRISTIQ.xml:S1:15367:1	O
0.9%	PRISTIQ.xml:S1:15368:4	O
,	PRISTIQ.xml:S1:15372:1	O
18	PRISTIQ.xml:S1:15374:2	O
1	PRISTIQ.xml:S1:15377:1	O
,	PRISTIQ.xml:S1:15378:1	O
937	PRISTIQ.xml:S1:15379:3	O
)	PRISTIQ.xml:S1:15382:1	O
versus	PRISTIQ.xml:S1:15384:6	O
placebo	PRISTIQ.xml:S1:15391:7	O
(	PRISTIQ.xml:S1:15399:1	O
0.7%	PRISTIQ.xml:S1:15400:4	O
,	PRISTIQ.xml:S1:15404:1	O
8	PRISTIQ.xml:S1:15406:1	O
1	PRISTIQ.xml:S1:15408:1	O
,	PRISTIQ.xml:S1:15409:1	O
218	PRISTIQ.xml:S1:15410:3	O
)	PRISTIQ.xml:S1:15413:1	O
.	PRISTIQ.xml:S1:15414:1	O

6.2	PRISTIQ.xml:S1:15422:3	O
Postmarketing	PRISTIQ.xml:S1:15426:13	O
Experience	PRISTIQ.xml:S1:15440:10	O

The	PRISTIQ.xml:S1:15454:3	O
following	PRISTIQ.xml:S1:15458:9	O
adverse	PRISTIQ.xml:S1:15468:7	O
reaction	PRISTIQ.xml:S1:15476:8	O
has	PRISTIQ.xml:S1:15485:3	O
been	PRISTIQ.xml:S1:15489:4	O
identified	PRISTIQ.xml:S1:15494:10	O
during	PRISTIQ.xml:S1:15505:6	O
post	PRISTIQ.xml:S1:15512:4	O
-	PRISTIQ.xml:S1:15516:1	O
approval	PRISTIQ.xml:S1:15517:8	O
use	PRISTIQ.xml:S1:15526:3	O
of	PRISTIQ.xml:S1:15530:2	O
PRISTIQ	PRISTIQ.xml:S1:15533:7	O
.	PRISTIQ.xml:S1:15540:1	O

Because	PRISTIQ.xml:S1:15542:7	O
these	PRISTIQ.xml:S1:15550:5	O
reactions	PRISTIQ.xml:S1:15556:9	O
are	PRISTIQ.xml:S1:15566:3	O
reported	PRISTIQ.xml:S1:15570:8	O
voluntarily	PRISTIQ.xml:S1:15579:11	O
from	PRISTIQ.xml:S1:15591:4	O
a	PRISTIQ.xml:S1:15596:1	O
population	PRISTIQ.xml:S1:15598:10	O
of	PRISTIQ.xml:S1:15609:2	O
uncertain	PRISTIQ.xml:S1:15612:9	O
size	PRISTIQ.xml:S1:15622:4	O
,	PRISTIQ.xml:S1:15626:1	O
it	PRISTIQ.xml:S1:15628:2	O
is	PRISTIQ.xml:S1:15631:2	O
not	PRISTIQ.xml:S1:15634:3	O
always	PRISTIQ.xml:S1:15638:6	O
possible	PRISTIQ.xml:S1:15645:8	O
to	PRISTIQ.xml:S1:15654:2	O
reliably	PRISTIQ.xml:S1:15657:8	O
estimate	PRISTIQ.xml:S1:15666:8	O
their	PRISTIQ.xml:S1:15675:5	O
frequency	PRISTIQ.xml:S1:15681:9	O
or	PRISTIQ.xml:S1:15691:2	O
establish	PRISTIQ.xml:S1:15694:9	O
a	PRISTIQ.xml:S1:15704:1	O
causal	PRISTIQ.xml:S1:15706:6	O
relationship	PRISTIQ.xml:S1:15713:12	O
to	PRISTIQ.xml:S1:15726:2	O
drug	PRISTIQ.xml:S1:15729:4	O
exposure	PRISTIQ.xml:S1:15734:8	O
:	PRISTIQ.xml:S1:15742:1	O

Skin	PRISTIQ.xml:S1:15752:4	O
and	PRISTIQ.xml:S1:15757:3	O
subcutaneous	PRISTIQ.xml:S1:15761:12	O
tissue	PRISTIQ.xml:S1:15774:6	O
disorders	PRISTIQ.xml:S1:15781:9	O
-	PRISTIQ.xml:S1:15794:1	O
Stevens	PRISTIQ.xml:S1:15796:7	B-AdverseReaction
-	PRISTIQ.xml:S1:15803:1	I-AdverseReaction
Johnson	PRISTIQ.xml:S1:15804:7	I-AdverseReaction
syndrome	PRISTIQ.xml:S1:15812:8	I-AdverseReaction
.	PRISTIQ.xml:S1:15820:1	O
\n\n	PRISTIQ.xml:S2:0:2	O
BOXED	PRISTIQ.xml:S2:6:5	O
WARNING	PRISTIQ.xml:S2:12:7	O
:	PRISTIQ.xml:S2:19:1	O
WARNING	PRISTIQ.xml:S2:21:7	O
:	PRISTIQ.xml:S2:28:1	O
SUICIDAL	PRISTIQ.xml:S2:30:8	B-AdverseReaction
THOUGHTS	PRISTIQ.xml:S2:39:8	I-AdverseReaction
AND	PRISTIQ.xml:S2:48:3	O
BEHAVIORS	PRISTIQ.xml:S2:52:9	I-AdverseReaction
\n\n	PRISTIQ.xml:S2:61:2	O
WARNING	PRISTIQ.xml:S2:67:7	O
:	PRISTIQ.xml:S2:74:1	O
SUICIDAL	PRISTIQ.xml:S2:76:8	B-AdverseReaction
THOUGHTS	PRISTIQ.xml:S2:85:8	I-AdverseReaction
AND	PRISTIQ.xml:S2:94:3	O
BEHAVIORS	PRISTIQ.xml:S2:98:9	I-AdverseReaction
\n\n	PRISTIQ.xml:S2:109:2	O
Antidepressants	PRISTIQ.xml:S2:115:15	B-DrugClass
increased	PRISTIQ.xml:S2:131:9	O
the	PRISTIQ.xml:S2:141:3	O
risk	PRISTIQ.xml:S2:145:4	O
of	PRISTIQ.xml:S2:150:2	O
suicidal	PRISTIQ.xml:S2:153:8	B-AdverseReaction
thoughts	PRISTIQ.xml:S2:162:8	I-AdverseReaction
and	PRISTIQ.xml:S2:171:3	O
behavior	PRISTIQ.xml:S2:175:8	I-AdverseReaction
in	PRISTIQ.xml:S2:184:2	O
children	PRISTIQ.xml:S2:187:8	O
,	PRISTIQ.xml:S2:195:1	O
adolescents	PRISTIQ.xml:S2:197:11	O
,	PRISTIQ.xml:S2:208:1	O
and	PRISTIQ.xml:S2:210:3	O
young	PRISTIQ.xml:S2:214:5	O
adults	PRISTIQ.xml:S2:220:6	O
in	PRISTIQ.xml:S2:227:2	O
short	PRISTIQ.xml:S2:230:5	O
-	PRISTIQ.xml:S2:235:1	O
term	PRISTIQ.xml:S2:236:4	O
studies	PRISTIQ.xml:S2:241:7	O
.	PRISTIQ.xml:S2:248:1	O

These	PRISTIQ.xml:S2:250:5	O
studies	PRISTIQ.xml:S2:256:7	O
did	PRISTIQ.xml:S2:264:3	O
not	PRISTIQ.xml:S2:268:3	B-Negation
show	PRISTIQ.xml:S2:272:4	O
an	PRISTIQ.xml:S2:277:2	O
increase	PRISTIQ.xml:S2:280:8	O
in	PRISTIQ.xml:S2:289:2	O
the	PRISTIQ.xml:S2:292:3	O
risk	PRISTIQ.xml:S2:296:4	O
of	PRISTIQ.xml:S2:301:2	O
suicidal	PRISTIQ.xml:S2:304:8	B-AdverseReaction
thoughts	PRISTIQ.xml:S2:313:8	I-AdverseReaction
and	PRISTIQ.xml:S2:322:3	O
behavior	PRISTIQ.xml:S2:326:8	I-AdverseReaction
with	PRISTIQ.xml:S2:335:4	O
antidepressant	PRISTIQ.xml:S2:340:14	O
use	PRISTIQ.xml:S2:355:3	O
in	PRISTIQ.xml:S2:359:2	O
patients	PRISTIQ.xml:S2:362:8	O
over	PRISTIQ.xml:S2:371:4	O
age	PRISTIQ.xml:S2:376:3	O
24	PRISTIQ.xml:S2:380:2	O
;	PRISTIQ.xml:S2:382:1	O
there	PRISTIQ.xml:S2:384:5	O
was	PRISTIQ.xml:S2:390:3	O
a	PRISTIQ.xml:S2:394:1	O
reduction	PRISTIQ.xml:S2:396:9	O
in	PRISTIQ.xml:S2:406:2	O
risk	PRISTIQ.xml:S2:409:4	O
with	PRISTIQ.xml:S2:414:4	O
antidepressant	PRISTIQ.xml:S2:419:14	O
use	PRISTIQ.xml:S2:434:3	O
in	PRISTIQ.xml:S2:438:2	O
patients	PRISTIQ.xml:S2:441:8	O
aged	PRISTIQ.xml:S2:450:4	O
65	PRISTIQ.xml:S2:455:2	O
and	PRISTIQ.xml:S2:458:3	O
older	PRISTIQ.xml:S2:462:5	O
[	PRISTIQ.xml:S2:468:1	O
see	PRISTIQ.xml:S2:471:3	O
Warnings	PRISTIQ.xml:S2:477:8	O
and	PRISTIQ.xml:S2:486:3	O
Precautions	PRISTIQ.xml:S2:490:11	O
(	PRISTIQ.xml:S2:502:1	O
5.1	PRISTIQ.xml:S2:503:3	O
)	PRISTIQ.xml:S2:506:1	O
]	PRISTIQ.xml:S2:511:1	O
.	PRISTIQ.xml:S2:512:1	O

In	PRISTIQ.xml:S2:523:2	O
patients	PRISTIQ.xml:S2:526:8	O
of	PRISTIQ.xml:S2:535:2	O
all	PRISTIQ.xml:S2:538:3	O
ages	PRISTIQ.xml:S2:542:4	O
who	PRISTIQ.xml:S2:547:3	O
are	PRISTIQ.xml:S2:551:3	O
started	PRISTIQ.xml:S2:555:7	O
on	PRISTIQ.xml:S2:563:2	O
antidepressant	PRISTIQ.xml:S2:566:14	O
therapy	PRISTIQ.xml:S2:581:7	O
,	PRISTIQ.xml:S2:588:1	O
monitor	PRISTIQ.xml:S2:590:7	O
closely	PRISTIQ.xml:S2:598:7	O
for	PRISTIQ.xml:S2:606:3	O
worsening	PRISTIQ.xml:S2:610:9	O
,	PRISTIQ.xml:S2:619:1	O
and	PRISTIQ.xml:S2:621:3	O
for	PRISTIQ.xml:S2:625:3	O
emergence	PRISTIQ.xml:S2:629:9	O
of	PRISTIQ.xml:S2:639:2	O
suicidal	PRISTIQ.xml:S2:642:8	O
thoughts	PRISTIQ.xml:S2:651:8	O
and	PRISTIQ.xml:S2:660:3	O
behaviors	PRISTIQ.xml:S2:664:9	O
.	PRISTIQ.xml:S2:673:1	O

Advise	PRISTIQ.xml:S2:675:6	O
families	PRISTIQ.xml:S2:682:8	O
and	PRISTIQ.xml:S2:691:3	O
caregivers	PRISTIQ.xml:S2:695:10	O
of	PRISTIQ.xml:S2:706:2	O
the	PRISTIQ.xml:S2:709:3	O
need	PRISTIQ.xml:S2:713:4	O
for	PRISTIQ.xml:S2:718:3	O
close	PRISTIQ.xml:S2:722:5	O
observation	PRISTIQ.xml:S2:728:11	O
and	PRISTIQ.xml:S2:740:3	O
communication	PRISTIQ.xml:S2:744:13	O
with	PRISTIQ.xml:S2:758:4	O
the	PRISTIQ.xml:S2:763:3	O
prescriber	PRISTIQ.xml:S2:767:10	O
[	PRISTIQ.xml:S2:778:1	O
see	PRISTIQ.xml:S2:781:3	O
Warnings	PRISTIQ.xml:S2:787:8	O
and	PRISTIQ.xml:S2:796:3	O
Precautions	PRISTIQ.xml:S2:800:11	O
(	PRISTIQ.xml:S2:812:1	O
5.1	PRISTIQ.xml:S2:813:3	O
)	PRISTIQ.xml:S2:816:1	O
]	PRISTIQ.xml:S2:821:1	O
.	PRISTIQ.xml:S2:822:1	O

PRISTIQ	PRISTIQ.xml:S2:833:7	O
is	PRISTIQ.xml:S2:841:2	O
not	PRISTIQ.xml:S2:844:3	O
approved	PRISTIQ.xml:S2:848:8	O
for	PRISTIQ.xml:S2:857:3	O
use	PRISTIQ.xml:S2:861:3	O
in	PRISTIQ.xml:S2:865:2	O
pediatric	PRISTIQ.xml:S2:868:9	O
patients	PRISTIQ.xml:S2:878:8	O
[	PRISTIQ.xml:S2:887:1	O
see	PRISTIQ.xml:S2:890:3	O
Use	PRISTIQ.xml:S2:896:3	O
in	PRISTIQ.xml:S2:900:2	O
Specific	PRISTIQ.xml:S2:903:8	O
Populations	PRISTIQ.xml:S2:912:11	O
(	PRISTIQ.xml:S2:924:1	O
8.4	PRISTIQ.xml:S2:925:3	O
)	PRISTIQ.xml:S2:928:1	O
]	PRISTIQ.xml:S2:933:1	O
.	PRISTIQ.xml:S2:934:1	O

EXCERPT	PRISTIQ.xml:S2:944:7	O
:	PRISTIQ.xml:S2:951:1	O
WARNING	PRISTIQ.xml:S2:955:7	O
:	PRISTIQ.xml:S2:962:1	O
SUICIDAL	PRISTIQ.xml:S2:964:8	B-AdverseReaction
THOUGHTS	PRISTIQ.xml:S2:973:8	I-AdverseReaction
AND	PRISTIQ.xml:S2:982:3	O
BEHAVIORS	PRISTIQ.xml:S2:986:9	I-AdverseReaction
\n\n\n\n	PRISTIQ.xml:S2:995:4	O
See	PRISTIQ.xml:S2:1004:3	O
full	PRISTIQ.xml:S2:1008:4	O
prescribing	PRISTIQ.xml:S2:1013:11	O
information	PRISTIQ.xml:S2:1025:11	O
for	PRISTIQ.xml:S2:1037:3	O
complete	PRISTIQ.xml:S2:1041:8	O
boxed	PRISTIQ.xml:S2:1050:5	O
warning	PRISTIQ.xml:S2:1056:7	O
.	PRISTIQ.xml:S2:1063:1	O

Increased	PRISTIQ.xml:S2:1076:9	O
risk	PRISTIQ.xml:S2:1086:4	O
of	PRISTIQ.xml:S2:1091:2	O
suicidal	PRISTIQ.xml:S2:1094:8	B-AdverseReaction
thinking	PRISTIQ.xml:S2:1103:8	I-AdverseReaction
and	PRISTIQ.xml:S2:1112:3	O
behavior	PRISTIQ.xml:S2:1116:8	I-AdverseReaction
in	PRISTIQ.xml:S2:1125:2	O
children	PRISTIQ.xml:S2:1128:8	O
,	PRISTIQ.xml:S2:1136:1	O
adolescents	PRISTIQ.xml:S2:1138:11	O
and	PRISTIQ.xml:S2:1150:3	O
young	PRISTIQ.xml:S2:1154:5	O
adults	PRISTIQ.xml:S2:1160:6	O
taking	PRISTIQ.xml:S2:1167:6	O
antidepressants	PRISTIQ.xml:S2:1174:15	B-DrugClass
(	PRISTIQ.xml:S2:1190:1	O
5.1	PRISTIQ.xml:S2:1191:3	O
)	PRISTIQ.xml:S2:1194:1	O
.	PRISTIQ.xml:S2:1195:1	O

Monitor	PRISTIQ.xml:S2:1202:7	O
for	PRISTIQ.xml:S2:1210:3	O
worsening	PRISTIQ.xml:S2:1214:9	O
and	PRISTIQ.xml:S2:1224:3	O
emergence	PRISTIQ.xml:S2:1228:9	O
of	PRISTIQ.xml:S2:1238:2	O
suicidal	PRISTIQ.xml:S2:1241:8	O
thoughts	PRISTIQ.xml:S2:1250:8	O
and	PRISTIQ.xml:S2:1259:3	O
behaviors	PRISTIQ.xml:S2:1263:9	O
(	PRISTIQ.xml:S2:1273:1	O
5.1	PRISTIQ.xml:S2:1274:3	O
)	PRISTIQ.xml:S2:1277:1	O
.	PRISTIQ.xml:S2:1278:1	O

PRISTIQ	PRISTIQ.xml:S2:1285:7	O
is	PRISTIQ.xml:S2:1293:2	O
not	PRISTIQ.xml:S2:1296:3	O
approved	PRISTIQ.xml:S2:1300:8	O
for	PRISTIQ.xml:S2:1309:3	O
use	PRISTIQ.xml:S2:1313:3	O
in	PRISTIQ.xml:S2:1317:2	O
pediatric	PRISTIQ.xml:S2:1320:9	O
patients	PRISTIQ.xml:S2:1330:8	O
(	PRISTIQ.xml:S2:1339:1	O
8.4	PRISTIQ.xml:S2:1340:3	O
)	PRISTIQ.xml:S2:1343:1	O
.	PRISTIQ.xml:S2:1344:1	O
\n	PRISTIQ.xml:S2:1346:1	O
5	PRISTIQ.xml:S3:4:1	O
WARNINGS	PRISTIQ.xml:S3:6:8	O
AND	PRISTIQ.xml:S3:15:3	O
PRECAUTIONS	PRISTIQ.xml:S3:19:11	O

EXCERPT	PRISTIQ.xml:S3:37:7	O
:	PRISTIQ.xml:S3:44:1	O
Clinical	PRISTIQ.xml:S3:55:8	B-AdverseReaction
Worsening	PRISTIQ.xml:S3:64:9	I-AdverseReaction
Suicide	PRISTIQ.xml:S3:74:7	B-AdverseReaction
Risk	PRISTIQ.xml:S3:82:4	I-AdverseReaction
:	PRISTIQ.xml:S3:86:1	O
Monitor	PRISTIQ.xml:S3:88:7	O
for	PRISTIQ.xml:S3:96:3	O
clinical	PRISTIQ.xml:S3:100:8	O
worsening	PRISTIQ.xml:S3:109:9	O
and	PRISTIQ.xml:S3:119:3	O
suicide	PRISTIQ.xml:S3:123:7	O
risk	PRISTIQ.xml:S3:131:4	O
(	PRISTIQ.xml:S3:136:1	O
5.1	PRISTIQ.xml:S3:139:3	O
)	PRISTIQ.xml:S3:144:1	O
.	PRISTIQ.xml:S3:145:1	O

Serotonin	PRISTIQ.xml:S3:155:9	B-AdverseReaction
Syndrome	PRISTIQ.xml:S3:165:8	I-AdverseReaction
:	PRISTIQ.xml:S3:173:1	O
Serotonin	PRISTIQ.xml:S3:175:9	B-AdverseReaction
syndrome	PRISTIQ.xml:S3:185:8	I-AdverseReaction
has	PRISTIQ.xml:S3:194:3	O
been	PRISTIQ.xml:S3:198:4	O
reported	PRISTIQ.xml:S3:203:8	O
with	PRISTIQ.xml:S3:212:4	O
SSRIs	PRISTIQ.xml:S3:217:5	O
and	PRISTIQ.xml:S3:223:3	O
SNRIs	PRISTIQ.xml:S3:227:5	O
,	PRISTIQ.xml:S3:232:1	O
including	PRISTIQ.xml:S3:234:9	O
with	PRISTIQ.xml:S3:244:4	O
PRISTIQ	PRISTIQ.xml:S3:249:7	O
,	PRISTIQ.xml:S3:256:1	O
both	PRISTIQ.xml:S3:258:4	O
when	PRISTIQ.xml:S3:263:4	O
taken	PRISTIQ.xml:S3:268:5	O
alone	PRISTIQ.xml:S3:274:5	O
,	PRISTIQ.xml:S3:279:1	O
but	PRISTIQ.xml:S3:281:3	O
especially	PRISTIQ.xml:S3:285:10	O
when	PRISTIQ.xml:S3:296:4	O
co	PRISTIQ.xml:S3:301:2	O
-	PRISTIQ.xml:S3:303:1	O
administered	PRISTIQ.xml:S3:304:12	O
with	PRISTIQ.xml:S3:317:4	O
other	PRISTIQ.xml:S3:322:5	O
serotonergic	PRISTIQ.xml:S3:328:12	O
agents	PRISTIQ.xml:S3:341:6	O
(	PRISTIQ.xml:S3:348:1	O
including	PRISTIQ.xml:S3:349:9	O
triptans	PRISTIQ.xml:S3:359:8	O
,	PRISTIQ.xml:S3:367:1	O
tricyclic	PRISTIQ.xml:S3:369:9	O
antidepressants	PRISTIQ.xml:S3:379:15	O
,	PRISTIQ.xml:S3:394:1	O
fentanyl	PRISTIQ.xml:S3:396:8	O
,	PRISTIQ.xml:S3:404:1	O
lithium	PRISTIQ.xml:S3:406:7	O
,	PRISTIQ.xml:S3:413:1	O
tramadol	PRISTIQ.xml:S3:415:8	O
,	PRISTIQ.xml:S3:423:1	O
tryptophan	PRISTIQ.xml:S3:425:10	O
,	PRISTIQ.xml:S3:435:1	O
buspirone	PRISTIQ.xml:S3:437:9	O
,	PRISTIQ.xml:S3:446:1	O
and	PRISTIQ.xml:S3:448:3	O
St	PRISTIQ.xml:S3:452:2	O
.	PRISTIQ.xml:S3:454:1	O

John	PRISTIQ.xml:S3:456:4	O
's	PRISTIQ.xml:S3:460:2	O
Wort	PRISTIQ.xml:S3:463:4	O
)	PRISTIQ.xml:S3:467:1	O
.	PRISTIQ.xml:S3:468:1	O

If	PRISTIQ.xml:S3:470:2	O
such	PRISTIQ.xml:S3:473:4	O
symptoms	PRISTIQ.xml:S3:478:8	O
occur	PRISTIQ.xml:S3:487:5	O
,	PRISTIQ.xml:S3:492:1	O
discontinue	PRISTIQ.xml:S3:494:11	O
PRISTIQ	PRISTIQ.xml:S3:506:7	O
and	PRISTIQ.xml:S3:514:3	O
initiate	PRISTIQ.xml:S3:518:8	O
supportive	PRISTIQ.xml:S3:527:10	O
treatment	PRISTIQ.xml:S3:538:9	O
.	PRISTIQ.xml:S3:547:1	O

If	PRISTIQ.xml:S3:549:2	O
concomitant	PRISTIQ.xml:S3:552:11	O
use	PRISTIQ.xml:S3:564:3	O
of	PRISTIQ.xml:S3:568:2	O
PRISTIQ	PRISTIQ.xml:S3:571:7	O
with	PRISTIQ.xml:S3:579:4	O
other	PRISTIQ.xml:S3:584:5	O
serotonergic	PRISTIQ.xml:S3:590:12	O
drugs	PRISTIQ.xml:S3:603:5	O
is	PRISTIQ.xml:S3:609:2	O
clinically	PRISTIQ.xml:S3:612:10	O
warranted	PRISTIQ.xml:S3:623:9	O
,	PRISTIQ.xml:S3:632:1	O
patients	PRISTIQ.xml:S3:634:8	O
should	PRISTIQ.xml:S3:643:6	O
be	PRISTIQ.xml:S3:650:2	O
made	PRISTIQ.xml:S3:653:4	O
aware	PRISTIQ.xml:S3:658:5	O
of	PRISTIQ.xml:S3:664:2	O
a	PRISTIQ.xml:S3:667:1	O
potential	PRISTIQ.xml:S3:669:9	O
increased	PRISTIQ.xml:S3:679:9	O
risk	PRISTIQ.xml:S3:689:4	O
for	PRISTIQ.xml:S3:694:3	O
serotonin	PRISTIQ.xml:S3:698:9	O
syndrome	PRISTIQ.xml:S3:708:8	O
,	PRISTIQ.xml:S3:716:1	O
particularly	PRISTIQ.xml:S3:718:12	O
during	PRISTIQ.xml:S3:731:6	O
treatment	PRISTIQ.xml:S3:738:9	O
initiation	PRISTIQ.xml:S3:748:10	O
and	PRISTIQ.xml:S3:759:3	O
dose	PRISTIQ.xml:S3:763:4	O
increases	PRISTIQ.xml:S3:768:9	O
(	PRISTIQ.xml:S3:778:1	O
5.2	PRISTIQ.xml:S3:781:3	O
)	PRISTIQ.xml:S3:786:1	O
.	PRISTIQ.xml:S3:787:1	O

Elevated	PRISTIQ.xml:S3:797:8	B-AdverseReaction
Blood	PRISTIQ.xml:S3:806:5	I-AdverseReaction
Pressure	PRISTIQ.xml:S3:812:8	I-AdverseReaction
:	PRISTIQ.xml:S3:820:1	O
Control	PRISTIQ.xml:S3:822:7	O
hypertension	PRISTIQ.xml:S3:830:12	O
before	PRISTIQ.xml:S3:843:6	O
initiating	PRISTIQ.xml:S3:850:10	O
treatment	PRISTIQ.xml:S3:861:9	O
.	PRISTIQ.xml:S3:870:1	O

Monitor	PRISTIQ.xml:S3:872:7	O
blood	PRISTIQ.xml:S3:880:5	O
pressure	PRISTIQ.xml:S3:886:8	O
regularly	PRISTIQ.xml:S3:895:9	O
during	PRISTIQ.xml:S3:905:6	O
treatment	PRISTIQ.xml:S3:912:9	O
(	PRISTIQ.xml:S3:922:1	O
5.3	PRISTIQ.xml:S3:925:3	O
)	PRISTIQ.xml:S3:930:1	O
.	PRISTIQ.xml:S3:931:1	O

Abnormal	PRISTIQ.xml:S3:941:8	B-AdverseReaction
Bleeding	PRISTIQ.xml:S3:950:8	I-AdverseReaction
:	PRISTIQ.xml:S3:958:1	O
PRISTIQ	PRISTIQ.xml:S3:960:7	O
may	PRISTIQ.xml:S3:968:3	B-Factor
increase	PRISTIQ.xml:S3:972:8	O
risk	PRISTIQ.xml:S3:981:4	O
of	PRISTIQ.xml:S3:986:2	O
bleeding	PRISTIQ.xml:S3:989:8	B-AdverseReaction
events	PRISTIQ.xml:S3:998:6	O
.	PRISTIQ.xml:S3:1004:1	O

Caution	PRISTIQ.xml:S3:1006:7	O
patients	PRISTIQ.xml:S3:1014:8	O
about	PRISTIQ.xml:S3:1023:5	O
risk	PRISTIQ.xml:S3:1029:4	O
of	PRISTIQ.xml:S3:1034:2	O
bleeding	PRISTIQ.xml:S3:1037:8	O
associated	PRISTIQ.xml:S3:1046:10	O
with	PRISTIQ.xml:S3:1057:4	O
concomitant	PRISTIQ.xml:S3:1062:11	O
use	PRISTIQ.xml:S3:1074:3	O
of	PRISTIQ.xml:S3:1078:2	O
PRISTIQ	PRISTIQ.xml:S3:1081:7	O
and	PRISTIQ.xml:S3:1089:3	O
NSAIDs	PRISTIQ.xml:S3:1093:6	O
,	PRISTIQ.xml:S3:1099:1	O
aspirin	PRISTIQ.xml:S3:1101:7	O
,	PRISTIQ.xml:S3:1108:1	O
or	PRISTIQ.xml:S3:1110:2	O
other	PRISTIQ.xml:S3:1113:5	O
drugs	PRISTIQ.xml:S3:1119:5	O
that	PRISTIQ.xml:S3:1125:4	O
affect	PRISTIQ.xml:S3:1130:6	O
coagulation	PRISTIQ.xml:S3:1137:11	O
(	PRISTIQ.xml:S3:1149:1	O
5.4	PRISTIQ.xml:S3:1152:3	O
)	PRISTIQ.xml:S3:1157:1	O
.	PRISTIQ.xml:S3:1158:1	O

Angle	PRISTIQ.xml:S3:1168:5	B-AdverseReaction
Closure	PRISTIQ.xml:S3:1174:7	I-AdverseReaction
Glaucoma	PRISTIQ.xml:S3:1182:8	I-AdverseReaction
:	PRISTIQ.xml:S3:1190:1	O
Angle	PRISTIQ.xml:S3:1192:5	B-AdverseReaction
closure	PRISTIQ.xml:S3:1198:7	I-AdverseReaction
glaucoma	PRISTIQ.xml:S3:1206:8	I-AdverseReaction
has	PRISTIQ.xml:S3:1215:3	O
occurred	PRISTIQ.xml:S3:1219:8	O
in	PRISTIQ.xml:S3:1228:2	O
patients	PRISTIQ.xml:S3:1231:8	O
with	PRISTIQ.xml:S3:1240:4	O
untreated	PRISTIQ.xml:S3:1245:9	O
anatomically	PRISTIQ.xml:S3:1255:12	O
narrow	PRISTIQ.xml:S3:1268:6	O
angles	PRISTIQ.xml:S3:1275:6	O
treated	PRISTIQ.xml:S3:1282:7	O
with	PRISTIQ.xml:S3:1290:4	O
antidepressants	PRISTIQ.xml:S3:1295:15	B-DrugClass
.	PRISTIQ.xml:S3:1310:1	O

(	PRISTIQ.xml:S3:1312:1	O
5.5	PRISTIQ.xml:S3:1315:3	O
)	PRISTIQ.xml:S3:1320:1	O

Activation	PRISTIQ.xml:S3:1330:10	B-AdverseReaction
of	PRISTIQ.xml:S3:1341:2	I-AdverseReaction
Mania	PRISTIQ.xml:S3:1344:5	I-AdverseReaction
Hypomania	PRISTIQ.xml:S3:1350:9	I-AdverseReaction
:	PRISTIQ.xml:S3:1359:1	O
Use	PRISTIQ.xml:S3:1361:3	O
cautiously	PRISTIQ.xml:S3:1365:10	O
in	PRISTIQ.xml:S3:1376:2	O
patients	PRISTIQ.xml:S3:1379:8	O
with	PRISTIQ.xml:S3:1388:4	O
Bipolar	PRISTIQ.xml:S3:1393:7	O
Disorder	PRISTIQ.xml:S3:1401:8	O
.	PRISTIQ.xml:S3:1409:1	O

Caution	PRISTIQ.xml:S3:1411:7	O
patients	PRISTIQ.xml:S3:1419:8	O
about	PRISTIQ.xml:S3:1428:5	O
risk	PRISTIQ.xml:S3:1434:4	O
of	PRISTIQ.xml:S3:1439:2	O
activation	PRISTIQ.xml:S3:1442:10	O
of	PRISTIQ.xml:S3:1453:2	O
mania	PRISTIQ.xml:S3:1456:5	O
hypomania	PRISTIQ.xml:S3:1462:9	O
(	PRISTIQ.xml:S3:1472:1	O
5.6	PRISTIQ.xml:S3:1475:3	O
)	PRISTIQ.xml:S3:1480:1	O
.	PRISTIQ.xml:S3:1481:1	O

Discontinuation	PRISTIQ.xml:S3:1491:15	B-AdverseReaction
Syndrome	PRISTIQ.xml:S3:1507:8	I-AdverseReaction
:	PRISTIQ.xml:S3:1515:1	O
Taper	PRISTIQ.xml:S3:1517:5	O
dose	PRISTIQ.xml:S3:1523:4	O
when	PRISTIQ.xml:S3:1528:4	O
possible	PRISTIQ.xml:S3:1533:8	O
and	PRISTIQ.xml:S3:1542:3	O
monitor	PRISTIQ.xml:S3:1546:7	O
for	PRISTIQ.xml:S3:1554:3	O
discontinuation	PRISTIQ.xml:S3:1558:15	O
symptoms	PRISTIQ.xml:S3:1574:8	O
(	PRISTIQ.xml:S3:1583:1	O
5.7	PRISTIQ.xml:S3:1586:3	O
)	PRISTIQ.xml:S3:1591:1	O
.	PRISTIQ.xml:S3:1592:1	O

Seizure	PRISTIQ.xml:S3:1602:7	B-AdverseReaction
:	PRISTIQ.xml:S3:1609:1	O
Can	PRISTIQ.xml:S3:1611:3	O
occur	PRISTIQ.xml:S3:1615:5	O
.	PRISTIQ.xml:S3:1620:1	O

Use	PRISTIQ.xml:S3:1622:3	O
cautiously	PRISTIQ.xml:S3:1626:10	O
in	PRISTIQ.xml:S3:1637:2	O
patients	PRISTIQ.xml:S3:1640:8	O
with	PRISTIQ.xml:S3:1649:4	O
seizure	PRISTIQ.xml:S3:1654:7	O
disorder	PRISTIQ.xml:S3:1662:8	O
(	PRISTIQ.xml:S3:1671:1	O
5.8	PRISTIQ.xml:S3:1674:3	O
)	PRISTIQ.xml:S3:1679:1	O
.	PRISTIQ.xml:S3:1680:1	O

Hyponatremia	PRISTIQ.xml:S3:1690:12	B-AdverseReaction
:	PRISTIQ.xml:S3:1702:1	O
Can	PRISTIQ.xml:S3:1704:3	O
occur	PRISTIQ.xml:S3:1708:5	O
in	PRISTIQ.xml:S3:1714:2	O
association	PRISTIQ.xml:S3:1717:11	O
with	PRISTIQ.xml:S3:1729:4	O
SIADH	PRISTIQ.xml:S3:1734:5	O
(	PRISTIQ.xml:S3:1740:1	O
5.9	PRISTIQ.xml:S3:1743:3	O
)	PRISTIQ.xml:S3:1748:1	O
.	PRISTIQ.xml:S3:1749:1	O

Interstitial	PRISTIQ.xml:S3:1759:12	B-AdverseReaction
Lung	PRISTIQ.xml:S3:1772:4	I-AdverseReaction
Disease	PRISTIQ.xml:S3:1777:7	I-AdverseReaction
and	PRISTIQ.xml:S3:1785:3	O
Eosinophilic	PRISTIQ.xml:S3:1789:12	B-AdverseReaction
Pneumonia	PRISTIQ.xml:S3:1802:9	I-AdverseReaction
:	PRISTIQ.xml:S3:1811:1	O
Can	PRISTIQ.xml:S3:1813:3	O
occur	PRISTIQ.xml:S3:1817:5	O
(	PRISTIQ.xml:S3:1823:1	O
5.10	PRISTIQ.xml:S3:1826:4	O
)	PRISTIQ.xml:S3:1832:1	O
.	PRISTIQ.xml:S3:1833:1	O

5.1	PRISTIQ.xml:S3:1847:3	O

Suicidal	PRISTIQ.xml:S3:1851:8	O

Thoughts	PRISTIQ.xml:S3:1860:8	O
and	PRISTIQ.xml:S3:1869:3	O
Behaviors	PRISTIQ.xml:S3:1873:9	O
in	PRISTIQ.xml:S3:1883:2	O
Children	PRISTIQ.xml:S3:1886:8	O
,	PRISTIQ.xml:S3:1894:1	O
Adolescents	PRISTIQ.xml:S3:1896:11	O
and	PRISTIQ.xml:S3:1908:3	O
Young	PRISTIQ.xml:S3:1912:5	O
Adults	PRISTIQ.xml:S3:1918:6	O

Patients	PRISTIQ.xml:S3:1930:8	O
with	PRISTIQ.xml:S3:1939:4	O
major	PRISTIQ.xml:S3:1944:5	O
depressive	PRISTIQ.xml:S3:1950:10	O
disorder	PRISTIQ.xml:S3:1961:8	O
(	PRISTIQ.xml:S3:1970:1	O
MDD	PRISTIQ.xml:S3:1971:3	O
)	PRISTIQ.xml:S3:1974:1	O
,	PRISTIQ.xml:S3:1975:1	O
both	PRISTIQ.xml:S3:1977:4	O
adult	PRISTIQ.xml:S3:1982:5	O
and	PRISTIQ.xml:S3:1988:3	O
pediatric	PRISTIQ.xml:S3:1992:9	O
,	PRISTIQ.xml:S3:2001:1	O
may	PRISTIQ.xml:S3:2003:3	O
experience	PRISTIQ.xml:S3:2007:10	O
worsening	PRISTIQ.xml:S3:2018:9	O
of	PRISTIQ.xml:S3:2028:2	O
their	PRISTIQ.xml:S3:2031:5	O
depression	PRISTIQ.xml:S3:2037:10	O
and	PRISTIQ.xml:S3:2048:3	O
or	PRISTIQ.xml:S3:2052:2	O
the	PRISTIQ.xml:S3:2055:3	O
emergence	PRISTIQ.xml:S3:2059:9	O
of	PRISTIQ.xml:S3:2069:2	O
suicidal	PRISTIQ.xml:S3:2072:8	O
ideation	PRISTIQ.xml:S3:2081:8	O
and	PRISTIQ.xml:S3:2090:3	O
behavior	PRISTIQ.xml:S3:2094:8	O
(	PRISTIQ.xml:S3:2103:1	O
suicidality	PRISTIQ.xml:S3:2104:11	O
)	PRISTIQ.xml:S3:2115:1	O
or	PRISTIQ.xml:S3:2117:2	O
unusual	PRISTIQ.xml:S3:2120:7	O
changes	PRISTIQ.xml:S3:2128:7	O
in	PRISTIQ.xml:S3:2136:2	O
behavior	PRISTIQ.xml:S3:2139:8	O
,	PRISTIQ.xml:S3:2147:1	O
whether	PRISTIQ.xml:S3:2149:7	O
or	PRISTIQ.xml:S3:2157:2	O
not	PRISTIQ.xml:S3:2160:3	O
they	PRISTIQ.xml:S3:2164:4	O
are	PRISTIQ.xml:S3:2169:3	O
taking	PRISTIQ.xml:S3:2173:6	O
antidepressant	PRISTIQ.xml:S3:2180:14	O
medications	PRISTIQ.xml:S3:2195:11	O
,	PRISTIQ.xml:S3:2206:1	O
and	PRISTIQ.xml:S3:2208:3	O
this	PRISTIQ.xml:S3:2212:4	O
risk	PRISTIQ.xml:S3:2217:4	O
may	PRISTIQ.xml:S3:2222:3	O
persist	PRISTIQ.xml:S3:2226:7	O
until	PRISTIQ.xml:S3:2234:5	O
significant	PRISTIQ.xml:S3:2240:11	O
remission	PRISTIQ.xml:S3:2252:9	O
occurs	PRISTIQ.xml:S3:2262:6	O
.	PRISTIQ.xml:S3:2268:1	O

Suicide	PRISTIQ.xml:S3:2270:7	O
is	PRISTIQ.xml:S3:2278:2	O
a	PRISTIQ.xml:S3:2281:1	O
known	PRISTIQ.xml:S3:2283:5	O
risk	PRISTIQ.xml:S3:2289:4	O
of	PRISTIQ.xml:S3:2294:2	O
depression	PRISTIQ.xml:S3:2297:10	O
and	PRISTIQ.xml:S3:2308:3	O
certain	PRISTIQ.xml:S3:2312:7	O
other	PRISTIQ.xml:S3:2320:5	O
psychiatric	PRISTIQ.xml:S3:2326:11	O
disorders	PRISTIQ.xml:S3:2338:9	O
,	PRISTIQ.xml:S3:2347:1	O
and	PRISTIQ.xml:S3:2349:3	O
these	PRISTIQ.xml:S3:2353:5	O
disorders	PRISTIQ.xml:S3:2359:9	O
themselves	PRISTIQ.xml:S3:2369:10	O
are	PRISTIQ.xml:S3:2380:3	O
the	PRISTIQ.xml:S3:2384:3	O
strongest	PRISTIQ.xml:S3:2388:9	O
predictors	PRISTIQ.xml:S3:2398:10	O
of	PRISTIQ.xml:S3:2409:2	O
suicide	PRISTIQ.xml:S3:2412:7	O
.	PRISTIQ.xml:S3:2419:1	O

There	PRISTIQ.xml:S3:2421:5	O
has	PRISTIQ.xml:S3:2427:3	O
been	PRISTIQ.xml:S3:2431:4	O
a	PRISTIQ.xml:S3:2436:1	O
long	PRISTIQ.xml:S3:2438:4	O
-	PRISTIQ.xml:S3:2442:1	O
standing	PRISTIQ.xml:S3:2443:8	O
concern	PRISTIQ.xml:S3:2452:7	O
,	PRISTIQ.xml:S3:2459:1	O
however	PRISTIQ.xml:S3:2461:7	O
,	PRISTIQ.xml:S3:2468:1	O
that	PRISTIQ.xml:S3:2470:4	O
antidepressants	PRISTIQ.xml:S3:2475:15	B-DrugClass
may	PRISTIQ.xml:S3:2491:3	O
have	PRISTIQ.xml:S3:2495:4	O
a	PRISTIQ.xml:S3:2500:1	O
role	PRISTIQ.xml:S3:2502:4	O
in	PRISTIQ.xml:S3:2507:2	O
inducing	PRISTIQ.xml:S3:2510:8	O
worsening	PRISTIQ.xml:S3:2519:9	B-AdverseReaction
of	PRISTIQ.xml:S3:2529:2	I-AdverseReaction
depression	PRISTIQ.xml:S3:2532:10	I-AdverseReaction
and	PRISTIQ.xml:S3:2543:3	O
the	PRISTIQ.xml:S3:2547:3	O
emergence	PRISTIQ.xml:S3:2551:9	O
of	PRISTIQ.xml:S3:2561:2	O
suicidality	PRISTIQ.xml:S3:2564:11	B-AdverseReaction
in	PRISTIQ.xml:S3:2576:2	O
certain	PRISTIQ.xml:S3:2579:7	O
patients	PRISTIQ.xml:S3:2587:8	O
during	PRISTIQ.xml:S3:2596:6	O
the	PRISTIQ.xml:S3:2603:3	O
early	PRISTIQ.xml:S3:2607:5	O
phases	PRISTIQ.xml:S3:2613:6	O
of	PRISTIQ.xml:S3:2620:2	O
treatment	PRISTIQ.xml:S3:2623:9	O
.	PRISTIQ.xml:S3:2632:1	O

Pooled	PRISTIQ.xml:S3:2634:6	O
analyses	PRISTIQ.xml:S3:2641:8	O
of	PRISTIQ.xml:S3:2650:2	O
short	PRISTIQ.xml:S3:2653:5	O
-	PRISTIQ.xml:S3:2658:1	O
term	PRISTIQ.xml:S3:2659:4	O
placebo	PRISTIQ.xml:S3:2664:7	O
-	PRISTIQ.xml:S3:2671:1	O
controlled	PRISTIQ.xml:S3:2672:10	O
studies	PRISTIQ.xml:S3:2683:7	O
of	PRISTIQ.xml:S3:2691:2	O
antidepressant	PRISTIQ.xml:S3:2694:14	B-DrugClass
drugs	PRISTIQ.xml:S3:2709:5	I-DrugClass
(	PRISTIQ.xml:S3:2715:1	O
SSRIs	PRISTIQ.xml:S3:2716:5	O
and	PRISTIQ.xml:S3:2722:3	O
others	PRISTIQ.xml:S3:2726:6	O
)	PRISTIQ.xml:S3:2732:1	O
showed	PRISTIQ.xml:S3:2734:6	O
that	PRISTIQ.xml:S3:2741:4	O
these	PRISTIQ.xml:S3:2746:5	O
drugs	PRISTIQ.xml:S3:2752:5	O
increase	PRISTIQ.xml:S3:2758:8	O
the	PRISTIQ.xml:S3:2767:3	O
risk	PRISTIQ.xml:S3:2771:4	O
of	PRISTIQ.xml:S3:2776:2	O
suicidal	PRISTIQ.xml:S3:2779:8	B-AdverseReaction
thinking	PRISTIQ.xml:S3:2788:8	I-AdverseReaction
and	PRISTIQ.xml:S3:2797:3	O
behavior	PRISTIQ.xml:S3:2801:8	I-AdverseReaction
(	PRISTIQ.xml:S3:2810:1	O
suicidality	PRISTIQ.xml:S3:2811:11	B-AdverseReaction
)	PRISTIQ.xml:S3:2822:1	O
in	PRISTIQ.xml:S3:2824:2	O
children	PRISTIQ.xml:S3:2827:8	O
,	PRISTIQ.xml:S3:2835:1	O
adolescents	PRISTIQ.xml:S3:2837:11	O
,	PRISTIQ.xml:S3:2848:1	O
and	PRISTIQ.xml:S3:2850:3	O
young	PRISTIQ.xml:S3:2854:5	O
adults	PRISTIQ.xml:S3:2860:6	O
(	PRISTIQ.xml:S3:2867:1	O
ages	PRISTIQ.xml:S3:2868:4	O
18	PRISTIQ.xml:S3:2873:2	O
to	PRISTIQ.xml:S3:2876:2	O
24	PRISTIQ.xml:S3:2879:2	O
)	PRISTIQ.xml:S3:2881:1	O
with	PRISTIQ.xml:S3:2883:4	O
major	PRISTIQ.xml:S3:2888:5	O
depressive	PRISTIQ.xml:S3:2894:10	O
disorder	PRISTIQ.xml:S3:2905:8	O
(	PRISTIQ.xml:S3:2914:1	O
MDD	PRISTIQ.xml:S3:2915:3	O
)	PRISTIQ.xml:S3:2918:1	O
and	PRISTIQ.xml:S3:2920:3	O
other	PRISTIQ.xml:S3:2924:5	O
psychiatric	PRISTIQ.xml:S3:2930:11	O
disorders	PRISTIQ.xml:S3:2942:9	O
.	PRISTIQ.xml:S3:2951:1	O

Short	PRISTIQ.xml:S3:2953:5	O
-	PRISTIQ.xml:S3:2958:1	O
term	PRISTIQ.xml:S3:2959:4	O
studies	PRISTIQ.xml:S3:2964:7	O
did	PRISTIQ.xml:S3:2972:3	O
not	PRISTIQ.xml:S3:2976:3	B-Negation
show	PRISTIQ.xml:S3:2980:4	O
an	PRISTIQ.xml:S3:2985:2	O
increase	PRISTIQ.xml:S3:2988:8	O
in	PRISTIQ.xml:S3:2997:2	O
the	PRISTIQ.xml:S3:3000:3	O
risk	PRISTIQ.xml:S3:3004:4	O
of	PRISTIQ.xml:S3:3009:2	O
suicidality	PRISTIQ.xml:S3:3012:11	B-AdverseReaction
with	PRISTIQ.xml:S3:3024:4	O
antidepressants	PRISTIQ.xml:S3:3029:15	O
compared	PRISTIQ.xml:S3:3045:8	O
to	PRISTIQ.xml:S3:3054:2	O
placebo	PRISTIQ.xml:S3:3057:7	O
in	PRISTIQ.xml:S3:3065:2	O
adults	PRISTIQ.xml:S3:3068:6	O
beyond	PRISTIQ.xml:S3:3075:6	O
age	PRISTIQ.xml:S3:3082:3	O
24	PRISTIQ.xml:S3:3086:2	O
;	PRISTIQ.xml:S3:3088:1	O
there	PRISTIQ.xml:S3:3090:5	O
was	PRISTIQ.xml:S3:3096:3	O
a	PRISTIQ.xml:S3:3100:1	O
reduction	PRISTIQ.xml:S3:3102:9	O
with	PRISTIQ.xml:S3:3112:4	O
antidepressants	PRISTIQ.xml:S3:3117:15	O
compared	PRISTIQ.xml:S3:3133:8	O
to	PRISTIQ.xml:S3:3142:2	O
placebo	PRISTIQ.xml:S3:3145:7	O
in	PRISTIQ.xml:S3:3153:2	O
adults	PRISTIQ.xml:S3:3156:6	O
aged	PRISTIQ.xml:S3:3163:4	O
65	PRISTIQ.xml:S3:3168:2	O
and	PRISTIQ.xml:S3:3171:3	O
older	PRISTIQ.xml:S3:3175:5	O
.	PRISTIQ.xml:S3:3180:1	O

The	PRISTIQ.xml:S3:3186:3	O
pooled	PRISTIQ.xml:S3:3190:6	O
analyses	PRISTIQ.xml:S3:3197:8	O
of	PRISTIQ.xml:S3:3206:2	O
placebo	PRISTIQ.xml:S3:3209:7	O
-	PRISTIQ.xml:S3:3216:1	O
controlled	PRISTIQ.xml:S3:3217:10	O
studies	PRISTIQ.xml:S3:3228:7	O
in	PRISTIQ.xml:S3:3236:2	O
children	PRISTIQ.xml:S3:3239:8	O
and	PRISTIQ.xml:S3:3248:3	O
adolescents	PRISTIQ.xml:S3:3252:11	O
with	PRISTIQ.xml:S3:3264:4	O
MDD	PRISTIQ.xml:S3:3269:3	O
,	PRISTIQ.xml:S3:3272:1	O
obsessive	PRISTIQ.xml:S3:3274:9	O
compulsive	PRISTIQ.xml:S3:3284:10	O
disorder	PRISTIQ.xml:S3:3295:8	O
(	PRISTIQ.xml:S3:3304:1	O
OCD	PRISTIQ.xml:S3:3305:3	O
)	PRISTIQ.xml:S3:3308:1	O
,	PRISTIQ.xml:S3:3309:1	O
or	PRISTIQ.xml:S3:3311:2	O
other	PRISTIQ.xml:S3:3314:5	O
psychiatric	PRISTIQ.xml:S3:3320:11	O
disorders	PRISTIQ.xml:S3:3332:9	O
included	PRISTIQ.xml:S3:3342:8	O
a	PRISTIQ.xml:S3:3351:1	O
total	PRISTIQ.xml:S3:3353:5	O
of	PRISTIQ.xml:S3:3359:2	O
24	PRISTIQ.xml:S3:3362:2	O
short	PRISTIQ.xml:S3:3365:5	O
-	PRISTIQ.xml:S3:3370:1	O
term	PRISTIQ.xml:S3:3371:4	O
studies	PRISTIQ.xml:S3:3376:7	O
of	PRISTIQ.xml:S3:3384:2	O
9	PRISTIQ.xml:S3:3387:1	O
antidepressant	PRISTIQ.xml:S3:3389:14	O
drugs	PRISTIQ.xml:S3:3404:5	O
in	PRISTIQ.xml:S3:3410:2	O
over	PRISTIQ.xml:S3:3413:4	O
4	PRISTIQ.xml:S3:3418:1	O
,	PRISTIQ.xml:S3:3419:1	O
400	PRISTIQ.xml:S3:3420:3	O
patients	PRISTIQ.xml:S3:3424:8	O
.	PRISTIQ.xml:S3:3432:1	O

The	PRISTIQ.xml:S3:3434:3	O
pooled	PRISTIQ.xml:S3:3438:6	O
analyses	PRISTIQ.xml:S3:3445:8	O
of	PRISTIQ.xml:S3:3454:2	O
placebo	PRISTIQ.xml:S3:3457:7	O
-	PRISTIQ.xml:S3:3464:1	O
controlled	PRISTIQ.xml:S3:3465:10	O
studies	PRISTIQ.xml:S3:3476:7	O
in	PRISTIQ.xml:S3:3484:2	O
adults	PRISTIQ.xml:S3:3487:6	O
with	PRISTIQ.xml:S3:3494:4	O
MDD	PRISTIQ.xml:S3:3499:3	O
or	PRISTIQ.xml:S3:3503:2	O
other	PRISTIQ.xml:S3:3506:5	O
psychiatric	PRISTIQ.xml:S3:3512:11	O
disorders	PRISTIQ.xml:S3:3524:9	O
included	PRISTIQ.xml:S3:3534:8	O
a	PRISTIQ.xml:S3:3543:1	O
total	PRISTIQ.xml:S3:3545:5	O
of	PRISTIQ.xml:S3:3551:2	O
295	PRISTIQ.xml:S3:3554:3	O
short	PRISTIQ.xml:S3:3558:5	O
-	PRISTIQ.xml:S3:3563:1	O
term	PRISTIQ.xml:S3:3564:4	O
studies	PRISTIQ.xml:S3:3569:7	O
(	PRISTIQ.xml:S3:3577:1	O
median	PRISTIQ.xml:S3:3578:6	O
duration	PRISTIQ.xml:S3:3585:8	O
of	PRISTIQ.xml:S3:3594:2	O
2	PRISTIQ.xml:S3:3597:1	O
months	PRISTIQ.xml:S3:3599:6	O
)	PRISTIQ.xml:S3:3605:1	O
of	PRISTIQ.xml:S3:3607:2	O
11	PRISTIQ.xml:S3:3610:2	O
antidepressant	PRISTIQ.xml:S3:3613:14	O
drugs	PRISTIQ.xml:S3:3628:5	O
in	PRISTIQ.xml:S3:3634:2	O
over	PRISTIQ.xml:S3:3637:4	O
77	PRISTIQ.xml:S3:3642:2	O
,	PRISTIQ.xml:S3:3644:1	O
000	PRISTIQ.xml:S3:3645:3	O
patients	PRISTIQ.xml:S3:3649:8	O
.	PRISTIQ.xml:S3:3657:1	O

There	PRISTIQ.xml:S3:3659:5	O
was	PRISTIQ.xml:S3:3665:3	O
considerable	PRISTIQ.xml:S3:3669:12	O
variation	PRISTIQ.xml:S3:3682:9	O
in	PRISTIQ.xml:S3:3692:2	O
risk	PRISTIQ.xml:S3:3695:4	O
of	PRISTIQ.xml:S3:3700:2	O
suicidality	PRISTIQ.xml:S3:3703:11	B-AdverseReaction
among	PRISTIQ.xml:S3:3715:5	O
drugs	PRISTIQ.xml:S3:3721:5	B-DrugClass
,	PRISTIQ.xml:S3:3726:1	O
but	PRISTIQ.xml:S3:3728:3	O
a	PRISTIQ.xml:S3:3732:1	O
tendency	PRISTIQ.xml:S3:3734:8	O
toward	PRISTIQ.xml:S3:3743:6	O
an	PRISTIQ.xml:S3:3750:2	O
increase	PRISTIQ.xml:S3:3753:8	O
in	PRISTIQ.xml:S3:3762:2	O
the	PRISTIQ.xml:S3:3765:3	O
younger	PRISTIQ.xml:S3:3769:7	O
patients	PRISTIQ.xml:S3:3777:8	O
for	PRISTIQ.xml:S3:3786:3	O
almost	PRISTIQ.xml:S3:3790:6	O
all	PRISTIQ.xml:S3:3797:3	O
drugs	PRISTIQ.xml:S3:3801:5	O
studied	PRISTIQ.xml:S3:3807:7	O
.	PRISTIQ.xml:S3:3814:1	O

There	PRISTIQ.xml:S3:3816:5	O
were	PRISTIQ.xml:S3:3822:4	O
differences	PRISTIQ.xml:S3:3827:11	O
in	PRISTIQ.xml:S3:3839:2	O
absolute	PRISTIQ.xml:S3:3842:8	O
risk	PRISTIQ.xml:S3:3851:4	O
of	PRISTIQ.xml:S3:3856:2	O
suicidality	PRISTIQ.xml:S3:3859:11	B-AdverseReaction
across	PRISTIQ.xml:S3:3871:6	O
the	PRISTIQ.xml:S3:3878:3	O
different	PRISTIQ.xml:S3:3882:9	O
indications	PRISTIQ.xml:S3:3892:11	O
,	PRISTIQ.xml:S3:3903:1	O
with	PRISTIQ.xml:S3:3905:4	O
the	PRISTIQ.xml:S3:3910:3	O
highest	PRISTIQ.xml:S3:3914:7	O
incidence	PRISTIQ.xml:S3:3922:9	O
in	PRISTIQ.xml:S3:3932:2	O
MDD	PRISTIQ.xml:S3:3935:3	O
.	PRISTIQ.xml:S3:3938:1	O

The	PRISTIQ.xml:S3:3940:3	O
risk	PRISTIQ.xml:S3:3944:4	O
differences	PRISTIQ.xml:S3:3949:11	O
(	PRISTIQ.xml:S3:3961:1	O
drug	PRISTIQ.xml:S3:3962:4	O
vs	PRISTIQ.xml:S3:3967:2	O
.	PRISTIQ.xml:S3:3969:1	O

placebo	PRISTIQ.xml:S3:3971:7	O
)	PRISTIQ.xml:S3:3978:1	O
,	PRISTIQ.xml:S3:3979:1	O
however	PRISTIQ.xml:S3:3981:7	O
,	PRISTIQ.xml:S3:3988:1	O
were	PRISTIQ.xml:S3:3990:4	O
relatively	PRISTIQ.xml:S3:3995:10	O
stable	PRISTIQ.xml:S3:4006:6	O
within	PRISTIQ.xml:S3:4013:6	O
age	PRISTIQ.xml:S3:4020:3	O
strata	PRISTIQ.xml:S3:4024:6	O
and	PRISTIQ.xml:S3:4031:3	O
across	PRISTIQ.xml:S3:4035:6	O
indications	PRISTIQ.xml:S3:4042:11	O
.	PRISTIQ.xml:S3:4053:1	O

These	PRISTIQ.xml:S3:4055:5	O
risk	PRISTIQ.xml:S3:4061:4	O
differences	PRISTIQ.xml:S3:4066:11	O
(	PRISTIQ.xml:S3:4078:1	O
drug	PRISTIQ.xml:S3:4079:4	O
-	PRISTIQ.xml:S3:4083:1	O
placebo	PRISTIQ.xml:S3:4084:7	O
difference	PRISTIQ.xml:S3:4092:10	O
in	PRISTIQ.xml:S3:4103:2	O
the	PRISTIQ.xml:S3:4106:3	O
number	PRISTIQ.xml:S3:4110:6	O
of	PRISTIQ.xml:S3:4117:2	O
cases	PRISTIQ.xml:S3:4120:5	O
of	PRISTIQ.xml:S3:4126:2	O
suicidality	PRISTIQ.xml:S3:4129:11	B-AdverseReaction
per	PRISTIQ.xml:S3:4141:3	O
1	PRISTIQ.xml:S3:4145:1	O
,	PRISTIQ.xml:S3:4146:1	O
000	PRISTIQ.xml:S3:4147:3	O
patients	PRISTIQ.xml:S3:4151:8	O
treated	PRISTIQ.xml:S3:4160:7	O
)	PRISTIQ.xml:S3:4167:1	O
are	PRISTIQ.xml:S3:4169:3	O
provided	PRISTIQ.xml:S3:4173:8	O
in	PRISTIQ.xml:S3:4182:2	O
Table	PRISTIQ.xml:S3:4185:5	O
1	PRISTIQ.xml:S3:4191:1	O
.	PRISTIQ.xml:S3:4192:1	O

Table	PRISTIQ.xml:S3:4198:5	O
1	PRISTIQ.xml:S3:4204:1	O

Age	PRISTIQ.xml:S3:4209:3	O
Range	PRISTIQ.xml:S3:4213:5	O
Drug	PRISTIQ.xml:S3:4229:4	O
-	PRISTIQ.xml:S3:4233:1	O
Placebo	PRISTIQ.xml:S3:4234:7	O
Difference	PRISTIQ.xml:S3:4242:10	O
in	PRISTIQ.xml:S3:4253:2	O
Number	PRISTIQ.xml:S3:4256:6	O
of	PRISTIQ.xml:S3:4263:2	O
Cases	PRISTIQ.xml:S3:4266:5	O
of	PRISTIQ.xml:S3:4272:2	O
Suicidality	PRISTIQ.xml:S3:4275:11	B-AdverseReaction
per	PRISTIQ.xml:S3:4287:3	O
1	PRISTIQ.xml:S3:4291:1	O
,	PRISTIQ.xml:S3:4292:1	O
000	PRISTIQ.xml:S3:4293:3	O
Patients	PRISTIQ.xml:S3:4297:8	O
Treated	PRISTIQ.xml:S3:4306:7	O

Increases	PRISTIQ.xml:S3:4344:9	O

Compared	PRISTIQ.xml:S3:4354:8	O
to	PRISTIQ.xml:S3:4363:2	O
Placebo	PRISTIQ.xml:S3:4366:7	O

18	PRISTIQ.xml:S3:4419:2	O
14	PRISTIQ.xml:S3:4438:2	O
additional	PRISTIQ.xml:S3:4441:10	O
cases	PRISTIQ.xml:S3:4452:5	O

18	PRISTIQ.xml:S3:4512:2	O
to	PRISTIQ.xml:S3:4515:2	O
24	PRISTIQ.xml:S3:4518:2	O
5	PRISTIQ.xml:S3:4532:1	O
additional	PRISTIQ.xml:S3:4534:10	O
cases	PRISTIQ.xml:S3:4545:5	O

Decreases	PRISTIQ.xml:S3:4626:9	O
Compared	PRISTIQ.xml:S3:4636:8	O
to	PRISTIQ.xml:S3:4645:2	O
Placebo	PRISTIQ.xml:S3:4648:7	O

25	PRISTIQ.xml:S3:4700:2	O
to	PRISTIQ.xml:S3:4703:2	O
64	PRISTIQ.xml:S3:4706:2	O
1	PRISTIQ.xml:S3:4720:1	O
fewer	PRISTIQ.xml:S3:4722:5	O
case	PRISTIQ.xml:S3:4728:4	O

65	PRISTIQ.xml:S3:4796:2	O
6	PRISTIQ.xml:S3:4814:1	O
fewer	PRISTIQ.xml:S3:4816:5	O
cases	PRISTIQ.xml:S3:4822:5	O

No	PRISTIQ.xml:S3:4894:2	B-Negation
suicides	PRISTIQ.xml:S3:4897:8	B-AdverseReaction
occurred	PRISTIQ.xml:S3:4906:8	O
in	PRISTIQ.xml:S3:4915:2	O
any	PRISTIQ.xml:S3:4918:3	O
of	PRISTIQ.xml:S3:4922:2	O
the	PRISTIQ.xml:S3:4925:3	O
pediatric	PRISTIQ.xml:S3:4929:9	O
studies	PRISTIQ.xml:S3:4939:7	O
.	PRISTIQ.xml:S3:4946:1	O

There	PRISTIQ.xml:S3:4948:5	O
were	PRISTIQ.xml:S3:4954:4	O
suicides	PRISTIQ.xml:S3:4959:8	B-AdverseReaction
in	PRISTIQ.xml:S3:4968:2	O
the	PRISTIQ.xml:S3:4971:3	O
adult	PRISTIQ.xml:S3:4975:5	O
studies	PRISTIQ.xml:S3:4981:7	O
,	PRISTIQ.xml:S3:4988:1	O
but	PRISTIQ.xml:S3:4990:3	O
the	PRISTIQ.xml:S3:4994:3	O
number	PRISTIQ.xml:S3:4998:6	O
was	PRISTIQ.xml:S3:5005:3	O
not	PRISTIQ.xml:S3:5009:3	O
sufficient	PRISTIQ.xml:S3:5013:10	O
to	PRISTIQ.xml:S3:5024:2	O
reach	PRISTIQ.xml:S3:5027:5	O
any	PRISTIQ.xml:S3:5033:3	O
conclusion	PRISTIQ.xml:S3:5037:10	O
about	PRISTIQ.xml:S3:5048:5	O
drug	PRISTIQ.xml:S3:5054:4	O
effect	PRISTIQ.xml:S3:5059:6	O
on	PRISTIQ.xml:S3:5066:2	O
suicide	PRISTIQ.xml:S3:5069:7	O
.	PRISTIQ.xml:S3:5076:1	O

It	PRISTIQ.xml:S3:5082:2	O

is	PRISTIQ.xml:S3:5085:2	O
unknown	PRISTIQ.xml:S3:5088:7	O
whether	PRISTIQ.xml:S3:5096:7	O
the	PRISTIQ.xml:S3:5104:3	O
suicidality	PRISTIQ.xml:S3:5108:11	B-AdverseReaction
risk	PRISTIQ.xml:S3:5120:4	B-Factor
extends	PRISTIQ.xml:S3:5125:7	O
to	PRISTIQ.xml:S3:5133:2	O
longer	PRISTIQ.xml:S3:5136:6	O
-	PRISTIQ.xml:S3:5142:1	O
term	PRISTIQ.xml:S3:5143:4	O
use	PRISTIQ.xml:S3:5148:3	O
,	PRISTIQ.xml:S3:5151:1	O
i	PRISTIQ.xml:S3:5153:1	O
.	PRISTIQ.xml:S3:5154:1	O
e	PRISTIQ.xml:S3:5155:1	O
.	PRISTIQ.xml:S3:5156:1	O
,	PRISTIQ.xml:S3:5157:1	O
beyond	PRISTIQ.xml:S3:5159:6	O
several	PRISTIQ.xml:S3:5166:7	O
months	PRISTIQ.xml:S3:5174:6	O
.	PRISTIQ.xml:S3:5180:1	O

However	PRISTIQ.xml:S3:5182:7	O
,	PRISTIQ.xml:S3:5189:1	O
there	PRISTIQ.xml:S3:5191:5	O
is	PRISTIQ.xml:S3:5197:2	O
substantial	PRISTIQ.xml:S3:5200:11	O
evidence	PRISTIQ.xml:S3:5212:8	O
from	PRISTIQ.xml:S3:5221:4	O
placebo	PRISTIQ.xml:S3:5226:7	O
-	PRISTIQ.xml:S3:5233:1	O
controlled	PRISTIQ.xml:S3:5234:10	O
maintenance	PRISTIQ.xml:S3:5245:11	O
studies	PRISTIQ.xml:S3:5257:7	O
in	PRISTIQ.xml:S3:5265:2	O
adults	PRISTIQ.xml:S3:5268:6	O
with	PRISTIQ.xml:S3:5275:4	O
depression	PRISTIQ.xml:S3:5280:10	O
that	PRISTIQ.xml:S3:5291:4	O
the	PRISTIQ.xml:S3:5296:3	O
use	PRISTIQ.xml:S3:5300:3	O
of	PRISTIQ.xml:S3:5304:2	O
antidepressants	PRISTIQ.xml:S3:5307:15	O
can	PRISTIQ.xml:S3:5323:3	O
delay	PRISTIQ.xml:S3:5327:5	O
the	PRISTIQ.xml:S3:5333:3	O
recurrence	PRISTIQ.xml:S3:5337:10	O
of	PRISTIQ.xml:S3:5348:2	O
depression	PRISTIQ.xml:S3:5351:10	O
.	PRISTIQ.xml:S3:5361:1	O

All	PRISTIQ.xml:S3:5368:3	O
patients	PRISTIQ.xml:S3:5372:8	O
being	PRISTIQ.xml:S3:5381:5	O
treated	PRISTIQ.xml:S3:5387:7	O
with	PRISTIQ.xml:S3:5395:4	O
antidepressants	PRISTIQ.xml:S3:5400:15	O
for	PRISTIQ.xml:S3:5416:3	O
any	PRISTIQ.xml:S3:5420:3	O
indication	PRISTIQ.xml:S3:5424:10	O
should	PRISTIQ.xml:S3:5435:6	O
be	PRISTIQ.xml:S3:5442:2	O
monitored	PRISTIQ.xml:S3:5445:9	O
appropriately	PRISTIQ.xml:S3:5455:13	O
and	PRISTIQ.xml:S3:5469:3	O
observed	PRISTIQ.xml:S3:5473:8	O
closely	PRISTIQ.xml:S3:5482:7	O
for	PRISTIQ.xml:S3:5490:3	O
clinical	PRISTIQ.xml:S3:5494:8	O
worsening	PRISTIQ.xml:S3:5503:9	O
,	PRISTIQ.xml:S3:5512:1	O
suicidality	PRISTIQ.xml:S3:5514:11	O
,	PRISTIQ.xml:S3:5525:1	O
and	PRISTIQ.xml:S3:5527:3	O
unusual	PRISTIQ.xml:S3:5531:7	O
changes	PRISTIQ.xml:S3:5539:7	O
in	PRISTIQ.xml:S3:5547:2	O
behavior	PRISTIQ.xml:S3:5550:8	O
,	PRISTIQ.xml:S3:5558:1	O
especially	PRISTIQ.xml:S3:5560:10	O
during	PRISTIQ.xml:S3:5571:6	O
the	PRISTIQ.xml:S3:5578:3	O
initial	PRISTIQ.xml:S3:5582:7	O
few	PRISTIQ.xml:S3:5590:3	O
months	PRISTIQ.xml:S3:5594:6	O
of	PRISTIQ.xml:S3:5601:2	O
a	PRISTIQ.xml:S3:5604:1	O
course	PRISTIQ.xml:S3:5606:6	O
of	PRISTIQ.xml:S3:5613:2	O
drug	PRISTIQ.xml:S3:5616:4	O
therapy	PRISTIQ.xml:S3:5621:7	O
,	PRISTIQ.xml:S3:5628:1	O
or	PRISTIQ.xml:S3:5630:2	O
at	PRISTIQ.xml:S3:5633:2	O
times	PRISTIQ.xml:S3:5636:5	O
of	PRISTIQ.xml:S3:5642:2	O
dose	PRISTIQ.xml:S3:5645:4	O
changes	PRISTIQ.xml:S3:5650:7	O
,	PRISTIQ.xml:S3:5657:1	O
either	PRISTIQ.xml:S3:5659:6	O
increases	PRISTIQ.xml:S3:5666:9	O
or	PRISTIQ.xml:S3:5676:2	O
decreases	PRISTIQ.xml:S3:5679:9	O
.	PRISTIQ.xml:S3:5688:1	O

The	PRISTIQ.xml:S3:5696:3	O
following	PRISTIQ.xml:S3:5700:9	O
symptoms	PRISTIQ.xml:S3:5710:8	O
,	PRISTIQ.xml:S3:5718:1	O
anxiety	PRISTIQ.xml:S3:5720:7	B-AdverseReaction
,	PRISTIQ.xml:S3:5727:1	O
agitation	PRISTIQ.xml:S3:5729:9	B-AdverseReaction
,	PRISTIQ.xml:S3:5738:1	O
panic	PRISTIQ.xml:S3:5740:5	B-AdverseReaction
attacks	PRISTIQ.xml:S3:5746:7	I-AdverseReaction
,	PRISTIQ.xml:S3:5753:1	O
insomnia	PRISTIQ.xml:S3:5755:8	B-AdverseReaction
,	PRISTIQ.xml:S3:5763:1	O
irritability	PRISTIQ.xml:S3:5765:12	B-AdverseReaction
,	PRISTIQ.xml:S3:5777:1	O
hostility	PRISTIQ.xml:S3:5779:9	B-AdverseReaction
,	PRISTIQ.xml:S3:5788:1	O
aggressiveness	PRISTIQ.xml:S3:5790:14	B-AdverseReaction
,	PRISTIQ.xml:S3:5804:1	O
impulsivity	PRISTIQ.xml:S3:5806:11	B-AdverseReaction
,	PRISTIQ.xml:S3:5817:1	O
akathisia	PRISTIQ.xml:S3:5819:9	B-AdverseReaction
(	PRISTIQ.xml:S3:5829:1	O
psychomotor	PRISTIQ.xml:S3:5830:11	B-AdverseReaction
restlessness	PRISTIQ.xml:S3:5842:12	I-AdverseReaction
)	PRISTIQ.xml:S3:5854:1	O
,	PRISTIQ.xml:S3:5855:1	O
hypomania	PRISTIQ.xml:S3:5857:9	B-AdverseReaction
,	PRISTIQ.xml:S3:5866:1	O
and	PRISTIQ.xml:S3:5868:3	O
mania	PRISTIQ.xml:S3:5872:5	B-AdverseReaction
,	PRISTIQ.xml:S3:5877:1	O
have	PRISTIQ.xml:S3:5879:4	O
been	PRISTIQ.xml:S3:5884:4	O
reported	PRISTIQ.xml:S3:5889:8	O
in	PRISTIQ.xml:S3:5898:2	O
adult	PRISTIQ.xml:S3:5901:5	O
and	PRISTIQ.xml:S3:5907:3	O
pediatric	PRISTIQ.xml:S3:5911:9	O
patients	PRISTIQ.xml:S3:5921:8	O
being	PRISTIQ.xml:S3:5930:5	O
treated	PRISTIQ.xml:S3:5936:7	O
with	PRISTIQ.xml:S3:5944:4	O
antidepressants	PRISTIQ.xml:S3:5949:15	B-DrugClass
for	PRISTIQ.xml:S3:5965:3	O
major	PRISTIQ.xml:S3:5969:5	O
depressive	PRISTIQ.xml:S3:5975:10	O
disorder	PRISTIQ.xml:S3:5986:8	O
as	PRISTIQ.xml:S3:5995:2	O
well	PRISTIQ.xml:S3:5998:4	O
as	PRISTIQ.xml:S3:6003:2	O
for	PRISTIQ.xml:S3:6006:3	O
other	PRISTIQ.xml:S3:6010:5	O
indications	PRISTIQ.xml:S3:6016:11	O
,	PRISTIQ.xml:S3:6027:1	O
both	PRISTIQ.xml:S3:6029:4	O
psychiatric	PRISTIQ.xml:S3:6034:11	O
and	PRISTIQ.xml:S3:6046:3	O
nonpsychiatric	PRISTIQ.xml:S3:6050:14	O
.	PRISTIQ.xml:S3:6064:1	O

Although	PRISTIQ.xml:S3:6066:8	O
a	PRISTIQ.xml:S3:6075:1	O
causal	PRISTIQ.xml:S3:6077:6	O
link	PRISTIQ.xml:S3:6084:4	O
between	PRISTIQ.xml:S3:6089:7	O
the	PRISTIQ.xml:S3:6097:3	O
emergence	PRISTIQ.xml:S3:6101:9	O
of	PRISTIQ.xml:S3:6111:2	O
such	PRISTIQ.xml:S3:6114:4	O
symptoms	PRISTIQ.xml:S3:6119:8	O
and	PRISTIQ.xml:S3:6128:3	O
either	PRISTIQ.xml:S3:6132:6	O
the	PRISTIQ.xml:S3:6139:3	O
worsening	PRISTIQ.xml:S3:6143:9	B-AdverseReaction
of	PRISTIQ.xml:S3:6153:2	I-AdverseReaction
depression	PRISTIQ.xml:S3:6156:10	I-AdverseReaction
and	PRISTIQ.xml:S3:6167:3	O
or	PRISTIQ.xml:S3:6171:2	O
the	PRISTIQ.xml:S3:6174:3	O
emergence	PRISTIQ.xml:S3:6178:9	O
of	PRISTIQ.xml:S3:6188:2	O
suicidal	PRISTIQ.xml:S3:6191:8	B-AdverseReaction
impulses	PRISTIQ.xml:S3:6200:8	I-AdverseReaction
has	PRISTIQ.xml:S3:6209:3	O
not	PRISTIQ.xml:S3:6213:3	B-Negation
been	PRISTIQ.xml:S3:6217:4	I-Negation
established	PRISTIQ.xml:S3:6222:11	I-Negation
,	PRISTIQ.xml:S3:6233:1	O
there	PRISTIQ.xml:S3:6235:5	O
is	PRISTIQ.xml:S3:6241:2	O
concern	PRISTIQ.xml:S3:6244:7	O
that	PRISTIQ.xml:S3:6252:4	O
such	PRISTIQ.xml:S3:6257:4	O
symptoms	PRISTIQ.xml:S3:6262:8	O
may	PRISTIQ.xml:S3:6271:3	B-Factor
represent	PRISTIQ.xml:S3:6275:9	O
precursors	PRISTIQ.xml:S3:6285:10	O
to	PRISTIQ.xml:S3:6296:2	O
emerging	PRISTIQ.xml:S3:6299:8	O
suicidality	PRISTIQ.xml:S3:6308:11	B-AdverseReaction
.	PRISTIQ.xml:S3:6319:1	O

Consideration	PRISTIQ.xml:S3:6325:13	O
should	PRISTIQ.xml:S3:6339:6	O
be	PRISTIQ.xml:S3:6346:2	O
given	PRISTIQ.xml:S3:6349:5	O
to	PRISTIQ.xml:S3:6355:2	O
changing	PRISTIQ.xml:S3:6358:8	O
the	PRISTIQ.xml:S3:6367:3	O
therapeutic	PRISTIQ.xml:S3:6371:11	O
regimen	PRISTIQ.xml:S3:6383:7	O
,	PRISTIQ.xml:S3:6390:1	O
including	PRISTIQ.xml:S3:6392:9	O
possibly	PRISTIQ.xml:S3:6402:8	O
discontinuing	PRISTIQ.xml:S3:6411:13	O
the	PRISTIQ.xml:S3:6425:3	O
medication	PRISTIQ.xml:S3:6429:10	O
,	PRISTIQ.xml:S3:6439:1	O
in	PRISTIQ.xml:S3:6441:2	O
patients	PRISTIQ.xml:S3:6444:8	O
whose	PRISTIQ.xml:S3:6453:5	O
depression	PRISTIQ.xml:S3:6459:10	O
is	PRISTIQ.xml:S3:6470:2	O
persistently	PRISTIQ.xml:S3:6473:12	O
worse	PRISTIQ.xml:S3:6486:5	O
,	PRISTIQ.xml:S3:6491:1	O
or	PRISTIQ.xml:S3:6493:2	O
who	PRISTIQ.xml:S3:6496:3	O
are	PRISTIQ.xml:S3:6500:3	O
experiencing	PRISTIQ.xml:S3:6504:12	O
emergent	PRISTIQ.xml:S3:6517:8	O
suicidality	PRISTIQ.xml:S3:6526:11	O
or	PRISTIQ.xml:S3:6538:2	O
symptoms	PRISTIQ.xml:S3:6541:8	O
that	PRISTIQ.xml:S3:6550:4	O
might	PRISTIQ.xml:S3:6555:5	O
be	PRISTIQ.xml:S3:6561:2	O
precursors	PRISTIQ.xml:S3:6564:10	O
to	PRISTIQ.xml:S3:6575:2	O
worsening	PRISTIQ.xml:S3:6578:9	O
depression	PRISTIQ.xml:S3:6588:10	O
or	PRISTIQ.xml:S3:6599:2	O
suicidality	PRISTIQ.xml:S3:6602:11	O
,	PRISTIQ.xml:S3:6613:1	O
especially	PRISTIQ.xml:S3:6615:10	O
if	PRISTIQ.xml:S3:6626:2	O
these	PRISTIQ.xml:S3:6629:5	O
symptoms	PRISTIQ.xml:S3:6635:8	O
are	PRISTIQ.xml:S3:6644:3	O
severe	PRISTIQ.xml:S3:6648:6	O
,	PRISTIQ.xml:S3:6654:1	O
abrupt	PRISTIQ.xml:S3:6656:6	O
in	PRISTIQ.xml:S3:6663:2	O
onset	PRISTIQ.xml:S3:6666:5	O
,	PRISTIQ.xml:S3:6671:1	O
or	PRISTIQ.xml:S3:6673:2	O
were	PRISTIQ.xml:S3:6676:4	O
not	PRISTIQ.xml:S3:6681:3	O
part	PRISTIQ.xml:S3:6685:4	O
of	PRISTIQ.xml:S3:6690:2	O
the	PRISTIQ.xml:S3:6693:3	O
patient	PRISTIQ.xml:S3:6697:7	O
's	PRISTIQ.xml:S3:6704:2	O
presenting	PRISTIQ.xml:S3:6707:10	O
symptoms	PRISTIQ.xml:S3:6718:8	O
.	PRISTIQ.xml:S3:6726:1	O

If	PRISTIQ.xml:S3:6732:2	O
the	PRISTIQ.xml:S3:6735:3	O
decision	PRISTIQ.xml:S3:6739:8	O
has	PRISTIQ.xml:S3:6748:3	O
been	PRISTIQ.xml:S3:6752:4	O
made	PRISTIQ.xml:S3:6757:4	O
to	PRISTIQ.xml:S3:6762:2	O
discontinue	PRISTIQ.xml:S3:6765:11	O
treatment	PRISTIQ.xml:S3:6777:9	O
,	PRISTIQ.xml:S3:6786:1	O
medication	PRISTIQ.xml:S3:6788:10	O
should	PRISTIQ.xml:S3:6799:6	O
be	PRISTIQ.xml:S3:6806:2	O
tapered	PRISTIQ.xml:S3:6809:7	O
,	PRISTIQ.xml:S3:6816:1	O
as	PRISTIQ.xml:S3:6818:2	O
rapidly	PRISTIQ.xml:S3:6821:7	O
as	PRISTIQ.xml:S3:6829:2	O
is	PRISTIQ.xml:S3:6832:2	O
feasible	PRISTIQ.xml:S3:6835:8	O
,	PRISTIQ.xml:S3:6843:1	O
but	PRISTIQ.xml:S3:6845:3	O
with	PRISTIQ.xml:S3:6849:4	O
recognition	PRISTIQ.xml:S3:6854:11	O
that	PRISTIQ.xml:S3:6866:4	O
abrupt	PRISTIQ.xml:S3:6871:6	O
discontinuation	PRISTIQ.xml:S3:6878:15	O
can	PRISTIQ.xml:S3:6894:3	O
be	PRISTIQ.xml:S3:6898:2	O
associated	PRISTIQ.xml:S3:6901:10	O
with	PRISTIQ.xml:S3:6912:4	O
certain	PRISTIQ.xml:S3:6917:7	O
symptoms	PRISTIQ.xml:S3:6925:8	O
[	PRISTIQ.xml:S3:6934:1	O
see	PRISTIQ.xml:S3:6935:3	O
Dosage	PRISTIQ.xml:S3:6940:6	O
and	PRISTIQ.xml:S3:6947:3	O
Administration	PRISTIQ.xml:S3:6951:14	O
(	PRISTIQ.xml:S3:6966:1	O
2.4	PRISTIQ.xml:S3:6967:3	O
)	PRISTIQ.xml:S3:6970:1	O
and	PRISTIQ.xml:S3:6973:3	O
Warnings	PRISTIQ.xml:S3:6978:8	O
and	PRISTIQ.xml:S3:6987:3	O
Precautions	PRISTIQ.xml:S3:6991:11	O
(	PRISTIQ.xml:S3:7003:1	O
5.7	PRISTIQ.xml:S3:7004:3	O
)	PRISTIQ.xml:S3:7007:1	O
for	PRISTIQ.xml:S3:7010:3	O
a	PRISTIQ.xml:S3:7014:1	O
description	PRISTIQ.xml:S3:7016:11	O
of	PRISTIQ.xml:S3:7028:2	O
the	PRISTIQ.xml:S3:7031:3	O
risks	PRISTIQ.xml:S3:7035:5	O
of	PRISTIQ.xml:S3:7041:2	O
discontinuation	PRISTIQ.xml:S3:7044:15	O
of	PRISTIQ.xml:S3:7060:2	O
PRISTIQ	PRISTIQ.xml:S3:7063:7	O
]	PRISTIQ.xml:S3:7070:1	O
.	PRISTIQ.xml:S3:7073:1	O

Families	PRISTIQ.xml:S3:7080:8	O
and	PRISTIQ.xml:S3:7089:3	O
caregivers	PRISTIQ.xml:S3:7093:10	O
of	PRISTIQ.xml:S3:7104:2	O
patients	PRISTIQ.xml:S3:7107:8	O
being	PRISTIQ.xml:S3:7116:5	O
treated	PRISTIQ.xml:S3:7122:7	O
with	PRISTIQ.xml:S3:7130:4	O
antidepressants	PRISTIQ.xml:S3:7135:15	O
for	PRISTIQ.xml:S3:7151:3	O
major	PRISTIQ.xml:S3:7155:5	O
depressive	PRISTIQ.xml:S3:7161:10	O
disorder	PRISTIQ.xml:S3:7172:8	O
or	PRISTIQ.xml:S3:7181:2	O
other	PRISTIQ.xml:S3:7184:5	O
indications	PRISTIQ.xml:S3:7190:11	O
,	PRISTIQ.xml:S3:7201:1	O
both	PRISTIQ.xml:S3:7203:4	O
psychiatric	PRISTIQ.xml:S3:7208:11	O
and	PRISTIQ.xml:S3:7220:3	O
nonpsychiatric	PRISTIQ.xml:S3:7224:14	O
,	PRISTIQ.xml:S3:7238:1	O
should	PRISTIQ.xml:S3:7240:6	O
be	PRISTIQ.xml:S3:7247:2	O
alerted	PRISTIQ.xml:S3:7250:7	O
about	PRISTIQ.xml:S3:7258:5	O
the	PRISTIQ.xml:S3:7264:3	O
need	PRISTIQ.xml:S3:7268:4	O
to	PRISTIQ.xml:S3:7273:2	O
monitor	PRISTIQ.xml:S3:7276:7	O
patients	PRISTIQ.xml:S3:7284:8	O
for	PRISTIQ.xml:S3:7293:3	O
the	PRISTIQ.xml:S3:7297:3	O
emergence	PRISTIQ.xml:S3:7301:9	O
of	PRISTIQ.xml:S3:7311:2	O
agitation	PRISTIQ.xml:S3:7314:9	O
,	PRISTIQ.xml:S3:7323:1	O
irritability	PRISTIQ.xml:S3:7325:12	O
,	PRISTIQ.xml:S3:7337:1	O
unusual	PRISTIQ.xml:S3:7339:7	O
changes	PRISTIQ.xml:S3:7347:7	O
in	PRISTIQ.xml:S3:7355:2	O
behavior	PRISTIQ.xml:S3:7358:8	O
,	PRISTIQ.xml:S3:7366:1	O
and	PRISTIQ.xml:S3:7368:3	O
the	PRISTIQ.xml:S3:7372:3	O
other	PRISTIQ.xml:S3:7376:5	O
symptoms	PRISTIQ.xml:S3:7382:8	O
described	PRISTIQ.xml:S3:7391:9	O
above	PRISTIQ.xml:S3:7401:5	O
,	PRISTIQ.xml:S3:7406:1	O
as	PRISTIQ.xml:S3:7408:2	O
well	PRISTIQ.xml:S3:7411:4	O
as	PRISTIQ.xml:S3:7416:2	O
the	PRISTIQ.xml:S3:7419:3	O
emergence	PRISTIQ.xml:S3:7423:9	O
of	PRISTIQ.xml:S3:7433:2	O
suicidality	PRISTIQ.xml:S3:7436:11	O
,	PRISTIQ.xml:S3:7447:1	O
and	PRISTIQ.xml:S3:7449:3	O
to	PRISTIQ.xml:S3:7453:2	O
report	PRISTIQ.xml:S3:7456:6	O
such	PRISTIQ.xml:S3:7463:4	O
symptoms	PRISTIQ.xml:S3:7468:8	O
immediately	PRISTIQ.xml:S3:7477:11	O
to	PRISTIQ.xml:S3:7489:2	O
healthcare	PRISTIQ.xml:S3:7492:10	O
providers	PRISTIQ.xml:S3:7503:9	O
.	PRISTIQ.xml:S3:7512:1	O

Such	PRISTIQ.xml:S3:7514:4	O
monitoring	PRISTIQ.xml:S3:7519:10	O
should	PRISTIQ.xml:S3:7530:6	O
include	PRISTIQ.xml:S3:7537:7	O
daily	PRISTIQ.xml:S3:7545:5	O
observation	PRISTIQ.xml:S3:7551:11	O
by	PRISTIQ.xml:S3:7563:2	O
families	PRISTIQ.xml:S3:7566:8	O
and	PRISTIQ.xml:S3:7575:3	O
caregivers	PRISTIQ.xml:S3:7579:10	O
.	PRISTIQ.xml:S3:7591:1	O

Prescriptions	PRISTIQ.xml:S3:7597:13	O
for	PRISTIQ.xml:S3:7611:3	O
PRISTIQ	PRISTIQ.xml:S3:7615:7	O
should	PRISTIQ.xml:S3:7623:6	O
be	PRISTIQ.xml:S3:7630:2	O
written	PRISTIQ.xml:S3:7633:7	O
for	PRISTIQ.xml:S3:7641:3	O
the	PRISTIQ.xml:S3:7645:3	O
smallest	PRISTIQ.xml:S3:7649:8	O
quantity	PRISTIQ.xml:S3:7658:8	O
of	PRISTIQ.xml:S3:7667:2	O
tablets	PRISTIQ.xml:S3:7670:7	O
consistent	PRISTIQ.xml:S3:7678:10	O
with	PRISTIQ.xml:S3:7689:4	O
good	PRISTIQ.xml:S3:7694:4	O
patient	PRISTIQ.xml:S3:7699:7	O
management	PRISTIQ.xml:S3:7707:10	O
,	PRISTIQ.xml:S3:7717:1	O
in	PRISTIQ.xml:S3:7719:2	O
order	PRISTIQ.xml:S3:7722:5	O
to	PRISTIQ.xml:S3:7728:2	O
reduce	PRISTIQ.xml:S3:7731:6	O
the	PRISTIQ.xml:S3:7738:3	O
risk	PRISTIQ.xml:S3:7742:4	O
of	PRISTIQ.xml:S3:7747:2	O
overdose	PRISTIQ.xml:S3:7750:8	O
.	PRISTIQ.xml:S3:7758:1	O

Screening	PRISTIQ.xml:S3:7767:9	O
patients	PRISTIQ.xml:S3:7777:8	O
for	PRISTIQ.xml:S3:7786:3	O
bipolar	PRISTIQ.xml:S3:7790:7	O
disorder	PRISTIQ.xml:S3:7798:8	O

A	PRISTIQ.xml:S3:7813:1	O
major	PRISTIQ.xml:S3:7815:5	O
depressive	PRISTIQ.xml:S3:7821:10	O
episode	PRISTIQ.xml:S3:7832:7	O
may	PRISTIQ.xml:S3:7840:3	O
be	PRISTIQ.xml:S3:7844:2	O
the	PRISTIQ.xml:S3:7847:3	O
initial	PRISTIQ.xml:S3:7851:7	O
presentation	PRISTIQ.xml:S3:7859:12	O
of	PRISTIQ.xml:S3:7872:2	O
bipolar	PRISTIQ.xml:S3:7875:7	O
disorder	PRISTIQ.xml:S3:7883:8	O
.	PRISTIQ.xml:S3:7891:1	O

It	PRISTIQ.xml:S3:7893:2	O
is	PRISTIQ.xml:S3:7896:2	O
generally	PRISTIQ.xml:S3:7899:9	O
believed	PRISTIQ.xml:S3:7909:8	O
(	PRISTIQ.xml:S3:7918:1	O
though	PRISTIQ.xml:S3:7919:6	O
not	PRISTIQ.xml:S3:7926:3	O
established	PRISTIQ.xml:S3:7930:11	O
in	PRISTIQ.xml:S3:7942:2	O
controlled	PRISTIQ.xml:S3:7945:10	O
studies	PRISTIQ.xml:S3:7956:7	O
)	PRISTIQ.xml:S3:7963:1	O
that	PRISTIQ.xml:S3:7965:4	O
treating	PRISTIQ.xml:S3:7970:8	O
such	PRISTIQ.xml:S3:7979:4	O
an	PRISTIQ.xml:S3:7984:2	O
episode	PRISTIQ.xml:S3:7987:7	O
with	PRISTIQ.xml:S3:7995:4	O
an	PRISTIQ.xml:S3:8000:2	O
antidepressant	PRISTIQ.xml:S3:8003:14	B-DrugClass
alone	PRISTIQ.xml:S3:8018:5	O
may	PRISTIQ.xml:S3:8024:3	O
increase	PRISTIQ.xml:S3:8028:8	O
the	PRISTIQ.xml:S3:8037:3	O
likelihood	PRISTIQ.xml:S3:8041:10	O
of	PRISTIQ.xml:S3:8052:2	O
precipitation	PRISTIQ.xml:S3:8055:13	B-AdverseReaction
of	PRISTIQ.xml:S3:8069:2	I-AdverseReaction
a	PRISTIQ.xml:S3:8072:1	I-AdverseReaction
mixed	PRISTIQ.xml:S3:8074:5	I-AdverseReaction
manic	PRISTIQ.xml:S3:8080:5	I-AdverseReaction
episode	PRISTIQ.xml:S3:8086:7	I-AdverseReaction
in	PRISTIQ.xml:S3:8094:2	O
patients	PRISTIQ.xml:S3:8097:8	O
at	PRISTIQ.xml:S3:8106:2	O
risk	PRISTIQ.xml:S3:8109:4	O
for	PRISTIQ.xml:S3:8114:3	O
bipolar	PRISTIQ.xml:S3:8118:7	O
disorder	PRISTIQ.xml:S3:8126:8	O
.	PRISTIQ.xml:S3:8134:1	O

Whether	PRISTIQ.xml:S3:8136:7	O
any	PRISTIQ.xml:S3:8144:3	O
of	PRISTIQ.xml:S3:8148:2	O
the	PRISTIQ.xml:S3:8151:3	O
symptoms	PRISTIQ.xml:S3:8155:8	O
described	PRISTIQ.xml:S3:8164:9	O
above	PRISTIQ.xml:S3:8174:5	O
represent	PRISTIQ.xml:S3:8180:9	O
such	PRISTIQ.xml:S3:8190:4	O
a	PRISTIQ.xml:S3:8195:1	O
conversion	PRISTIQ.xml:S3:8197:10	O
is	PRISTIQ.xml:S3:8208:2	O
unknown	PRISTIQ.xml:S3:8211:7	O
.	PRISTIQ.xml:S3:8218:1	O

However	PRISTIQ.xml:S3:8220:7	O
,	PRISTIQ.xml:S3:8227:1	O
prior	PRISTIQ.xml:S3:8229:5	O
to	PRISTIQ.xml:S3:8235:2	O
initiating	PRISTIQ.xml:S3:8238:10	O
treatment	PRISTIQ.xml:S3:8249:9	O
with	PRISTIQ.xml:S3:8259:4	O
an	PRISTIQ.xml:S3:8264:2	O
antidepressant	PRISTIQ.xml:S3:8267:14	O
,	PRISTIQ.xml:S3:8281:1	O
patients	PRISTIQ.xml:S3:8283:8	O
with	PRISTIQ.xml:S3:8292:4	O
depressive	PRISTIQ.xml:S3:8297:10	O
symptoms	PRISTIQ.xml:S3:8308:8	O
should	PRISTIQ.xml:S3:8317:6	O
be	PRISTIQ.xml:S3:8324:2	O
adequately	PRISTIQ.xml:S3:8327:10	O
screened	PRISTIQ.xml:S3:8338:8	O
to	PRISTIQ.xml:S3:8347:2	O
determine	PRISTIQ.xml:S3:8350:9	O
if	PRISTIQ.xml:S3:8360:2	O
they	PRISTIQ.xml:S3:8363:4	O
are	PRISTIQ.xml:S3:8368:3	O
at	PRISTIQ.xml:S3:8372:2	O
risk	PRISTIQ.xml:S3:8375:4	O
for	PRISTIQ.xml:S3:8380:3	O
bipolar	PRISTIQ.xml:S3:8384:7	O
disorder	PRISTIQ.xml:S3:8392:8	O
;	PRISTIQ.xml:S3:8400:1	O
such	PRISTIQ.xml:S3:8402:4	O
screening	PRISTIQ.xml:S3:8407:9	O
should	PRISTIQ.xml:S3:8417:6	O
include	PRISTIQ.xml:S3:8424:7	O
a	PRISTIQ.xml:S3:8432:1	O
detailed	PRISTIQ.xml:S3:8434:8	O
psychiatric	PRISTIQ.xml:S3:8443:11	O
history	PRISTIQ.xml:S3:8455:7	O
,	PRISTIQ.xml:S3:8462:1	O
including	PRISTIQ.xml:S3:8464:9	O
a	PRISTIQ.xml:S3:8474:1	O
family	PRISTIQ.xml:S3:8476:6	O
history	PRISTIQ.xml:S3:8483:7	O
of	PRISTIQ.xml:S3:8491:2	O
suicide	PRISTIQ.xml:S3:8494:7	O
,	PRISTIQ.xml:S3:8501:1	O
bipolar	PRISTIQ.xml:S3:8503:7	O
disorder	PRISTIQ.xml:S3:8511:8	O
,	PRISTIQ.xml:S3:8519:1	O
and	PRISTIQ.xml:S3:8521:3	O
depression	PRISTIQ.xml:S3:8525:10	O
.	PRISTIQ.xml:S3:8535:1	O

It	PRISTIQ.xml:S3:8537:2	O
should	PRISTIQ.xml:S3:8540:6	O
be	PRISTIQ.xml:S3:8547:2	O
noted	PRISTIQ.xml:S3:8550:5	O
that	PRISTIQ.xml:S3:8556:4	O
PRISTIQ	PRISTIQ.xml:S3:8561:7	O
is	PRISTIQ.xml:S3:8569:2	O
not	PRISTIQ.xml:S3:8572:3	O
approved	PRISTIQ.xml:S3:8576:8	O
for	PRISTIQ.xml:S3:8585:3	O
use	PRISTIQ.xml:S3:8589:3	O
in	PRISTIQ.xml:S3:8593:2	O
treating	PRISTIQ.xml:S3:8596:8	O
bipolar	PRISTIQ.xml:S3:8605:7	O
depression	PRISTIQ.xml:S3:8613:10	O
.	PRISTIQ.xml:S3:8623:1	O

5.2	PRISTIQ.xml:S3:8632:3	O
Serotonin	PRISTIQ.xml:S3:8636:9	O
Syndrome	PRISTIQ.xml:S3:8646:8	O

The	PRISTIQ.xml:S3:8660:3	O
development	PRISTIQ.xml:S3:8664:11	O
of	PRISTIQ.xml:S3:8676:2	O
a	PRISTIQ.xml:S3:8679:1	O
potentially	PRISTIQ.xml:S3:8681:11	B-Factor
life	PRISTIQ.xml:S3:8693:4	B-Severity
-	PRISTIQ.xml:S3:8697:1	I-Severity
threatening	PRISTIQ.xml:S3:8698:11	I-Severity
serotonin	PRISTIQ.xml:S3:8710:9	B-AdverseReaction
syndrome	PRISTIQ.xml:S3:8720:8	I-AdverseReaction
has	PRISTIQ.xml:S3:8729:3	O
been	PRISTIQ.xml:S3:8733:4	O
reported	PRISTIQ.xml:S3:8738:8	O
with	PRISTIQ.xml:S3:8747:4	O
SNRIs	PRISTIQ.xml:S3:8752:5	O
and	PRISTIQ.xml:S3:8758:3	O
SSRIs	PRISTIQ.xml:S3:8762:5	O
,	PRISTIQ.xml:S3:8767:1	O
including	PRISTIQ.xml:S3:8769:9	O
PRISTIQ	PRISTIQ.xml:S3:8779:7	O
,	PRISTIQ.xml:S3:8786:1	O
alone	PRISTIQ.xml:S3:8788:5	O
but	PRISTIQ.xml:S3:8794:3	O
particularly	PRISTIQ.xml:S3:8798:12	O
with	PRISTIQ.xml:S3:8811:4	O
concomitant	PRISTIQ.xml:S3:8816:11	O
use	PRISTIQ.xml:S3:8828:3	O
of	PRISTIQ.xml:S3:8832:2	O
other	PRISTIQ.xml:S3:8835:5	O
serotonergic	PRISTIQ.xml:S3:8841:12	O
drugs	PRISTIQ.xml:S3:8854:5	O
(	PRISTIQ.xml:S3:8860:1	O
including	PRISTIQ.xml:S3:8861:9	O
triptans	PRISTIQ.xml:S3:8871:8	O
,	PRISTIQ.xml:S3:8879:1	O
tricyclic	PRISTIQ.xml:S3:8881:9	O
antidepressants	PRISTIQ.xml:S3:8891:15	O
,	PRISTIQ.xml:S3:8906:1	O
fentanyl	PRISTIQ.xml:S3:8908:8	O
,	PRISTIQ.xml:S3:8916:1	O
lithium	PRISTIQ.xml:S3:8918:7	O
,	PRISTIQ.xml:S3:8925:1	O
tramadol	PRISTIQ.xml:S3:8927:8	O
,	PRISTIQ.xml:S3:8935:1	O
tryptophan	PRISTIQ.xml:S3:8937:10	O
,	PRISTIQ.xml:S3:8947:1	O
buspirone	PRISTIQ.xml:S3:8949:9	O
,	PRISTIQ.xml:S3:8958:1	O
and	PRISTIQ.xml:S3:8960:3	O
St	PRISTIQ.xml:S3:8964:2	O
.	PRISTIQ.xml:S3:8966:1	O

John	PRISTIQ.xml:S3:8968:4	O
's	PRISTIQ.xml:S3:8972:2	O
Wort	PRISTIQ.xml:S3:8975:4	O
)	PRISTIQ.xml:S3:8979:1	O
,	PRISTIQ.xml:S3:8980:1	O
and	PRISTIQ.xml:S3:8982:3	O
with	PRISTIQ.xml:S3:8986:4	O
drugs	PRISTIQ.xml:S3:8991:5	O
that	PRISTIQ.xml:S3:8997:4	O
impair	PRISTIQ.xml:S3:9002:6	O
metabolism	PRISTIQ.xml:S3:9009:10	O
of	PRISTIQ.xml:S3:9020:2	O
serotonin	PRISTIQ.xml:S3:9023:9	O
(	PRISTIQ.xml:S3:9033:1	O
in	PRISTIQ.xml:S3:9034:2	O
particular	PRISTIQ.xml:S3:9037:10	O
,	PRISTIQ.xml:S3:9047:1	O
MAOIs	PRISTIQ.xml:S3:9049:5	O
,	PRISTIQ.xml:S3:9054:1	O
both	PRISTIQ.xml:S3:9056:4	O
those	PRISTIQ.xml:S3:9061:5	O
intended	PRISTIQ.xml:S3:9067:8	O
to	PRISTIQ.xml:S3:9076:2	O
treat	PRISTIQ.xml:S3:9079:5	O
psychiatric	PRISTIQ.xml:S3:9085:11	O
disorders	PRISTIQ.xml:S3:9097:9	O
and	PRISTIQ.xml:S3:9107:3	O
also	PRISTIQ.xml:S3:9111:4	O
others	PRISTIQ.xml:S3:9116:6	O
,	PRISTIQ.xml:S3:9122:1	O
such	PRISTIQ.xml:S3:9124:4	O
as	PRISTIQ.xml:S3:9129:2	O
linezolid	PRISTIQ.xml:S3:9132:9	O
and	PRISTIQ.xml:S3:9142:3	O
intravenous	PRISTIQ.xml:S3:9146:11	O
methylene	PRISTIQ.xml:S3:9158:9	O
blue	PRISTIQ.xml:S3:9168:4	O
)	PRISTIQ.xml:S3:9172:1	O
.	PRISTIQ.xml:S3:9173:1	O

Serotonin	PRISTIQ.xml:S3:9179:9	B-AdverseReaction
syndrome	PRISTIQ.xml:S3:9189:8	I-AdverseReaction
symptoms	PRISTIQ.xml:S3:9198:8	O
may	PRISTIQ.xml:S3:9207:3	B-Factor
include	PRISTIQ.xml:S3:9211:7	O
mental	PRISTIQ.xml:S3:9219:6	B-AdverseReaction
status	PRISTIQ.xml:S3:9226:6	I-AdverseReaction
changes	PRISTIQ.xml:S3:9233:7	I-AdverseReaction
(	PRISTIQ.xml:S3:9241:1	O
e	PRISTIQ.xml:S3:9242:1	O
.	PRISTIQ.xml:S3:9243:1	O
g	PRISTIQ.xml:S3:9244:1	O
.	PRISTIQ.xml:S3:9245:1	O
,	PRISTIQ.xml:S3:9246:1	O
agitation	PRISTIQ.xml:S3:9248:9	B-AdverseReaction
,	PRISTIQ.xml:S3:9257:1	O
hallucinations	PRISTIQ.xml:S3:9259:14	B-AdverseReaction
,	PRISTIQ.xml:S3:9273:1	O
delirium	PRISTIQ.xml:S3:9275:8	B-AdverseReaction
,	PRISTIQ.xml:S3:9283:1	O
and	PRISTIQ.xml:S3:9285:3	O
coma	PRISTIQ.xml:S3:9289:4	B-AdverseReaction
)	PRISTIQ.xml:S3:9293:1	O
,	PRISTIQ.xml:S3:9294:1	O
autonomic	PRISTIQ.xml:S3:9296:9	B-AdverseReaction
instability	PRISTIQ.xml:S3:9306:11	I-AdverseReaction
(	PRISTIQ.xml:S3:9318:1	O
e	PRISTIQ.xml:S3:9319:1	O
.	PRISTIQ.xml:S3:9320:1	O
g	PRISTIQ.xml:S3:9321:1	O
.	PRISTIQ.xml:S3:9322:1	O
,	PRISTIQ.xml:S3:9323:1	O
tachycardia	PRISTIQ.xml:S3:9325:11	B-AdverseReaction
,	PRISTIQ.xml:S3:9336:1	O
labile	PRISTIQ.xml:S3:9338:6	B-AdverseReaction
blood	PRISTIQ.xml:S3:9345:5	I-AdverseReaction
pressure	PRISTIQ.xml:S3:9351:8	I-AdverseReaction
,	PRISTIQ.xml:S3:9359:1	O
dizziness	PRISTIQ.xml:S3:9361:9	B-AdverseReaction
,	PRISTIQ.xml:S3:9370:1	O
diaphoresis	PRISTIQ.xml:S3:9372:11	B-AdverseReaction
,	PRISTIQ.xml:S3:9383:1	O
flushing	PRISTIQ.xml:S3:9385:8	B-AdverseReaction
,	PRISTIQ.xml:S3:9393:1	O
hyperthermia	PRISTIQ.xml:S3:9395:12	B-AdverseReaction
)	PRISTIQ.xml:S3:9407:1	O
,	PRISTIQ.xml:S3:9408:1	O
neuromuscular	PRISTIQ.xml:S3:9410:13	B-AdverseReaction
symptoms	PRISTIQ.xml:S3:9424:8	I-AdverseReaction
(	PRISTIQ.xml:S3:9433:1	O
e	PRISTIQ.xml:S3:9434:1	O
.	PRISTIQ.xml:S3:9435:1	O
g	PRISTIQ.xml:S3:9436:1	O
.	PRISTIQ.xml:S3:9437:1	O
,	PRISTIQ.xml:S3:9438:1	O
tremor	PRISTIQ.xml:S3:9440:6	B-AdverseReaction
,	PRISTIQ.xml:S3:9446:1	O
rigidity	PRISTIQ.xml:S3:9448:8	B-AdverseReaction
,	PRISTIQ.xml:S3:9456:1	O
myoclonus	PRISTIQ.xml:S3:9458:9	B-AdverseReaction
,	PRISTIQ.xml:S3:9467:1	O
hyperreflexia	PRISTIQ.xml:S3:9469:13	B-AdverseReaction
,	PRISTIQ.xml:S3:9482:1	O
incoordination	PRISTIQ.xml:S3:9484:14	B-AdverseReaction
)	PRISTIQ.xml:S3:9498:1	O
,	PRISTIQ.xml:S3:9499:1	O
seizures	PRISTIQ.xml:S3:9501:8	B-AdverseReaction
,	PRISTIQ.xml:S3:9509:1	O
and	PRISTIQ.xml:S3:9511:3	O
or	PRISTIQ.xml:S3:9515:2	O
gastrointestinal	PRISTIQ.xml:S3:9518:16	B-AdverseReaction
symptoms	PRISTIQ.xml:S3:9535:8	I-AdverseReaction
(	PRISTIQ.xml:S3:9544:1	O
e	PRISTIQ.xml:S3:9545:1	O
.	PRISTIQ.xml:S3:9546:1	O
g	PRISTIQ.xml:S3:9547:1	O
.	PRISTIQ.xml:S3:9548:1	O
,	PRISTIQ.xml:S3:9549:1	O
nausea	PRISTIQ.xml:S3:9551:6	B-AdverseReaction
,	PRISTIQ.xml:S3:9557:1	O
vomiting	PRISTIQ.xml:S3:9559:8	B-AdverseReaction
,	PRISTIQ.xml:S3:9567:1	O
diarrhea	PRISTIQ.xml:S3:9569:8	B-AdverseReaction
)	PRISTIQ.xml:S3:9577:1	O
.	PRISTIQ.xml:S3:9578:1	O

Patients	PRISTIQ.xml:S3:9580:8	O
should	PRISTIQ.xml:S3:9589:6	O
be	PRISTIQ.xml:S3:9596:2	O
monitored	PRISTIQ.xml:S3:9599:9	O
for	PRISTIQ.xml:S3:9609:3	O
the	PRISTIQ.xml:S3:9613:3	O
emergence	PRISTIQ.xml:S3:9617:9	O
of	PRISTIQ.xml:S3:9627:2	O
serotonin	PRISTIQ.xml:S3:9630:9	O
syndrome	PRISTIQ.xml:S3:9640:8	O
.	PRISTIQ.xml:S3:9648:1	O

The	PRISTIQ.xml:S3:9654:3	O
concomitant	PRISTIQ.xml:S3:9658:11	O
use	PRISTIQ.xml:S3:9670:3	O
of	PRISTIQ.xml:S3:9674:2	O
PRISTIQ	PRISTIQ.xml:S3:9677:7	O
with	PRISTIQ.xml:S3:9685:4	O
MAOIs	PRISTIQ.xml:S3:9690:5	O
intended	PRISTIQ.xml:S3:9696:8	O
to	PRISTIQ.xml:S3:9705:2	O
treat	PRISTIQ.xml:S3:9708:5	O
psychiatric	PRISTIQ.xml:S3:9714:11	O
disorders	PRISTIQ.xml:S3:9726:9	O
is	PRISTIQ.xml:S3:9736:2	O
contraindicated	PRISTIQ.xml:S3:9739:15	O
.	PRISTIQ.xml:S3:9754:1	O

PRISTIQ	PRISTIQ.xml:S3:9756:7	O
should	PRISTIQ.xml:S3:9764:6	O
also	PRISTIQ.xml:S3:9771:4	O
not	PRISTIQ.xml:S3:9776:3	O
be	PRISTIQ.xml:S3:9780:2	O
started	PRISTIQ.xml:S3:9783:7	O
in	PRISTIQ.xml:S3:9791:2	O
a	PRISTIQ.xml:S3:9794:1	O
patient	PRISTIQ.xml:S3:9796:7	O
who	PRISTIQ.xml:S3:9804:3	O
is	PRISTIQ.xml:S3:9808:2	O
being	PRISTIQ.xml:S3:9811:5	O
treated	PRISTIQ.xml:S3:9817:7	O
with	PRISTIQ.xml:S3:9825:4	O
MAOIs	PRISTIQ.xml:S3:9830:5	O
such	PRISTIQ.xml:S3:9836:4	O
as	PRISTIQ.xml:S3:9841:2	O
linezolid	PRISTIQ.xml:S3:9844:9	O
or	PRISTIQ.xml:S3:9854:2	O
intravenous	PRISTIQ.xml:S3:9857:11	O
methylene	PRISTIQ.xml:S3:9869:9	O
blue	PRISTIQ.xml:S3:9879:4	O
.	PRISTIQ.xml:S3:9883:1	O

All	PRISTIQ.xml:S3:9885:3	O
reports	PRISTIQ.xml:S3:9889:7	O
with	PRISTIQ.xml:S3:9897:4	O
methylene	PRISTIQ.xml:S3:9902:9	O
blue	PRISTIQ.xml:S3:9912:4	O
that	PRISTIQ.xml:S3:9917:4	O
provided	PRISTIQ.xml:S3:9922:8	O
information	PRISTIQ.xml:S3:9931:11	O
on	PRISTIQ.xml:S3:9943:2	O
the	PRISTIQ.xml:S3:9946:3	O
route	PRISTIQ.xml:S3:9950:5	O
of	PRISTIQ.xml:S3:9956:2	O
administration	PRISTIQ.xml:S3:9959:14	O
involved	PRISTIQ.xml:S3:9974:8	O
intravenous	PRISTIQ.xml:S3:9983:11	O
administration	PRISTIQ.xml:S3:9995:14	O
in	PRISTIQ.xml:S3:10010:2	O
the	PRISTIQ.xml:S3:10013:3	O
dose	PRISTIQ.xml:S3:10017:4	O
range	PRISTIQ.xml:S3:10022:5	O
of	PRISTIQ.xml:S3:10028:2	O
1	PRISTIQ.xml:S3:10031:1	O
mg	PRISTIQ.xml:S3:10033:2	O
kg	PRISTIQ.xml:S3:10036:2	O
to	PRISTIQ.xml:S3:10039:2	O
8	PRISTIQ.xml:S3:10042:1	O
mg	PRISTIQ.xml:S3:10044:2	O
kg	PRISTIQ.xml:S3:10047:2	O
.	PRISTIQ.xml:S3:10049:1	O

No	PRISTIQ.xml:S3:10051:2	O
reports	PRISTIQ.xml:S3:10054:7	O
involved	PRISTIQ.xml:S3:10062:8	O
the	PRISTIQ.xml:S3:10071:3	O
administration	PRISTIQ.xml:S3:10075:14	O
of	PRISTIQ.xml:S3:10090:2	O
methylene	PRISTIQ.xml:S3:10093:9	O
blue	PRISTIQ.xml:S3:10103:4	O
by	PRISTIQ.xml:S3:10108:2	O
other	PRISTIQ.xml:S3:10111:5	O
routes	PRISTIQ.xml:S3:10117:6	O
(	PRISTIQ.xml:S3:10124:1	O
such	PRISTIQ.xml:S3:10125:4	O
as	PRISTIQ.xml:S3:10130:2	O
oral	PRISTIQ.xml:S3:10133:4	O
tablets	PRISTIQ.xml:S3:10138:7	O
or	PRISTIQ.xml:S3:10146:2	O
local	PRISTIQ.xml:S3:10149:5	O
tissue	PRISTIQ.xml:S3:10155:6	O
injection	PRISTIQ.xml:S3:10162:9	O
)	PRISTIQ.xml:S3:10171:1	O
or	PRISTIQ.xml:S3:10173:2	O
at	PRISTIQ.xml:S3:10176:2	O
lower	PRISTIQ.xml:S3:10179:5	O
doses	PRISTIQ.xml:S3:10185:5	O
.	PRISTIQ.xml:S3:10190:1	O

There	PRISTIQ.xml:S3:10192:5	O
may	PRISTIQ.xml:S3:10198:3	O
be	PRISTIQ.xml:S3:10202:2	O
circumstances	PRISTIQ.xml:S3:10205:13	O
when	PRISTIQ.xml:S3:10219:4	O
it	PRISTIQ.xml:S3:10224:2	O
is	PRISTIQ.xml:S3:10227:2	O
necessary	PRISTIQ.xml:S3:10230:9	O
to	PRISTIQ.xml:S3:10240:2	O
initiate	PRISTIQ.xml:S3:10243:8	O
treatment	PRISTIQ.xml:S3:10252:9	O
with	PRISTIQ.xml:S3:10262:4	O
a	PRISTIQ.xml:S3:10267:1	O
MAOI	PRISTIQ.xml:S3:10269:4	O
such	PRISTIQ.xml:S3:10274:4	O
as	PRISTIQ.xml:S3:10279:2	O
linezolid	PRISTIQ.xml:S3:10282:9	O
or	PRISTIQ.xml:S3:10292:2	O
intravenous	PRISTIQ.xml:S3:10295:11	O
methylene	PRISTIQ.xml:S3:10307:9	O
blue	PRISTIQ.xml:S3:10317:4	O
in	PRISTIQ.xml:S3:10322:2	O
a	PRISTIQ.xml:S3:10325:1	O
patient	PRISTIQ.xml:S3:10327:7	O
taking	PRISTIQ.xml:S3:10335:6	O
PRISTIQ	PRISTIQ.xml:S3:10342:7	O
.	PRISTIQ.xml:S3:10349:1	O

PRISTIQ	PRISTIQ.xml:S3:10351:7	O
should	PRISTIQ.xml:S3:10359:6	O
be	PRISTIQ.xml:S3:10366:2	O
discontinued	PRISTIQ.xml:S3:10369:12	O
before	PRISTIQ.xml:S3:10382:6	O
initiating	PRISTIQ.xml:S3:10389:10	O
treatment	PRISTIQ.xml:S3:10400:9	O
with	PRISTIQ.xml:S3:10410:4	O
the	PRISTIQ.xml:S3:10415:3	O
MAOI	PRISTIQ.xml:S3:10419:4	O
[	PRISTIQ.xml:S3:10424:1	O
see	PRISTIQ.xml:S3:10425:3	O
Contraindications	PRISTIQ.xml:S3:10429:17	O
(	PRISTIQ.xml:S3:10447:1	O
4.2	PRISTIQ.xml:S3:10448:3	O
)	PRISTIQ.xml:S3:10451:1	O
and	PRISTIQ.xml:S3:10454:3	O
Dosage	PRISTIQ.xml:S3:10460:6	O
and	PRISTIQ.xml:S3:10467:3	O
Administration	PRISTIQ.xml:S3:10471:14	O
(	PRISTIQ.xml:S3:10486:1	O
2.6	PRISTIQ.xml:S3:10487:3	O
)	PRISTIQ.xml:S3:10490:1	O
]	PRISTIQ.xml:S3:10493:1	O
.	PRISTIQ.xml:S3:10496:1	O

If	PRISTIQ.xml:S3:10502:2	O
concomitant	PRISTIQ.xml:S3:10505:11	O
use	PRISTIQ.xml:S3:10517:3	O
of	PRISTIQ.xml:S3:10521:2	O
PRISTIQ	PRISTIQ.xml:S3:10524:7	O
with	PRISTIQ.xml:S3:10532:4	O
other	PRISTIQ.xml:S3:10537:5	O
serotonergic	PRISTIQ.xml:S3:10543:12	O
drugs	PRISTIQ.xml:S3:10556:5	O
,	PRISTIQ.xml:S3:10561:1	O
including	PRISTIQ.xml:S3:10563:9	O
triptans	PRISTIQ.xml:S3:10573:8	O
,	PRISTIQ.xml:S3:10581:1	O
tricyclic	PRISTIQ.xml:S3:10583:9	O
antidepressants	PRISTIQ.xml:S3:10593:15	O
,	PRISTIQ.xml:S3:10608:1	O
fentanyl	PRISTIQ.xml:S3:10610:8	O
,	PRISTIQ.xml:S3:10618:1	O
lithium	PRISTIQ.xml:S3:10620:7	O
,	PRISTIQ.xml:S3:10627:1	O
tramadol	PRISTIQ.xml:S3:10629:8	O
,	PRISTIQ.xml:S3:10637:1	O
buspirone	PRISTIQ.xml:S3:10639:9	O
,	PRISTIQ.xml:S3:10648:1	O
tryptophan	PRISTIQ.xml:S3:10650:10	O
,	PRISTIQ.xml:S3:10660:1	O
and	PRISTIQ.xml:S3:10662:3	O
St	PRISTIQ.xml:S3:10666:2	O
.	PRISTIQ.xml:S3:10668:1	O

John	PRISTIQ.xml:S3:10670:4	O
's	PRISTIQ.xml:S3:10674:2	O
Wort	PRISTIQ.xml:S3:10677:4	O
is	PRISTIQ.xml:S3:10682:2	O
clinically	PRISTIQ.xml:S3:10685:10	O
warranted	PRISTIQ.xml:S3:10696:9	O
,	PRISTIQ.xml:S3:10705:1	O
patients	PRISTIQ.xml:S3:10707:8	O
should	PRISTIQ.xml:S3:10716:6	O
be	PRISTIQ.xml:S3:10723:2	O
made	PRISTIQ.xml:S3:10726:4	O
aware	PRISTIQ.xml:S3:10731:5	O
of	PRISTIQ.xml:S3:10737:2	O
a	PRISTIQ.xml:S3:10740:1	O
potential	PRISTIQ.xml:S3:10742:9	O
increased	PRISTIQ.xml:S3:10752:9	O
risk	PRISTIQ.xml:S3:10762:4	O
for	PRISTIQ.xml:S3:10767:3	O
serotonin	PRISTIQ.xml:S3:10771:9	O
syndrome	PRISTIQ.xml:S3:10781:8	O
,	PRISTIQ.xml:S3:10789:1	O
particularly	PRISTIQ.xml:S3:10791:12	O
during	PRISTIQ.xml:S3:10804:6	O
treatment	PRISTIQ.xml:S3:10811:9	O
initiation	PRISTIQ.xml:S3:10821:10	O
and	PRISTIQ.xml:S3:10832:3	O
dose	PRISTIQ.xml:S3:10836:4	O
increases	PRISTIQ.xml:S3:10841:9	O
.	PRISTIQ.xml:S3:10850:1	O

Treatment	PRISTIQ.xml:S3:10856:9	O
with	PRISTIQ.xml:S3:10866:4	O
PRISTIQ	PRISTIQ.xml:S3:10871:7	O
and	PRISTIQ.xml:S3:10879:3	O
any	PRISTIQ.xml:S3:10883:3	O
concomitant	PRISTIQ.xml:S3:10887:11	O
serotonergic	PRISTIQ.xml:S3:10899:12	O
agents	PRISTIQ.xml:S3:10912:6	O
should	PRISTIQ.xml:S3:10919:6	O
be	PRISTIQ.xml:S3:10926:2	O
discontinued	PRISTIQ.xml:S3:10929:12	O
immediately	PRISTIQ.xml:S3:10942:11	O
if	PRISTIQ.xml:S3:10954:2	O
the	PRISTIQ.xml:S3:10957:3	O
above	PRISTIQ.xml:S3:10961:5	O
events	PRISTIQ.xml:S3:10967:6	O
occur	PRISTIQ.xml:S3:10974:5	O
and	PRISTIQ.xml:S3:10980:3	O
supportive	PRISTIQ.xml:S3:10984:10	O
symptomatic	PRISTIQ.xml:S3:10995:11	O
treatment	PRISTIQ.xml:S3:11007:9	O
should	PRISTIQ.xml:S3:11017:6	O
be	PRISTIQ.xml:S3:11024:2	O
initiated	PRISTIQ.xml:S3:11027:9	O
.	PRISTIQ.xml:S3:11036:1	O

5.3	PRISTIQ.xml:S3:11045:3	O
Elevated	PRISTIQ.xml:S3:11049:8	O
Blood	PRISTIQ.xml:S3:11058:5	O
Pressure	PRISTIQ.xml:S3:11064:8	O

Patients	PRISTIQ.xml:S3:11078:8	O
receiving	PRISTIQ.xml:S3:11087:9	O
PRISTIQ	PRISTIQ.xml:S3:11097:7	O
should	PRISTIQ.xml:S3:11105:6	O
have	PRISTIQ.xml:S3:11112:4	O
regular	PRISTIQ.xml:S3:11117:7	O
monitoring	PRISTIQ.xml:S3:11125:10	O
of	PRISTIQ.xml:S3:11136:2	O
blood	PRISTIQ.xml:S3:11139:5	O
pressure	PRISTIQ.xml:S3:11145:8	O
since	PRISTIQ.xml:S3:11154:5	O
increases	PRISTIQ.xml:S3:11160:9	B-AdverseReaction
in	PRISTIQ.xml:S3:11170:2	I-AdverseReaction
blood	PRISTIQ.xml:S3:11173:5	I-AdverseReaction
pressure	PRISTIQ.xml:S3:11179:8	I-AdverseReaction
were	PRISTIQ.xml:S3:11188:4	O
observed	PRISTIQ.xml:S3:11193:8	O
in	PRISTIQ.xml:S3:11202:2	O
clinical	PRISTIQ.xml:S3:11205:8	O
studies	PRISTIQ.xml:S3:11214:7	O
[	PRISTIQ.xml:S3:11222:1	O
see	PRISTIQ.xml:S3:11223:3	O
Adverse	PRISTIQ.xml:S3:11228:7	O
Reactions	PRISTIQ.xml:S3:11236:9	O
(	PRISTIQ.xml:S3:11246:1	O
6.1	PRISTIQ.xml:S3:11247:3	O
)	PRISTIQ.xml:S3:11250:1	O
]	PRISTIQ.xml:S3:11253:1	O
.	PRISTIQ.xml:S3:11256:1	O

Pre	PRISTIQ.xml:S3:11258:3	O
-	PRISTIQ.xml:S3:11261:1	O
existing	PRISTIQ.xml:S3:11262:8	O
hypertension	PRISTIQ.xml:S3:11271:12	O
should	PRISTIQ.xml:S3:11284:6	O
be	PRISTIQ.xml:S3:11291:2	O
controlled	PRISTIQ.xml:S3:11294:10	O
before	PRISTIQ.xml:S3:11305:6	O
initiating	PRISTIQ.xml:S3:11312:10	O
treatment	PRISTIQ.xml:S3:11323:9	O
with	PRISTIQ.xml:S3:11333:4	O
PRISTIQ	PRISTIQ.xml:S3:11338:7	O
.	PRISTIQ.xml:S3:11345:1	O

Caution	PRISTIQ.xml:S3:11347:7	O
should	PRISTIQ.xml:S3:11355:6	O
be	PRISTIQ.xml:S3:11362:2	O
exercised	PRISTIQ.xml:S3:11365:9	O
in	PRISTIQ.xml:S3:11375:2	O
treating	PRISTIQ.xml:S3:11378:8	O
patients	PRISTIQ.xml:S3:11387:8	O
with	PRISTIQ.xml:S3:11396:4	O
pre	PRISTIQ.xml:S3:11401:3	O
-	PRISTIQ.xml:S3:11404:1	O
existing	PRISTIQ.xml:S3:11405:8	O
hypertension	PRISTIQ.xml:S3:11414:12	O
,	PRISTIQ.xml:S3:11426:1	O
cardiovascular	PRISTIQ.xml:S3:11428:14	O
,	PRISTIQ.xml:S3:11442:1	O
or	PRISTIQ.xml:S3:11444:2	O
cerebrovascular	PRISTIQ.xml:S3:11447:15	O
conditions	PRISTIQ.xml:S3:11463:10	O
that	PRISTIQ.xml:S3:11474:4	O
might	PRISTIQ.xml:S3:11479:5	O
be	PRISTIQ.xml:S3:11485:2	O
compromised	PRISTIQ.xml:S3:11488:11	O
by	PRISTIQ.xml:S3:11500:2	O
increases	PRISTIQ.xml:S3:11503:9	O
in	PRISTIQ.xml:S3:11513:2	O
blood	PRISTIQ.xml:S3:11516:5	O
pressure	PRISTIQ.xml:S3:11522:8	O
.	PRISTIQ.xml:S3:11530:1	O

Cases	PRISTIQ.xml:S3:11532:5	O
of	PRISTIQ.xml:S3:11538:2	O
elevated	PRISTIQ.xml:S3:11541:8	B-AdverseReaction
blood	PRISTIQ.xml:S3:11550:5	I-AdverseReaction
pressure	PRISTIQ.xml:S3:11556:8	I-AdverseReaction
requiring	PRISTIQ.xml:S3:11565:9	O
immediate	PRISTIQ.xml:S3:11575:9	O
treatment	PRISTIQ.xml:S3:11585:9	O
have	PRISTIQ.xml:S3:11595:4	O
been	PRISTIQ.xml:S3:11600:4	O
reported	PRISTIQ.xml:S3:11605:8	O
with	PRISTIQ.xml:S3:11614:4	O
PRISTIQ	PRISTIQ.xml:S3:11619:7	O
.	PRISTIQ.xml:S3:11626:1	O

Sustained	PRISTIQ.xml:S3:11632:9	B-Severity
blood	PRISTIQ.xml:S3:11642:5	B-AdverseReaction
pressure	PRISTIQ.xml:S3:11648:8	I-AdverseReaction
increases	PRISTIQ.xml:S3:11657:9	I-AdverseReaction
could	PRISTIQ.xml:S3:11667:5	O
have	PRISTIQ.xml:S3:11673:4	O
adverse	PRISTIQ.xml:S3:11678:7	O
consequences	PRISTIQ.xml:S3:11686:12	O
.	PRISTIQ.xml:S3:11698:1	O

For	PRISTIQ.xml:S3:11700:3	O
patients	PRISTIQ.xml:S3:11704:8	O
who	PRISTIQ.xml:S3:11713:3	O
experience	PRISTIQ.xml:S3:11717:10	O
a	PRISTIQ.xml:S3:11728:1	O
sustained	PRISTIQ.xml:S3:11730:9	O
increase	PRISTIQ.xml:S3:11740:8	O
in	PRISTIQ.xml:S3:11749:2	O
blood	PRISTIQ.xml:S3:11752:5	O
pressure	PRISTIQ.xml:S3:11758:8	O
while	PRISTIQ.xml:S3:11767:5	O
receiving	PRISTIQ.xml:S3:11773:9	O
PRISTIQ	PRISTIQ.xml:S3:11783:7	O
,	PRISTIQ.xml:S3:11790:1	O
either	PRISTIQ.xml:S3:11792:6	O
dose	PRISTIQ.xml:S3:11799:4	O
reduction	PRISTIQ.xml:S3:11804:9	O
or	PRISTIQ.xml:S3:11814:2	O
discontinuation	PRISTIQ.xml:S3:11817:15	O
should	PRISTIQ.xml:S3:11833:6	O
be	PRISTIQ.xml:S3:11840:2	O
considered	PRISTIQ.xml:S3:11843:10	O
[	PRISTIQ.xml:S3:11854:1	O
see	PRISTIQ.xml:S3:11855:3	O
Adverse	PRISTIQ.xml:S3:11860:7	O
Reactions	PRISTIQ.xml:S3:11868:9	O
(	PRISTIQ.xml:S3:11878:1	O
6.1	PRISTIQ.xml:S3:11879:3	O
)	PRISTIQ.xml:S3:11882:1	O
]	PRISTIQ.xml:S3:11885:1	O
.	PRISTIQ.xml:S3:11888:1	O

5.4	PRISTIQ.xml:S3:11897:3	O
Abnormal	PRISTIQ.xml:S3:11901:8	O
Bleeding	PRISTIQ.xml:S3:11910:8	O

SSRIs	PRISTIQ.xml:S3:11924:5	O
and	PRISTIQ.xml:S3:11930:3	O
SNRIs	PRISTIQ.xml:S3:11934:5	O
,	PRISTIQ.xml:S3:11939:1	O
including	PRISTIQ.xml:S3:11941:9	O
PRISTIQ	PRISTIQ.xml:S3:11951:7	O
,	PRISTIQ.xml:S3:11958:1	O
may	PRISTIQ.xml:S3:11960:3	O
increase	PRISTIQ.xml:S3:11964:8	O
the	PRISTIQ.xml:S3:11973:3	O
risk	PRISTIQ.xml:S3:11977:4	B-Factor
of	PRISTIQ.xml:S3:11982:2	O
bleeding	PRISTIQ.xml:S3:11985:8	B-AdverseReaction
events	PRISTIQ.xml:S3:11994:6	O
.	PRISTIQ.xml:S3:12000:1	O

Concomitant	PRISTIQ.xml:S3:12002:11	O
use	PRISTIQ.xml:S3:12014:3	O
of	PRISTIQ.xml:S3:12018:2	O
aspirin	PRISTIQ.xml:S3:12021:7	O
,	PRISTIQ.xml:S3:12028:1	O
nonsteroidal	PRISTIQ.xml:S3:12030:12	O
anti	PRISTIQ.xml:S3:12043:4	O
-	PRISTIQ.xml:S3:12047:1	O
inflammatory	PRISTIQ.xml:S3:12048:12	O
drugs	PRISTIQ.xml:S3:12061:5	O
,	PRISTIQ.xml:S3:12066:1	O
warfarin	PRISTIQ.xml:S3:12068:8	O
,	PRISTIQ.xml:S3:12076:1	O
and	PRISTIQ.xml:S3:12078:3	O
other	PRISTIQ.xml:S3:12082:5	O
anticoagulants	PRISTIQ.xml:S3:12088:14	O
may	PRISTIQ.xml:S3:12103:3	O
add	PRISTIQ.xml:S3:12107:3	O
to	PRISTIQ.xml:S3:12111:2	O
this	PRISTIQ.xml:S3:12114:4	O
risk	PRISTIQ.xml:S3:12119:4	O
.	PRISTIQ.xml:S3:12123:1	O

Case	PRISTIQ.xml:S3:12125:4	O
reports	PRISTIQ.xml:S3:12130:7	O
and	PRISTIQ.xml:S3:12138:3	O
epidemiological	PRISTIQ.xml:S3:12142:15	O
studies	PRISTIQ.xml:S3:12158:7	O
(	PRISTIQ.xml:S3:12166:1	O
case	PRISTIQ.xml:S3:12167:4	O
-	PRISTIQ.xml:S3:12171:1	O
control	PRISTIQ.xml:S3:12172:7	O
and	PRISTIQ.xml:S3:12180:3	O
cohort	PRISTIQ.xml:S3:12184:6	O
design	PRISTIQ.xml:S3:12191:6	O
)	PRISTIQ.xml:S3:12197:1	O
have	PRISTIQ.xml:S3:12199:4	O
demonstrated	PRISTIQ.xml:S3:12204:12	O
an	PRISTIQ.xml:S3:12217:2	O
association	PRISTIQ.xml:S3:12220:11	O
between	PRISTIQ.xml:S3:12232:7	O
use	PRISTIQ.xml:S3:12240:3	O
of	PRISTIQ.xml:S3:12244:2	O
drugs	PRISTIQ.xml:S3:12247:5	B-DrugClass
that	PRISTIQ.xml:S3:12253:4	I-DrugClass
interfere	PRISTIQ.xml:S3:12258:9	I-DrugClass
with	PRISTIQ.xml:S3:12268:4	I-DrugClass
serotonin	PRISTIQ.xml:S3:12273:9	I-DrugClass
reuptake	PRISTIQ.xml:S3:12283:8	I-DrugClass
and	PRISTIQ.xml:S3:12292:3	O
the	PRISTIQ.xml:S3:12296:3	O
occurrence	PRISTIQ.xml:S3:12300:10	O
of	PRISTIQ.xml:S3:12311:2	O
gastrointestinal	PRISTIQ.xml:S3:12314:16	B-AdverseReaction
bleeding	PRISTIQ.xml:S3:12331:8	I-AdverseReaction
.	PRISTIQ.xml:S3:12339:1	O

Bleeding	PRISTIQ.xml:S3:12341:8	B-AdverseReaction
events	PRISTIQ.xml:S3:12350:6	O
related	PRISTIQ.xml:S3:12357:7	O
to	PRISTIQ.xml:S3:12365:2	O
SSRIs	PRISTIQ.xml:S3:12368:5	O
and	PRISTIQ.xml:S3:12374:3	O
SNRIs	PRISTIQ.xml:S3:12378:5	B-DrugClass
have	PRISTIQ.xml:S3:12384:4	O
ranged	PRISTIQ.xml:S3:12389:6	O
from	PRISTIQ.xml:S3:12396:4	O
ecchymosis	PRISTIQ.xml:S3:12401:10	B-AdverseReaction
,	PRISTIQ.xml:S3:12411:1	O
hematoma	PRISTIQ.xml:S3:12413:8	B-AdverseReaction
,	PRISTIQ.xml:S3:12421:1	O
epistaxis	PRISTIQ.xml:S3:12423:9	B-AdverseReaction
,	PRISTIQ.xml:S3:12432:1	O
and	PRISTIQ.xml:S3:12434:3	O
petechiae	PRISTIQ.xml:S3:12438:9	B-AdverseReaction
to	PRISTIQ.xml:S3:12448:2	O
life	PRISTIQ.xml:S3:12451:4	B-Severity
-	PRISTIQ.xml:S3:12455:1	I-Severity
threatening	PRISTIQ.xml:S3:12456:11	I-Severity
hemorrhages	PRISTIQ.xml:S3:12468:11	B-AdverseReaction
.	PRISTIQ.xml:S3:12479:1	O

Patients	PRISTIQ.xml:S3:12481:8	O
should	PRISTIQ.xml:S3:12490:6	O
be	PRISTIQ.xml:S3:12497:2	O
cautioned	PRISTIQ.xml:S3:12500:9	O
about	PRISTIQ.xml:S3:12510:5	O
the	PRISTIQ.xml:S3:12516:3	O
risk	PRISTIQ.xml:S3:12520:4	O
of	PRISTIQ.xml:S3:12525:2	O
bleeding	PRISTIQ.xml:S3:12528:8	O
associated	PRISTIQ.xml:S3:12537:10	O
with	PRISTIQ.xml:S3:12548:4	O
the	PRISTIQ.xml:S3:12553:3	O
concomitant	PRISTIQ.xml:S3:12557:11	O
use	PRISTIQ.xml:S3:12569:3	O
of	PRISTIQ.xml:S3:12573:2	O
PRISTIQ	PRISTIQ.xml:S3:12576:7	O
and	PRISTIQ.xml:S3:12584:3	O
NSAIDs	PRISTIQ.xml:S3:12588:6	O
,	PRISTIQ.xml:S3:12594:1	O
aspirin	PRISTIQ.xml:S3:12596:7	O
,	PRISTIQ.xml:S3:12603:1	O
or	PRISTIQ.xml:S3:12605:2	O
other	PRISTIQ.xml:S3:12608:5	O
drugs	PRISTIQ.xml:S3:12614:5	O
that	PRISTIQ.xml:S3:12620:4	O
affect	PRISTIQ.xml:S3:12625:6	O
coagulation	PRISTIQ.xml:S3:12632:11	O
or	PRISTIQ.xml:S3:12644:2	O
bleeding	PRISTIQ.xml:S3:12647:8	O
.	PRISTIQ.xml:S3:12655:1	O

5.5	PRISTIQ.xml:S3:12664:3	O
Angle	PRISTIQ.xml:S3:12668:5	O
Closure	PRISTIQ.xml:S3:12674:7	O
Glaucoma	PRISTIQ.xml:S3:12682:8	O

Angle	PRISTIQ.xml:S3:12697:5	B-AdverseReaction
-	PRISTIQ.xml:S3:12702:1	I-AdverseReaction
Closure	PRISTIQ.xml:S3:12703:7	I-AdverseReaction
Glaucoma	PRISTIQ.xml:S3:12711:8	I-AdverseReaction
:	PRISTIQ.xml:S3:12719:1	O
The	PRISTIQ.xml:S3:12721:3	O
pupillary	PRISTIQ.xml:S3:12725:9	O
dilation	PRISTIQ.xml:S3:12735:8	O
that	PRISTIQ.xml:S3:12744:4	O
occurs	PRISTIQ.xml:S3:12749:6	O
following	PRISTIQ.xml:S3:12756:9	O
use	PRISTIQ.xml:S3:12766:3	O
of	PRISTIQ.xml:S3:12770:2	O
many	PRISTIQ.xml:S3:12773:4	O
antidepressant	PRISTIQ.xml:S3:12778:14	O
drugs	PRISTIQ.xml:S3:12793:5	O
including	PRISTIQ.xml:S3:12799:9	O
Pristiq	PRISTIQ.xml:S3:12809:7	O
may	PRISTIQ.xml:S3:12817:3	B-Factor
trigger	PRISTIQ.xml:S3:12821:7	O
an	PRISTIQ.xml:S3:12829:2	O
angle	PRISTIQ.xml:S3:12832:5	B-AdverseReaction
closure	PRISTIQ.xml:S3:12838:7	I-AdverseReaction
attack	PRISTIQ.xml:S3:12846:6	I-AdverseReaction
in	PRISTIQ.xml:S3:12853:2	O
a	PRISTIQ.xml:S3:12856:1	O
patient	PRISTIQ.xml:S3:12858:7	O
with	PRISTIQ.xml:S3:12866:4	O
anatomically	PRISTIQ.xml:S3:12871:12	O
narrow	PRISTIQ.xml:S3:12884:6	O
angles	PRISTIQ.xml:S3:12891:6	O
who	PRISTIQ.xml:S3:12898:3	O
does	PRISTIQ.xml:S3:12902:4	O
not	PRISTIQ.xml:S3:12907:3	O
have	PRISTIQ.xml:S3:12911:4	O
a	PRISTIQ.xml:S3:12916:1	O
patent	PRISTIQ.xml:S3:12918:6	O
iridectomy	PRISTIQ.xml:S3:12925:10	O
.	PRISTIQ.xml:S3:12935:1	O

5.6	PRISTIQ.xml:S3:12946:3	O
Activation	PRISTIQ.xml:S3:12950:10	O
of	PRISTIQ.xml:S3:12961:2	O
Mania	PRISTIQ.xml:S3:12964:5	O
Hypomania	PRISTIQ.xml:S3:12970:9	O

During	PRISTIQ.xml:S3:12985:6	O
all	PRISTIQ.xml:S3:12992:3	O
MDD	PRISTIQ.xml:S3:12996:3	O
phase	PRISTIQ.xml:S3:13000:5	O
2	PRISTIQ.xml:S3:13006:1	O
and	PRISTIQ.xml:S3:13008:3	O
phase	PRISTIQ.xml:S3:13012:5	O
3	PRISTIQ.xml:S3:13018:1	O
studies	PRISTIQ.xml:S3:13020:7	O
,	PRISTIQ.xml:S3:13027:1	O
mania	PRISTIQ.xml:S3:13029:5	B-AdverseReaction
was	PRISTIQ.xml:S3:13035:3	O
reported	PRISTIQ.xml:S3:13039:8	O
for	PRISTIQ.xml:S3:13048:3	O
approximately	PRISTIQ.xml:S3:13052:13	O
0.02%	PRISTIQ.xml:S3:13066:5	O
of	PRISTIQ.xml:S3:13072:2	O
patients	PRISTIQ.xml:S3:13075:8	O
treated	PRISTIQ.xml:S3:13084:7	O
with	PRISTIQ.xml:S3:13092:4	O
PRISTIQ	PRISTIQ.xml:S3:13097:7	O
.	PRISTIQ.xml:S3:13104:1	O

Activation	PRISTIQ.xml:S3:13106:10	B-AdverseReaction
of	PRISTIQ.xml:S3:13117:2	I-AdverseReaction
mania	PRISTIQ.xml:S3:13120:5	I-AdverseReaction
hypomania	PRISTIQ.xml:S3:13126:9	I-AdverseReaction
has	PRISTIQ.xml:S3:13136:3	O
also	PRISTIQ.xml:S3:13140:4	O
been	PRISTIQ.xml:S3:13145:4	O
reported	PRISTIQ.xml:S3:13150:8	O
in	PRISTIQ.xml:S3:13159:2	O
a	PRISTIQ.xml:S3:13162:1	O
small	PRISTIQ.xml:S3:13164:5	O
proportion	PRISTIQ.xml:S3:13170:10	O
of	PRISTIQ.xml:S3:13181:2	O
patients	PRISTIQ.xml:S3:13184:8	O
with	PRISTIQ.xml:S3:13193:4	O
major	PRISTIQ.xml:S3:13198:5	O
affective	PRISTIQ.xml:S3:13204:9	O
disorder	PRISTIQ.xml:S3:13214:8	O
who	PRISTIQ.xml:S3:13223:3	O
were	PRISTIQ.xml:S3:13227:4	O
treated	PRISTIQ.xml:S3:13232:7	O
with	PRISTIQ.xml:S3:13240:4	O
other	PRISTIQ.xml:S3:13245:5	O
marketed	PRISTIQ.xml:S3:13251:8	O
antidepressants	PRISTIQ.xml:S3:13260:15	B-DrugClass
.	PRISTIQ.xml:S3:13275:1	O

As	PRISTIQ.xml:S3:13277:2	O
with	PRISTIQ.xml:S3:13280:4	O
all	PRISTIQ.xml:S3:13285:3	O
antidepressants	PRISTIQ.xml:S3:13289:15	O
,	PRISTIQ.xml:S3:13304:1	O
PRISTIQ	PRISTIQ.xml:S3:13306:7	O
should	PRISTIQ.xml:S3:13314:6	O
be	PRISTIQ.xml:S3:13321:2	O
used	PRISTIQ.xml:S3:13324:4	O
cautiously	PRISTIQ.xml:S3:13329:10	O
in	PRISTIQ.xml:S3:13340:2	O
patients	PRISTIQ.xml:S3:13343:8	O
with	PRISTIQ.xml:S3:13352:4	O
a	PRISTIQ.xml:S3:13357:1	O
history	PRISTIQ.xml:S3:13359:7	O
or	PRISTIQ.xml:S3:13367:2	O
family	PRISTIQ.xml:S3:13370:6	O
history	PRISTIQ.xml:S3:13377:7	O
of	PRISTIQ.xml:S3:13385:2	O
mania	PRISTIQ.xml:S3:13388:5	O
or	PRISTIQ.xml:S3:13394:2	O
hypomania	PRISTIQ.xml:S3:13397:9	O
.	PRISTIQ.xml:S3:13406:1	O

5.7	PRISTIQ.xml:S3:13415:3	O
Discontinuation	PRISTIQ.xml:S3:13419:15	O
Syndrome	PRISTIQ.xml:S3:13435:8	O

Discontinuation	PRISTIQ.xml:S3:13449:15	O
symptoms	PRISTIQ.xml:S3:13465:8	O
have	PRISTIQ.xml:S3:13474:4	O
been	PRISTIQ.xml:S3:13479:4	O
systematically	PRISTIQ.xml:S3:13484:14	O
and	PRISTIQ.xml:S3:13499:3	O
prospectively	PRISTIQ.xml:S3:13503:13	O
evaluated	PRISTIQ.xml:S3:13517:9	O
in	PRISTIQ.xml:S3:13527:2	O
patients	PRISTIQ.xml:S3:13530:8	O
treated	PRISTIQ.xml:S3:13539:7	O
with	PRISTIQ.xml:S3:13547:4	O
PRISTIQ	PRISTIQ.xml:S3:13552:7	O
during	PRISTIQ.xml:S3:13560:6	O
clinical	PRISTIQ.xml:S3:13567:8	O
studies	PRISTIQ.xml:S3:13576:7	O
in	PRISTIQ.xml:S3:13584:2	O
Major	PRISTIQ.xml:S3:13587:5	O
Depressive	PRISTIQ.xml:S3:13593:10	O
Disorder	PRISTIQ.xml:S3:13604:8	O
.	PRISTIQ.xml:S3:13612:1	O

Abrupt	PRISTIQ.xml:S3:13614:6	O
discontinuation	PRISTIQ.xml:S3:13621:15	O
or	PRISTIQ.xml:S3:13637:2	O
dose	PRISTIQ.xml:S3:13640:4	O
reduction	PRISTIQ.xml:S3:13645:9	O
has	PRISTIQ.xml:S3:13655:3	O
been	PRISTIQ.xml:S3:13659:4	O
associated	PRISTIQ.xml:S3:13664:10	O
with	PRISTIQ.xml:S3:13675:4	O
the	PRISTIQ.xml:S3:13680:3	O
appearance	PRISTIQ.xml:S3:13684:10	O
of	PRISTIQ.xml:S3:13695:2	O
new	PRISTIQ.xml:S3:13698:3	O
symptoms	PRISTIQ.xml:S3:13702:8	O
that	PRISTIQ.xml:S3:13711:4	O
include	PRISTIQ.xml:S3:13716:7	O
dizziness	PRISTIQ.xml:S3:13724:9	B-AdverseReaction
,	PRISTIQ.xml:S3:13733:1	O
nausea	PRISTIQ.xml:S3:13735:6	B-AdverseReaction
,	PRISTIQ.xml:S3:13741:1	O
headache	PRISTIQ.xml:S3:13743:8	B-AdverseReaction
,	PRISTIQ.xml:S3:13751:1	O
irritability	PRISTIQ.xml:S3:13753:12	B-AdverseReaction
,	PRISTIQ.xml:S3:13765:1	O
insomnia	PRISTIQ.xml:S3:13767:8	B-AdverseReaction
,	PRISTIQ.xml:S3:13775:1	O
diarrhea	PRISTIQ.xml:S3:13777:8	B-AdverseReaction
,	PRISTIQ.xml:S3:13785:1	O
anxiety	PRISTIQ.xml:S3:13787:7	B-AdverseReaction
,	PRISTIQ.xml:S3:13794:1	O
fatigue	PRISTIQ.xml:S3:13796:7	B-AdverseReaction
,	PRISTIQ.xml:S3:13803:1	O
abnormal	PRISTIQ.xml:S3:13805:8	B-AdverseReaction
dreams	PRISTIQ.xml:S3:13814:6	I-AdverseReaction
,	PRISTIQ.xml:S3:13820:1	O
and	PRISTIQ.xml:S3:13822:3	O
hyperhidrosis	PRISTIQ.xml:S3:13826:13	B-AdverseReaction
.	PRISTIQ.xml:S3:13839:1	O

In	PRISTIQ.xml:S3:13841:2	O
general	PRISTIQ.xml:S3:13844:7	O
,	PRISTIQ.xml:S3:13851:1	O
discontinuation	PRISTIQ.xml:S3:13853:15	O
events	PRISTIQ.xml:S3:13869:6	O
occurred	PRISTIQ.xml:S3:13876:8	O
more	PRISTIQ.xml:S3:13885:4	O
frequently	PRISTIQ.xml:S3:13890:10	O
with	PRISTIQ.xml:S3:13901:4	O
longer	PRISTIQ.xml:S3:13906:6	O
duration	PRISTIQ.xml:S3:13913:8	O
of	PRISTIQ.xml:S3:13922:2	O
therapy	PRISTIQ.xml:S3:13925:7	O
.	PRISTIQ.xml:S3:13932:1	O

During	PRISTIQ.xml:S3:13938:6	O
marketing	PRISTIQ.xml:S3:13945:9	O
of	PRISTIQ.xml:S3:13955:2	O
SNRIs	PRISTIQ.xml:S3:13958:5	O
(	PRISTIQ.xml:S3:13964:1	O
Serotonin	PRISTIQ.xml:S3:13965:9	O
and	PRISTIQ.xml:S3:13975:3	O
Norepinephrine	PRISTIQ.xml:S3:13979:14	O
Reuptake	PRISTIQ.xml:S3:13994:8	O
Inhibitors	PRISTIQ.xml:S3:14003:10	O
)	PRISTIQ.xml:S3:14013:1	O
,	PRISTIQ.xml:S3:14014:1	O
and	PRISTIQ.xml:S3:14016:3	O
SSRIs	PRISTIQ.xml:S3:14020:5	O
(	PRISTIQ.xml:S3:14026:1	O
Selective	PRISTIQ.xml:S3:14027:9	O
Serotonin	PRISTIQ.xml:S3:14037:9	O
Reuptake	PRISTIQ.xml:S3:14047:8	O
Inhibitors	PRISTIQ.xml:S3:14056:10	O
)	PRISTIQ.xml:S3:14066:1	O
,	PRISTIQ.xml:S3:14067:1	O
there	PRISTIQ.xml:S3:14069:5	O
have	PRISTIQ.xml:S3:14075:4	O
been	PRISTIQ.xml:S3:14080:4	O
spontaneous	PRISTIQ.xml:S3:14085:11	O
reports	PRISTIQ.xml:S3:14097:7	O
of	PRISTIQ.xml:S3:14105:2	O
adverse	PRISTIQ.xml:S3:14108:7	O
events	PRISTIQ.xml:S3:14116:6	O
occurring	PRISTIQ.xml:S3:14123:9	O
upon	PRISTIQ.xml:S3:14133:4	O
discontinuation	PRISTIQ.xml:S3:14138:15	O
of	PRISTIQ.xml:S3:14154:2	O
these	PRISTIQ.xml:S3:14157:5	O
drugs	PRISTIQ.xml:S3:14163:5	O
,	PRISTIQ.xml:S3:14168:1	O
particularly	PRISTIQ.xml:S3:14170:12	O
when	PRISTIQ.xml:S3:14183:4	O
abrupt	PRISTIQ.xml:S3:14188:6	O
,	PRISTIQ.xml:S3:14194:1	O
including	PRISTIQ.xml:S3:14196:9	O
the	PRISTIQ.xml:S3:14206:3	O
following	PRISTIQ.xml:S3:14210:9	O
:	PRISTIQ.xml:S3:14219:1	O
dysphoric	PRISTIQ.xml:S3:14221:9	O
mood	PRISTIQ.xml:S3:14231:4	O
,	PRISTIQ.xml:S3:14235:1	O
irritability	PRISTIQ.xml:S3:14237:12	O
,	PRISTIQ.xml:S3:14249:1	O
agitation	PRISTIQ.xml:S3:14251:9	O
,	PRISTIQ.xml:S3:14260:1	O
dizziness	PRISTIQ.xml:S3:14262:9	O
,	PRISTIQ.xml:S3:14271:1	O
sensory	PRISTIQ.xml:S3:14273:7	O
disturbances	PRISTIQ.xml:S3:14281:12	O
(	PRISTIQ.xml:S3:14294:1	O
e	PRISTIQ.xml:S3:14295:1	O
.	PRISTIQ.xml:S3:14296:1	O
g	PRISTIQ.xml:S3:14297:1	O
.	PRISTIQ.xml:S3:14298:1	O
,	PRISTIQ.xml:S3:14299:1	O
paresthesia	PRISTIQ.xml:S3:14301:11	O
,	PRISTIQ.xml:S3:14312:1	O
such	PRISTIQ.xml:S3:14314:4	O
as	PRISTIQ.xml:S3:14319:2	O
electric	PRISTIQ.xml:S3:14322:8	O
shock	PRISTIQ.xml:S3:14331:5	O
sensations	PRISTIQ.xml:S3:14337:10	O
)	PRISTIQ.xml:S3:14347:1	O
,	PRISTIQ.xml:S3:14348:1	O
anxiety	PRISTIQ.xml:S3:14350:7	O
,	PRISTIQ.xml:S3:14357:1	O
confusion	PRISTIQ.xml:S3:14359:9	O
,	PRISTIQ.xml:S3:14368:1	O
headache	PRISTIQ.xml:S3:14370:8	O
,	PRISTIQ.xml:S3:14378:1	O
lethargy	PRISTIQ.xml:S3:14380:8	O
,	PRISTIQ.xml:S3:14388:1	O
emotional	PRISTIQ.xml:S3:14390:9	O
lability	PRISTIQ.xml:S3:14400:8	O
,	PRISTIQ.xml:S3:14408:1	O
insomnia	PRISTIQ.xml:S3:14410:8	O
,	PRISTIQ.xml:S3:14418:1	O
hypomania	PRISTIQ.xml:S3:14420:9	O
,	PRISTIQ.xml:S3:14429:1	O
tinnitus	PRISTIQ.xml:S3:14431:8	O
,	PRISTIQ.xml:S3:14439:1	O
and	PRISTIQ.xml:S3:14441:3	O
seizures	PRISTIQ.xml:S3:14445:8	O
.	PRISTIQ.xml:S3:14453:1	O

While	PRISTIQ.xml:S3:14455:5	O
these	PRISTIQ.xml:S3:14461:5	O
events	PRISTIQ.xml:S3:14467:6	O
are	PRISTIQ.xml:S3:14474:3	O
generally	PRISTIQ.xml:S3:14478:9	O
self	PRISTIQ.xml:S3:14488:4	O
-	PRISTIQ.xml:S3:14492:1	O
limiting	PRISTIQ.xml:S3:14493:8	O
,	PRISTIQ.xml:S3:14501:1	O
there	PRISTIQ.xml:S3:14503:5	O
have	PRISTIQ.xml:S3:14509:4	O
been	PRISTIQ.xml:S3:14514:4	O
reports	PRISTIQ.xml:S3:14519:7	O
of	PRISTIQ.xml:S3:14527:2	O
serious	PRISTIQ.xml:S3:14530:7	O
discontinuation	PRISTIQ.xml:S3:14538:15	O
symptoms	PRISTIQ.xml:S3:14554:8	O
.	PRISTIQ.xml:S3:14562:1	O

Patients	PRISTIQ.xml:S3:14568:8	O
should	PRISTIQ.xml:S3:14577:6	O
be	PRISTIQ.xml:S3:14584:2	O
monitored	PRISTIQ.xml:S3:14587:9	O
for	PRISTIQ.xml:S3:14597:3	O
these	PRISTIQ.xml:S3:14601:5	O
symptoms	PRISTIQ.xml:S3:14607:8	O
when	PRISTIQ.xml:S3:14616:4	O
discontinuing	PRISTIQ.xml:S3:14621:13	O
treatment	PRISTIQ.xml:S3:14635:9	O
with	PRISTIQ.xml:S3:14645:4	O
PRISTIQ	PRISTIQ.xml:S3:14650:7	O
.	PRISTIQ.xml:S3:14657:1	O

A	PRISTIQ.xml:S3:14659:1	O
gradual	PRISTIQ.xml:S3:14661:7	O
reduction	PRISTIQ.xml:S3:14669:9	O
in	PRISTIQ.xml:S3:14679:2	O
the	PRISTIQ.xml:S3:14682:3	O
dose	PRISTIQ.xml:S3:14686:4	O
rather	PRISTIQ.xml:S3:14691:6	O
than	PRISTIQ.xml:S3:14698:4	O
abrupt	PRISTIQ.xml:S3:14703:6	O
cessation	PRISTIQ.xml:S3:14710:9	O
is	PRISTIQ.xml:S3:14720:2	O
recommended	PRISTIQ.xml:S3:14723:11	O
whenever	PRISTIQ.xml:S3:14735:8	O
possible	PRISTIQ.xml:S3:14744:8	O
.	PRISTIQ.xml:S3:14752:1	O

If	PRISTIQ.xml:S3:14754:2	O
intolerable	PRISTIQ.xml:S3:14757:11	O
symptoms	PRISTIQ.xml:S3:14769:8	O
occur	PRISTIQ.xml:S3:14778:5	O
following	PRISTIQ.xml:S3:14784:9	O
a	PRISTIQ.xml:S3:14794:1	O
decrease	PRISTIQ.xml:S3:14796:8	O
in	PRISTIQ.xml:S3:14805:2	O
the	PRISTIQ.xml:S3:14808:3	O
dose	PRISTIQ.xml:S3:14812:4	O
or	PRISTIQ.xml:S3:14817:2	O
upon	PRISTIQ.xml:S3:14820:4	O
discontinuation	PRISTIQ.xml:S3:14825:15	O
of	PRISTIQ.xml:S3:14841:2	O
treatment	PRISTIQ.xml:S3:14844:9	O
,	PRISTIQ.xml:S3:14853:1	O
then	PRISTIQ.xml:S3:14855:4	O
resuming	PRISTIQ.xml:S3:14860:8	O
the	PRISTIQ.xml:S3:14869:3	O
previously	PRISTIQ.xml:S3:14873:10	O
prescribed	PRISTIQ.xml:S3:14884:10	O
dose	PRISTIQ.xml:S3:14895:4	O
may	PRISTIQ.xml:S3:14900:3	O
be	PRISTIQ.xml:S3:14904:2	O
considered	PRISTIQ.xml:S3:14907:10	O
.	PRISTIQ.xml:S3:14917:1	O

Subsequently	PRISTIQ.xml:S3:14919:12	O
,	PRISTIQ.xml:S3:14931:1	O
the	PRISTIQ.xml:S3:14933:3	O
physician	PRISTIQ.xml:S3:14937:9	O
may	PRISTIQ.xml:S3:14947:3	O
continue	PRISTIQ.xml:S3:14951:8	O
decreasing	PRISTIQ.xml:S3:14960:10	O
the	PRISTIQ.xml:S3:14971:3	O
dose	PRISTIQ.xml:S3:14975:4	O
,	PRISTIQ.xml:S3:14979:1	O
but	PRISTIQ.xml:S3:14981:3	O
at	PRISTIQ.xml:S3:14985:2	O
a	PRISTIQ.xml:S3:14988:1	O
more	PRISTIQ.xml:S3:14990:4	O
gradual	PRISTIQ.xml:S3:14995:7	O
rate	PRISTIQ.xml:S3:15003:4	O
[	PRISTIQ.xml:S3:15008:1	O
see	PRISTIQ.xml:S3:15009:3	O
Dosage	PRISTIQ.xml:S3:15014:6	O
and	PRISTIQ.xml:S3:15021:3	O
Administration	PRISTIQ.xml:S3:15025:14	O
(	PRISTIQ.xml:S3:15040:1	O
2.4	PRISTIQ.xml:S3:15041:3	O
)	PRISTIQ.xml:S3:15044:1	O
and	PRISTIQ.xml:S3:15047:3	O
Adverse	PRISTIQ.xml:S3:15052:7	O
Reactions	PRISTIQ.xml:S3:15060:9	O
(	PRISTIQ.xml:S3:15070:1	O
6.1	PRISTIQ.xml:S3:15071:3	O
)	PRISTIQ.xml:S3:15074:1	O
]	PRISTIQ.xml:S3:15077:1	O
.	PRISTIQ.xml:S3:15080:1	O

5.8	PRISTIQ.xml:S3:15089:3	O
Seizure	PRISTIQ.xml:S3:15093:7	O

Cases	PRISTIQ.xml:S3:15106:5	O
of	PRISTIQ.xml:S3:15112:2	O
seizure	PRISTIQ.xml:S3:15115:7	B-AdverseReaction
have	PRISTIQ.xml:S3:15123:4	O
been	PRISTIQ.xml:S3:15128:4	O
reported	PRISTIQ.xml:S3:15133:8	O
in	PRISTIQ.xml:S3:15142:2	O
pre	PRISTIQ.xml:S3:15145:3	O
-	PRISTIQ.xml:S3:15148:1	O
marketing	PRISTIQ.xml:S3:15149:9	O
clinical	PRISTIQ.xml:S3:15159:8	O
studies	PRISTIQ.xml:S3:15168:7	O
with	PRISTIQ.xml:S3:15176:4	O
PRISTIQ	PRISTIQ.xml:S3:15181:7	O
.	PRISTIQ.xml:S3:15188:1	O

PRISTIQ	PRISTIQ.xml:S3:15190:7	O
has	PRISTIQ.xml:S3:15198:3	O
not	PRISTIQ.xml:S3:15202:3	O
been	PRISTIQ.xml:S3:15206:4	O
systematically	PRISTIQ.xml:S3:15211:14	O
evaluated	PRISTIQ.xml:S3:15226:9	O
in	PRISTIQ.xml:S3:15236:2	O
patients	PRISTIQ.xml:S3:15239:8	O
with	PRISTIQ.xml:S3:15248:4	O
a	PRISTIQ.xml:S3:15253:1	O
seizure	PRISTIQ.xml:S3:15255:7	O
disorder	PRISTIQ.xml:S3:15263:8	O
.	PRISTIQ.xml:S3:15271:1	O

Patients	PRISTIQ.xml:S3:15273:8	O
with	PRISTIQ.xml:S3:15282:4	O
a	PRISTIQ.xml:S3:15287:1	O
history	PRISTIQ.xml:S3:15289:7	O
of	PRISTIQ.xml:S3:15297:2	O
seizures	PRISTIQ.xml:S3:15300:8	O
were	PRISTIQ.xml:S3:15309:4	O
excluded	PRISTIQ.xml:S3:15314:8	O
from	PRISTIQ.xml:S3:15323:4	O
pre	PRISTIQ.xml:S3:15328:3	O
-	PRISTIQ.xml:S3:15331:1	O
marketing	PRISTIQ.xml:S3:15332:9	O
clinical	PRISTIQ.xml:S3:15342:8	O
studies	PRISTIQ.xml:S3:15351:7	O
.	PRISTIQ.xml:S3:15358:1	O

PRISTIQ	PRISTIQ.xml:S3:15360:7	O
should	PRISTIQ.xml:S3:15368:6	O
be	PRISTIQ.xml:S3:15375:2	O
prescribed	PRISTIQ.xml:S3:15378:10	O
with	PRISTIQ.xml:S3:15389:4	O
caution	PRISTIQ.xml:S3:15394:7	O
in	PRISTIQ.xml:S3:15402:2	O
patients	PRISTIQ.xml:S3:15405:8	O
with	PRISTIQ.xml:S3:15414:4	O
a	PRISTIQ.xml:S3:15419:1	O
seizure	PRISTIQ.xml:S3:15421:7	O
disorder	PRISTIQ.xml:S3:15429:8	O
.	PRISTIQ.xml:S3:15437:1	O

5.9	PRISTIQ.xml:S3:15446:3	O
Hyponatremia	PRISTIQ.xml:S3:15450:12	O

Hyponatremia	PRISTIQ.xml:S3:15468:12	B-AdverseReaction
may	PRISTIQ.xml:S3:15481:3	B-Factor
occur	PRISTIQ.xml:S3:15485:5	O
as	PRISTIQ.xml:S3:15491:2	O
a	PRISTIQ.xml:S3:15494:1	O
result	PRISTIQ.xml:S3:15496:6	O
of	PRISTIQ.xml:S3:15503:2	O
treatment	PRISTIQ.xml:S3:15506:9	O
with	PRISTIQ.xml:S3:15516:4	O
SSRIs	PRISTIQ.xml:S3:15521:5	O
and	PRISTIQ.xml:S3:15527:3	O
SNRIs	PRISTIQ.xml:S3:15531:5	O
,	PRISTIQ.xml:S3:15536:1	O
including	PRISTIQ.xml:S3:15538:9	O
PRISTIQ	PRISTIQ.xml:S3:15548:7	O
.	PRISTIQ.xml:S3:15555:1	O

In	PRISTIQ.xml:S3:15557:2	O
many	PRISTIQ.xml:S3:15560:4	O
cases	PRISTIQ.xml:S3:15565:5	O
,	PRISTIQ.xml:S3:15570:1	O
this	PRISTIQ.xml:S3:15572:4	O
hyponatremia	PRISTIQ.xml:S3:15577:12	B-AdverseReaction
appears	PRISTIQ.xml:S3:15590:7	O
to	PRISTIQ.xml:S3:15598:2	O
be	PRISTIQ.xml:S3:15601:2	O
the	PRISTIQ.xml:S3:15604:3	O
result	PRISTIQ.xml:S3:15608:6	O
of	PRISTIQ.xml:S3:15615:2	O
the	PRISTIQ.xml:S3:15618:3	O
syndrome	PRISTIQ.xml:S3:15622:8	B-AdverseReaction
of	PRISTIQ.xml:S3:15631:2	I-AdverseReaction
inappropriate	PRISTIQ.xml:S3:15634:13	I-AdverseReaction
antidiuretic	PRISTIQ.xml:S3:15648:12	I-AdverseReaction
hormone	PRISTIQ.xml:S3:15661:7	I-AdverseReaction
secretion	PRISTIQ.xml:S3:15669:9	I-AdverseReaction
(	PRISTIQ.xml:S3:15679:1	O
SIADH	PRISTIQ.xml:S3:15680:5	B-AdverseReaction
)	PRISTIQ.xml:S3:15685:1	O
.	PRISTIQ.xml:S3:15686:1	O

Cases	PRISTIQ.xml:S3:15688:5	O
with	PRISTIQ.xml:S3:15694:4	O
serum	PRISTIQ.xml:S3:15699:5	B-AdverseReaction
sodium	PRISTIQ.xml:S3:15705:6	I-AdverseReaction
lower	PRISTIQ.xml:S3:15712:5	I-AdverseReaction
than	PRISTIQ.xml:S3:15718:4	I-AdverseReaction
110	PRISTIQ.xml:S3:15723:3	I-AdverseReaction
mmol	PRISTIQ.xml:S3:15727:4	I-AdverseReaction
L	PRISTIQ.xml:S3:15732:1	I-AdverseReaction
have	PRISTIQ.xml:S3:15734:4	O
been	PRISTIQ.xml:S3:15739:4	O
reported	PRISTIQ.xml:S3:15744:8	O
.	PRISTIQ.xml:S3:15752:1	O

Elderly	PRISTIQ.xml:S3:15754:7	O
patients	PRISTIQ.xml:S3:15762:8	O
may	PRISTIQ.xml:S3:15771:3	O
be	PRISTIQ.xml:S3:15775:2	O
at	PRISTIQ.xml:S3:15778:2	O
greater	PRISTIQ.xml:S3:15781:7	O
risk	PRISTIQ.xml:S3:15789:4	O
of	PRISTIQ.xml:S3:15794:2	O
developing	PRISTIQ.xml:S3:15797:10	O
hyponatremia	PRISTIQ.xml:S3:15808:12	B-AdverseReaction
with	PRISTIQ.xml:S3:15821:4	O
SSRIs	PRISTIQ.xml:S3:15826:5	O
and	PRISTIQ.xml:S3:15832:3	O
SNRIs	PRISTIQ.xml:S3:15836:5	B-DrugClass
.	PRISTIQ.xml:S3:15841:1	O

Also	PRISTIQ.xml:S3:15843:4	O
,	PRISTIQ.xml:S3:15847:1	O
patients	PRISTIQ.xml:S3:15849:8	O
taking	PRISTIQ.xml:S3:15858:6	O
diuretics	PRISTIQ.xml:S3:15865:9	O
or	PRISTIQ.xml:S3:15875:2	O
who	PRISTIQ.xml:S3:15878:3	O
are	PRISTIQ.xml:S3:15882:3	O
otherwise	PRISTIQ.xml:S3:15886:9	O
volume	PRISTIQ.xml:S3:15896:6	O
depleted	PRISTIQ.xml:S3:15903:8	O
can	PRISTIQ.xml:S3:15912:3	O
be	PRISTIQ.xml:S3:15916:2	O
at	PRISTIQ.xml:S3:15919:2	O
greater	PRISTIQ.xml:S3:15922:7	O
risk	PRISTIQ.xml:S3:15930:4	O
[	PRISTIQ.xml:S3:15935:1	O
see	PRISTIQ.xml:S3:15936:3	O
Use	PRISTIQ.xml:S3:15941:3	O
in	PRISTIQ.xml:S3:15945:2	O
Specific	PRISTIQ.xml:S3:15948:8	O
Populations	PRISTIQ.xml:S3:15957:11	O
(	PRISTIQ.xml:S3:15969:1	O
8.5	PRISTIQ.xml:S3:15970:3	O
)	PRISTIQ.xml:S3:15973:1	O
and	PRISTIQ.xml:S3:15976:3	O
Clinical	PRISTIQ.xml:S3:15980:8	O
Pharmacology	PRISTIQ.xml:S3:15989:12	O
(	PRISTIQ.xml:S3:16002:1	O
12.6	PRISTIQ.xml:S3:16003:4	O
)]	PRISTIQ.xml:S3:16007:2	O
.	PRISTIQ.xml:S3:16011:1	O

Discontinuation	PRISTIQ.xml:S3:16013:15	O
of	PRISTIQ.xml:S3:16029:2	O
PRISTIQ	PRISTIQ.xml:S3:16032:7	O
should	PRISTIQ.xml:S3:16040:6	O
be	PRISTIQ.xml:S3:16047:2	O
considered	PRISTIQ.xml:S3:16050:10	O
in	PRISTIQ.xml:S3:16061:2	O
patients	PRISTIQ.xml:S3:16064:8	O
with	PRISTIQ.xml:S3:16073:4	O
symptomatic	PRISTIQ.xml:S3:16078:11	O
hyponatremia	PRISTIQ.xml:S3:16090:12	O
and	PRISTIQ.xml:S3:16103:3	O
appropriate	PRISTIQ.xml:S3:16107:11	O
medical	PRISTIQ.xml:S3:16119:7	O
intervention	PRISTIQ.xml:S3:16127:12	O
should	PRISTIQ.xml:S3:16140:6	O
be	PRISTIQ.xml:S3:16147:2	O
instituted	PRISTIQ.xml:S3:16150:10	O
.	PRISTIQ.xml:S3:16160:1	O

Signs	PRISTIQ.xml:S3:16166:5	O
and	PRISTIQ.xml:S3:16172:3	O
symptoms	PRISTIQ.xml:S3:16176:8	O
of	PRISTIQ.xml:S3:16185:2	O
hyponatremia	PRISTIQ.xml:S3:16188:12	B-AdverseReaction
include	PRISTIQ.xml:S3:16201:7	O
headache	PRISTIQ.xml:S3:16209:8	B-AdverseReaction
,	PRISTIQ.xml:S3:16217:1	O
difficulty	PRISTIQ.xml:S3:16219:10	B-AdverseReaction
concentrating	PRISTIQ.xml:S3:16230:13	I-AdverseReaction
,	PRISTIQ.xml:S3:16243:1	O
memory	PRISTIQ.xml:S3:16245:6	B-AdverseReaction
impairment	PRISTIQ.xml:S3:16252:10	I-AdverseReaction
,	PRISTIQ.xml:S3:16262:1	O
confusion	PRISTIQ.xml:S3:16264:9	B-AdverseReaction
,	PRISTIQ.xml:S3:16273:1	O
weakness	PRISTIQ.xml:S3:16275:8	B-AdverseReaction
,	PRISTIQ.xml:S3:16283:1	O
and	PRISTIQ.xml:S3:16285:3	O
unsteadiness	PRISTIQ.xml:S3:16289:12	B-AdverseReaction
,	PRISTIQ.xml:S3:16301:1	O
which	PRISTIQ.xml:S3:16303:5	O
can	PRISTIQ.xml:S3:16309:3	B-Factor
lead	PRISTIQ.xml:S3:16313:4	O
to	PRISTIQ.xml:S3:16318:2	O
falls	PRISTIQ.xml:S3:16321:5	B-AdverseReaction
.	PRISTIQ.xml:S3:16326:1	O

Signs	PRISTIQ.xml:S3:16328:5	O
and	PRISTIQ.xml:S3:16334:3	O
symptoms	PRISTIQ.xml:S3:16338:8	O
associated	PRISTIQ.xml:S3:16347:10	O
with	PRISTIQ.xml:S3:16358:4	O
more	PRISTIQ.xml:S3:16363:4	O
severe	PRISTIQ.xml:S3:16368:6	O
and	PRISTIQ.xml:S3:16375:3	O
or	PRISTIQ.xml:S3:16379:2	O
acute	PRISTIQ.xml:S3:16382:5	O
cases	PRISTIQ.xml:S3:16388:5	O
have	PRISTIQ.xml:S3:16394:4	O
included	PRISTIQ.xml:S3:16399:8	O
hallucination	PRISTIQ.xml:S3:16408:13	B-AdverseReaction
,	PRISTIQ.xml:S3:16421:1	O
syncope	PRISTIQ.xml:S3:16423:7	B-AdverseReaction
,	PRISTIQ.xml:S3:16430:1	O
seizure	PRISTIQ.xml:S3:16432:7	B-AdverseReaction
,	PRISTIQ.xml:S3:16439:1	O
coma	PRISTIQ.xml:S3:16441:4	B-AdverseReaction
,	PRISTIQ.xml:S3:16445:1	O
respiratory	PRISTIQ.xml:S3:16447:11	B-AdverseReaction
arrest	PRISTIQ.xml:S3:16459:6	I-AdverseReaction
,	PRISTIQ.xml:S3:16465:1	O
and	PRISTIQ.xml:S3:16467:3	O
death	PRISTIQ.xml:S3:16471:5	B-AdverseReaction
.	PRISTIQ.xml:S3:16476:1	O

5.10	PRISTIQ.xml:S3:16485:4	O
Interstitial	PRISTIQ.xml:S3:16490:12	O
Lung	PRISTIQ.xml:S3:16503:4	O
Disease	PRISTIQ.xml:S3:16508:7	O
and	PRISTIQ.xml:S3:16516:3	O
Eosinophilic	PRISTIQ.xml:S3:16520:12	O
Pneumonia	PRISTIQ.xml:S3:16533:9	O

Interstitial	PRISTIQ.xml:S3:16548:12	B-AdverseReaction
lung	PRISTIQ.xml:S3:16561:4	I-AdverseReaction
disease	PRISTIQ.xml:S3:16566:7	I-AdverseReaction
and	PRISTIQ.xml:S3:16574:3	O
eosinophilic	PRISTIQ.xml:S3:16578:12	B-AdverseReaction
pneumonia	PRISTIQ.xml:S3:16591:9	I-AdverseReaction
associated	PRISTIQ.xml:S3:16601:10	O
with	PRISTIQ.xml:S3:16612:4	O
venlafaxine	PRISTIQ.xml:S3:16617:11	B-DrugClass
(	PRISTIQ.xml:S3:16629:1	O
the	PRISTIQ.xml:S3:16630:3	O
parent	PRISTIQ.xml:S3:16634:6	O
drug	PRISTIQ.xml:S3:16641:4	O
of	PRISTIQ.xml:S3:16646:2	O
PRISTIQ	PRISTIQ.xml:S3:16649:7	O
)	PRISTIQ.xml:S3:16656:1	O
therapy	PRISTIQ.xml:S3:16658:7	O
have	PRISTIQ.xml:S3:16666:4	O
been	PRISTIQ.xml:S3:16671:4	O
rarely	PRISTIQ.xml:S3:16676:6	O
reported	PRISTIQ.xml:S3:16683:8	O
.	PRISTIQ.xml:S3:16691:1	O

The	PRISTIQ.xml:S3:16693:3	O
possibility	PRISTIQ.xml:S3:16697:11	O
of	PRISTIQ.xml:S3:16709:2	O
these	PRISTIQ.xml:S3:16712:5	O
adverse	PRISTIQ.xml:S3:16718:7	O
events	PRISTIQ.xml:S3:16726:6	O
should	PRISTIQ.xml:S3:16733:6	O
be	PRISTIQ.xml:S3:16740:2	O
considered	PRISTIQ.xml:S3:16743:10	O
in	PRISTIQ.xml:S3:16754:2	O
patients	PRISTIQ.xml:S3:16757:8	O
treated	PRISTIQ.xml:S3:16766:7	O
with	PRISTIQ.xml:S3:16774:4	O
PRISTIQ	PRISTIQ.xml:S3:16779:7	O
who	PRISTIQ.xml:S3:16787:3	O
present	PRISTIQ.xml:S3:16791:7	O
with	PRISTIQ.xml:S3:16799:4	O
progressive	PRISTIQ.xml:S3:16804:11	O
dyspnea	PRISTIQ.xml:S3:16816:7	O
,	PRISTIQ.xml:S3:16823:1	O
cough	PRISTIQ.xml:S3:16825:5	O
,	PRISTIQ.xml:S3:16830:1	O
or	PRISTIQ.xml:S3:16832:2	O
chest	PRISTIQ.xml:S3:16835:5	O
discomfort	PRISTIQ.xml:S3:16841:10	O
.	PRISTIQ.xml:S3:16851:1	O

Such	PRISTIQ.xml:S3:16853:4	O
patients	PRISTIQ.xml:S3:16858:8	O
should	PRISTIQ.xml:S3:16867:6	O
undergo	PRISTIQ.xml:S3:16874:7	O
a	PRISTIQ.xml:S3:16882:1	O
prompt	PRISTIQ.xml:S3:16884:6	O
medical	PRISTIQ.xml:S3:16891:7	O
evaluation	PRISTIQ.xml:S3:16899:10	O
,	PRISTIQ.xml:S3:16909:1	O
and	PRISTIQ.xml:S3:16911:3	O
discontinuation	PRISTIQ.xml:S3:16915:15	O
of	PRISTIQ.xml:S3:16931:2	O
PRISTIQ	PRISTIQ.xml:S3:16934:7	O
should	PRISTIQ.xml:S3:16942:6	O
be	PRISTIQ.xml:S3:16949:2	O
considered	PRISTIQ.xml:S3:16952:10	O
.	PRISTIQ.xml:S3:16962:1	O
